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LIST OF ABBREVIATIONS 
 
a  at maximal atrial contraction 
AD  amiodarone 
AERP  atrial effective refractory period 
AF  atrial fibrillation 
AFCL  atrial fibrillation cycle length 
Ao  aorta 
AOD  aortic diameter 
AODV aortic diameter at valvular level 
AUC  area under the curve 
CL  cycle length 
Cl  clearance 
Cmax  maximum plasma concentration 
Cp  plasma concentration 
CV  conduction velocity 
d  at the end of ventricular diastole 
DAD  desethylamiodarone 
ECG  electrocardiogram 
F   absolute bioavailability 
FAC  fractional area change 
FS  fractional shortening 
HPLC  high-performance liquid chromatography 
HR  heart rate 
IRAF  immediate recurrence of atrial fibrillation 
IV  intravenous 
k  elimination rate constant 
LA  left atrium 
LAA  left atrial area 
LAsx  left atrial short-axis 
LAD   left atrial internal diameter 
LAS  left atrial surface 
LOD  limit of detection 
LOQ  limit of quantification 
LPA  left pulmonary artery 
LVIDd left ventricular internal diameter in diastole 
LVIDs  left ventricular internal diameter in systole 
p  at the onset of the P wave 
PCL  pacing cycle length 
PO  per os 
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R  rate of infusion 
RA  right atrium 
RPA  right pulmonary artery 
RV  right ventricle 
s  at the end of the ventricular systole 
SF  French saddle horse 
SVT  supraventricular tachycardia 
t  time 
t1/2  half-life  
t1/2el  terminal elimination half-life 
Tmax  time of Cmax 
TV  tricuspid valve 
Vd  volume of distribution 
VERP  ventricular effective refractory period 
Vmax  maximum upstroke velocity of the action potential 
Vp  volume of distribution of the central compartment 
WL  wavelength 
QS  quinidine sulphate 
 
 
 
 
 3 
PREFACE 
 
 
Atrial fibrillation is the most important arrhythmia in horses as it develops relatively easy and 
because it commonly affects athletic ability. When no other predisposing cardiac pathology is 
present, prognosis after conversion to sinus rhythm is good because horses generally regain 
their full athletic potential. Therefore, in competition horses, treatment by ‘rhythm control’ is 
indicated and worthwhile. Quinidine sulphate is the gold standard treatment for this 
arrhythmia in horses. However, the drug becomes more difficult to obtain in several countries. 
Nowadays, quinidine is almost completely abandoned in human medicine because many, less 
toxic but effective alternatives are available.  
For the first section of this thesis electrical and contractile remodeling and reverse remodeling 
associated with acute and chronic atrial fibrillation were studied to better understand the 
pathophysiology of this arrhythmia in horses. In the second and third section, the results of 
new pharmacological treatments and a non-pharmacological therapy for horses with AF are 
described. 
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GENERAL INTRODUCTION 
 
1. Atrial fibrillation 
With a prevalence of around 2.5% (based on patient data of 2477 horses) (Else and Holmes, 
1971) and an important impact on athletic performance, atrial fibrillation (AF) represents the 
most important supraventricular arrhythmia in horses. AF is characterized by disorganised 
atrial electrical activity and a loss of atrial contribution to ventricular filling. In human 
patients, AF prevalence is around 1-2% and increases with age: the median age of patients 
with AF is 75 years and whereby 84% of the patients with AF are older than 65 years 
(Benjamin et al. 1994; Feinberg et al., 1995; Benjamin et al., 1998; Go et al., 2001). In horses, 
AF shows no clear relationship with age. 
2. Classification of AF  
AF can be classified based upon the presence of predisposing disease or based upon AF 
duration. AF can be found as a result of an underlying disease such as mitral regurgitation, 
atrial dilatation, or it can be found as ‘lone’ (uncomplicated, primary) AF. Based upon AF 
duration, human patients are subdivided in (1) paroxysmal AF, when AF terminates 
spontaneously within hours or days, in (2) persistent AF, when it continues for a longer period 
or when it requires a pharmacological or electrical cardioversion, and in (3) permanent AF, 
when AF continues with or without treatment attempts (Allesie et al., 2001; Crijns et al., 
1999; Gallagher and Camm, 1998; Fuster et al., 2006). Paroxysmal and lone AF tends to be 
seen more often in younger people. Epidemiological data suggest that 29% of the patients 
with paroxysmal AF without underlying heart disease progressed to permanent AF within 15-
30 years (Jahangir et al., 2007). The prevalence of paroxysmal AF was reported to be 1.39% 
in slowly finishing and non-finishing race horses (Ohmura et al., 2003).  
3. Initiation of AF 
The normal action potential of a myocardial cell shows 4 different phases (Figure 1). 
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Phase 0 is the rapid depolarization phase. The slope of phase 0 represents the maximum 
upstroke velocity of the action potential and is known as Vmax. During this phase the fast Na+-
channels open and a rapid increase in the membrane conductance for Na+ appears. The Na+-
channels contain different gates which gradually open. They are totally closed at the onset of 
phase 0 and totally opened at the end of phase 0. During phase 1, the cell partially repolarizes 
through a transient outward K+ current (Ito), inactivation of which produces a notch in the 
action potential. Phase 2, the “plateau phase”, is sustained by an inward L-type calcium 
current. A series of K+ current that activate in a time-dependent way, the delayed rectifiers 
(IK), lead to cellular repolarization, phase 3. The delayed rectifiers consist of 3 components: 
an ultrarapid component (IKur), a rapid component (IKr) and a slow component (IKs). The 
balance between the inward movement of Ca²+ through the L-type Ca²+-channels and the 
outward movement of K+ through the delayed rectifiers determines the duration of the action 
potential: increased inward current prolongs the action potential and increased outward 
current abbreviates it. At the end of phase 3, when the membrane potential is restored, the 
delayed rectifiers close again. During phase 4, the negative resting membrane potential is 
maintained by the inwardly rectifying K+ current (IK1) and the Na+-K+ pump. The latter 
transports 3 Na+ outward the cell for 2 K+ ions inward, thereby generating a net outward 
movement of positive charges. This phase of the action potential is associated with the 
diastole.  
Figure 1. The different phases (0-4) during a ventricular action potential. At rest (phase 4) resting membrane 
potential is between 70 and -85 mV. A rapid sodium influx during phase 0 makes the membrane potential 
positive. Due to a rapid inactivation of the sodium channels and an efflux of potassium (Ito) the cell begins to 
repolarize (phase1). However, repolarization is interrupted by an influx of calcium and partial closure of 
potassium channels (phase 2) resulting in a plateau phase in the action potential. Due to re-opening of the 
potassium channels (IK) and closing of the calcium channels the cell further repolarizes (phase 3) and eventually 
reaches its resting membrane potential (phase 4).  
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Some myocardial cells show a spontaneous depolarization. These pacemaker cells are located 
at the sinus node, which is located at the junction of the right atrium and vena cava cranialis. 
Under normal circumstances during sinus rhythm, these cells repetitively produce an action 
potential at a specific rate. The electrical impulse depolarizes right and left atrium, which 
results in a P wave on a surface electrocardiogram (ECG) (Figure 2). Subsequently, the 
impulse is slowly conducted through the atrioventricular (AV) node, which is the only 
electrical connection between atria and ventricles. When the impulse leaves the AV node, a 
rapid conduction via the His- and Purkinje-system depolarizes both ventricles. The latter 
results in a QRS complex on the surface ECG (Figure 2). After depolarization, the 
repolarization of the ventricles produces the T wave on the surface ECG. 
Figure 2. The surface ECG of a horse in sinus rhythm. 
 
During the depolarization-repolarization process, myocardial cells are unresponsive or 
refractory, to further excitation. This refractory period can be subdivided in the absolute 
refractory period and relative refractory period (Figure 3). During the absolute refractory 
period the myocardial cell is totally unresponsive to external stimuli whatever the strength. 
During the relative refractory period the myocardial cell is only responsive to external stimuli 
with a higher than normal amount of energy. 
Figure 3. The normal atrial action potential duration and the absolute (ARP) and relative refractory period (RRP) 
of the myocardium. 
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Human and experimental data 
Different theories have been proposed to explain the mechanism of AF primarily based upon 
ectopic foci, the presence of multiple re-entry waves, the leading circle concept or the 
presence of rotors and spiral waves.  
3.1 Ectopic foci 
One of the oldest theories about the initiation of AF, described by Lewis and Schleiter in 
1912, is based on the presence of ectopic foci. These ectopic foci are regions in the atria 
which are able to deliver premature electrical impulses. With atrial mapping techniques, the 
presence and localisation of such ectopic foci has been demonstrated with most of the foci 
being located in the pulmonary veins or vena cava superior. Other locations are the right 
atrium, left atrium, vein of Marshall, crista terminalis and the coronary sinus (Shah et al., 
1999).  
In 95% of the cases the foci are typically localised in the pulmonary veins. Sleeves of 
myocardial tissue extending into the pulmonary veins are supposed to be the cause, because 
these sleeves have the same embryonic origin as the conduction system, which could explain 
their arrhythmogenic nature (Blom et al., 1999).  
Multiple ectopic foci as well as single foci from individual heart fibres, firing at a high rate, 
may give rise to the uncoordinated electrical activity that initiates or even maintains AF 
(Engelman, 1896; Winterberg, 1906). 
3.2 Re-entry and multiple waves 
Re-entry is caused by abnormal impulse propagation and it can be initiated when an extra 
stimulus is delivered near a region with different electrophysiological properties, i.e. a 
different refractoriness and conduction velocity. The premature impulse will conduct through 
the cells with a short refractory period (these cells have recovered more rapidly) but will be 
blocked by the cells with a longer refractory period. As such, ‘unidirectional block’ occurs. 
By the time the impulse reaches the tissue with the longer refractory period, this tissue has 
fully recovered and the impulse can loop back to its origin to excite the tissue with the short 
refractory period again. As such a re-entry loop is formed, this can, under the right 
circumstances, continue to loop around and act as a continuous source of electrical activity. 
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The size or path length (PL) of the loop is determined by the length of the depolarisation 
wave, the wavelength (WL), and the amount of excitable tissue in between the ‘head’ and 
‘tail’ of the depolarisation wave, the so called excitable gap (EG). As such PL=WL+EG. The 
WL depends on the conduction velocity (CV) and the atrial effective refractory period of 
those cells (AERP). As such WL=CV • AERP (Moe, 1962).  
It is obvious that due to an increase in conduction velocity and/or an increase in refractoriness 
the excitable gap will become smaller. If sufficient reduction in the excitable gap occurs, the 
head of depolarisation wave will hit its own tail. This means that it will be blocked by 
refractory tissue which would terminate the re-entry loop (Figure 4). 
Figure 4. At the end of the depolarization wave (black arrow), tissue gradually regains excitability (grey area) 
until it becomes fully excitable again (white area). The excitable gap (white area) allows the depolarization wave 
to continue its looping movement. The distance the wave travels during the duration of the refractory period is 
the wavelength (black + grey area). An increase in refractory period (right image) might terminate the loop as 
the ‘head’ of the wave hits refractory tissue.  
          
 
During atrial fibrillation multiple re-entry circuits are thought to be present simultaneously, 
all meandering chaotically through the atria. The more wavelets that can coexist in the atria, 
the more stable AF becomes. An increase in atrial size or a decrease in wavelength (for 
example by a decrease in refractory period) increases the number of wavelets and thus 
promotes AF (Figure 5). It has been suggested that at least 6 re-entry circuits must coexist in 
order for AF to become self-sustained (Allessie et al., 1985). 
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Figure 5. A large atrium (A) can contain more wavelets than a small atrium (B). 
 
3.3 The leading circle concept 
The theory of the leading circle is based on an impulse that makes a circular movement in a 
certain direction due to unidirectional block (Figure 6) (Allessie et al., 1973). The length of 
this circle is approximately equal to the wavelength of the impulse (WL=CV·RP), i.e the 
distance the impulse travels during the refractory period. The excitable gap is very small. The 
impulse will also conduct to the centre of the circle (Figure 6) maintaining the centre 
constantly in a refractory state. The leading circle acts as a continuous source of electrical 
pulses that conduct centrifugally, activating the rest of the myocardium. 
Figure 6. The leading circle (large black arrow) is a re-entry wave that follows the smallest possible pathway, 
whereby the excitable gap is very small. Centripetal waves originating from this leading circle constantly 
maintain the central core in a refractory state.  
 
3.4 Rotors and spiral waves 
Another possible mechanism of AF is based on re-entry by one or more rotors that produce 
spiral waves (Figure 7), thereby acting as a continuous source of electrical activity (Jalife et 
al., 2002).  
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Figure 7. A rotor is a stable rotating reaction around a pivot point which gives rise to spiralling wave fronts.  
 
A rotor is a depolarisation wave that continuously turns around a small pivot point in the 
centre of the spiral, whereby the depolarisation wave propagates away from this centre 
(Comtois et al., 2005). The front of the central depolarisation wave is curved (convex) (Figure 
8). Due to differences in excitability, whereby the most central area shows lower excitability 
(small central arrow) than the rest of the curved depolarization front (larger arrows), a 
twisting movement is made (Cosio and Delpon, 2002). The tissue excitability determines the 
size of the pivot point and thus the spiral wave. In excitable tissue the rotor will easily turn 
around a small pivot point. However, due to a decreased excitability of the myocardium, the 
centre of the rotor fails to conduct in a small circle. The rotor needs more space to proceed 
and turns around in a larger circle, whereby it is more likely that the rotor and spiral waves 
terminate. 
Figure 8. Because the front of the rotor (black line) is curved and because the most central part shows lower 
excitability (small arrow) than the more outer parts (larger arrows), the rotor makes a turning movement, 
producing a spiral wave. The radius of rotation is determined by the excitability of the tissue. The repolarization 
front is shown in red. 
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The presence of more rotors in both atria have been described and optical mapping techniques 
have shown that most dominant rotors are localised at or near the pulmonary veins and the 
posterior left atrial (LA) wall. Intermittent or permanent high frequency activation initiated by 
the rotors in the LA, results in conduction towards the right atrium and induces and maintains 
AF (Jalife, 2003).  
Equine data 
Similar to human medicine, AF is thought to be initiated by one or more premature beats 
coming from an ectopic focus but the exact localisation of ectopy has never been documented 
in horses. Whether the mechanism of AF is ectopy, re-entry or a rotor is also not known. 
Clinical data have demonstrated increased ectopy in horses with an increased susceptibility 
for AF (Figure 9).  
Figure 9. The resting surface ECG of this horse shows a bout of rapid atrial ectopy (the start is indicated by the 
arrow). Within a few weeks this horse had developed persistent AF.  
 
 
4. Perpetuation of AF 
Human and experimental data 
Besides the initiation of AF, the substrate, i.e. the atria, must be able to allow perpetuation of 
the arrhythmia. As already mentioned, atrial size, atrial electrical characteristics and 
electrolyte balance, alterations in autonomic tone and the presence of structural lesions have a 
major impact on AF stability. In addition, AF per se induces important electrical, contractile 
and structural remodeling that further promote the perpetuation of the arrhythmia 
(‘domestication’ of AF) (Wijffels et al., 1995). 
 
 
 
General Introduction
 
13 
4.1 Electrical remodeling 
When a cardiac cell is activated, the depolarization time, identified by an inward flux of 
positively charged ions (Na+-influx), is followed by a membrane potential plateau which is 
associated with an L-type inward calcium current. Both parameters, but especially the 
membrane potential plateau, contribute to the duration, and thus refractory period, of the 
action potential. 
Rapid rates, as observed in atrial fibrillation, increase the myocyte calcium load because of 
the rapid and repetitive inward calcium flow. Because high calcium concentrations can be 
toxic, the cell will protect it self by a down regulation of the L-type calcium channel. This 
process reduces the inward calcium current which results in a shortening of the action 
potential and thus a shortened refractory period (Figure 10). 
Figure 10. Due to atrial fibrillation the duration of the action potential and therefore the refractory period 
decrease as a result of a decreased calcium current during the plateau phase. 
 
The reduction in refractory period implies a shortening in re-entry wavelength whereby more 
wavelets can coexist in the same atrium, which promotes the self-sustainability of AF. 
In humans, goats, dogs and ponies, research has illustrated that shortening of the atrial 
refractory period develops within the first days of AF (Morillo et al., 1995; van Loon et al., 
2001; Wijffels et al., 1995). 
 
4.2 Contractile remodeling 
Intracellular calcium (Ca2+) concentration plays a major role in the contractile activity of the 
myocardial cell. During the contraction phase, Ca2+ is pumped into the cell followed by an 
outward Ca2+ current during the relaxation phase. When depolarisation rate increases 
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permanently, Ca2+ cannot properly be pumped out of the cell resulting in changes in the Ca²+ 
induced Ca²+ release and contractile function. These changes would then be responsible for 
the contractile deficit of the myocyte during AF. Research has demonstrated that such a 
reduction in atrial contractile function appears after a few days of AF (Courtemanche et al., 
1998; Allessie et al., 2002). In addition, in human patients and dogs, prolonged AF is 
associated with myolysis which further reduces atrial contractile function. The atrial 
contractile dysfunction contributes to impaired atrial transport function and the occurrence of 
atrial thrombi (Stoddard, 2000).  
Equine data 
In horses, atrial contractile function can be assessed by cardiac ultrasound (Schwarzwald et 
al., 2007b). Atrial contractile dysfunction was found after successful cardioversion of AF in 
horses (Schwarzwald et al., 2007c). However, from that study, the influence of residual 
treatment effects or the presence of underlying primary myopathy could not be ruled out. In 
an experimental AF model in healthy ponies and in the absence of drug interference, atrial 
contractile dysfunction was clearly shown as a result of maintained AF (van Loon, 2001).  
 
4.3 Structural remodeling 
Histological changes that appear as a result of AF include cellular hypertrophy, glycogen 
accumulation, increased interstitial fibrosis, disruption in the sarcoplasmatic reticulum, 
redistribution of the gap junctions and apoptosis (Ausma et al., 1997; Elvan et al., 1997; Van 
der Velden et al., 1998). 
Equine data 
Electrical and contractile remodeling during an induced chronic AF protocol in ponies 
indicated rapid electrical remodeling and contractile remodeling and a slower occurring 
dilatation of the left atrium (van Loon et al., 2001).  
Data on structural remodeling in ponies or horses are not available yet.  
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5. Effect of AF on ventricular function 
Human data 
Due to the high atrial rate, AF is usually associated with an increase in heart rate. The 
reduction in diastolic time reduces ventricular filling and impairs cardiac function. Ventricular 
filling is further reduced because of the atrial contractile dysfunction. Especially at higher 
rates, under normal circumstances, the atrial contraction accounts for up to 15% of ventricular 
filling (Veng-Kin and Sagawa, 1979).  
Equine data 
In horses, the atrial activation rate during AF is about 250-450/min. Nevertheless, because of 
the high vagal tone in horses, the atrioventricular (AV) node blocks most of these pulses. As a 
result the final ventricular rate at rest is normal, at least if no other significant cardiac disease 
is present. As the normal heart rate allows sufficient passive ventricular filling and thus a 
sufficient cardiac function (Muir and McGuirk, 1984), the horse shows no symptoms at rest. 
However during exercise, the sympathetic tone supersedes the vagal tone whereby conduction 
through the AV node is suddenly facilitated, resulting in a disproportionate tachycardia. Both 
the loss of atrial contraction and the extreme increase in heart rate during exercise result in a 
reduced cardiac function and exercise intolerance. However, the latter is predominantly seen 
at higher performance levels as sufficient compensation usually occurs at lower exercise 
intensity.  
 
6. Diagnosis of AF in horses 
AF is characterized by a totally disorganized atrial electrical activation without effective atrial 
contraction. It can be detected by auscultation as an ‘irregularly irregular’ heart beat. Final 
diagnosis is made by an electrocardiogram that shows irregular baseline undulations (‘f 
waves’), absence of P waves, normal QRS morphology and irregular RR intervals. The 
fibrillation ‘frequency’ or ‘rate’ is difficult to derive from the surface ECG because the f 
waves represent a summation of all individual atrial wavelets. Moreover, the f waves on the 
surface ECG continuously change in amplitude and morphology. The local frequency of 
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fibrillation can be accurately determined by recording an intra-atrial electrogram and is 
usually between 250 and 450 per minute when measured in the right atrium (Figure 11).  
Figure 11. Surface ECG and simultaneous intra-atrial recording from a horse with atrial fibrillation at rest. f 
waves are found, P waves are absent, QRS morphology is normal and RR intervals are irregular.  
 
As mentioned before, high vagal tone maintains a normal, although irregular, heart rate at 
rest. During exercise, however, heart rates of more than 280 beats per minute are commonly 
observed in otherwise healthy horses (Figure 12) (Deegen, 1986; Deegen and Buttenkotter, 
1976; Maier-Bock and Ehrlein, 1978).  
Figure 12. Exercise electrocardiogram from a horse with atrial fibrillation. An irregular R-R interval is detectable 
and instantaneous heart rate reaches 258 beats per minute. 
 
 
Diagnosis of paroxysmal AF as a cause of poor performance is hampered by the fact that the 
arrhythmia suddenly develops during strenuous exercise and disappears shortly thereafter. As 
such, examination of the horse before and after a race might reveal no abnormalities. In order 
to diagnose paroxysmal AF, continuous ECG recordings during exercise are mandatory. 
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7. Symptoms of AF in horses 
Symptoms depend on the degree of underlying heart disease and the exercise demanded from 
the patient. In breeding or pleasure horses, AF is usually an incidental finding unless 
concomitant congestive heart failure would be present.  
In maximal or submaximal performance, exercise intolerance is always observed (Mitten, 
1996). Especially in Thoroughbreds paroxysmal AF has been found during racing and was 
associated with a sudden decrease in performance (Amada and Kurita, 1975; Hiraga and 
Kubo, 1999; Holmes et al., 1986; Miller et al., 1992; Rose and Davis, 1977). Such horses may 
suddenly pull-up and show signs of lung oedema, epistaxis, incoordination and even collapse, 
presumably because of a decreased cardiac pumping function and an increased atrial pressure 
with a reduction in pulmonary circulation. 
 
8. Prognosis for horses with AF 
Prognosis for life is excellent if no other cardiac disease is present. Horses with lone AF and 
with an AF duration of less than 2 months generally respond well to treatment in more than 
85% of the cases and even return to their previous athletic performance (Reef et al., 1988). 
However, AF recurrence rate in these horses varies from 15 to 30% and horses with more 
longstanding AF are more difficult to treat (Deegen and Buntenkotter, 1976; Deem and 
Fregin, 1982; Reef et al., 1988).  
In horses with mild to moderate underlying cardiac disease, such as atrial dilatation due to 
mitral regurgitation, conversion rate is lower and recurrence rate is higher. 
 
9. Treatment 
Because prognosis is rather good in horses without underlying heart disease, treatment is 
generally recommended if these animals are further intended to perform.  
Pharmacological as well as non-pharmacological treatment of the arrhythmia has been 
described. 
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9.1 Pharmacological treatment  
General 
In human patients, anti-arrhythmic drugs are administered to decrease heart rate (‘rate 
control’) or to restore the normal heart rhythm (‘rhythm control’) (Herzog et al., 2005; King 
et al., 2002). The ‘Vaughan-Williams’ classification is one of the most widely used 
classifications for anti-arrhythmic agents. Although many anti-arrhythmic drugs have multiple 
action mechanisms, they are classified based on the primary mechanism of anti-arrhythmic 
effect and the effect on the different phases during the cardiac action potential. 
There are five main classes in the ‘Vaughan-Williams’ classification. 
 
9.1.1 Class I agents 
These anti-arrhythmic agents interfere with the functioning of the Na+-channel. Based on its 
effect on the cardiac action potential the class I agents are subdivided in Class IA, IB and IC. 
9.1.1.1 Class IA agents 
The main property of a Class IA agent is blocking the fast Na+-channel. This effect results in 
a depression of the phase 0 depolarisation and a reduction of the maximum upstroke velocity 
of the action potential (Vmax) (Figure 13). The other action mechanisms include a decrease in 
conductivity and therefore an increase in the refractory period.  
Figure 13. A class IA anti-arrhythmic drug reduces Vmax during phase 0 thereby increasing the duration of the 
action potential. 
 
 
The most important Class IA agents are quinidine, procainamide and disopyramide. 
General Introduction
 
19 
9.1.1.2 Class IB 
Class IB anti-arrhythmic drugs also block Na+-channels but have little or no effect at slow 
heart rates because of their fast onset and offset kinetics. The effects are more pronounced at 
faster heart rates such as ventricular tachycardia. These drugs reduce electrical conductance 
among the cells by stabilizing the inactive state of Na+-channels resulting in a slower heart 
rate. The duration of the action potential and the refractory period are reduced but there is no 
effect on the Vmax (Figure 14).  
Figure 14. A class IB anti-arrhythmic drug shortens the action potential duration. 
 
Important class IB agents include lidocaine, mexiletine, tocainide and phenytoin. 
9.1.1.3 Class IC agents 
Class IC anti-arrhythmic drugs strongly depress the Vmax and thus phase 0. A decrease in 
conductivity and excitability of the cardiac cells but minimal effects on the duration of the 
action potential is observed (Figure 15). Class IC agents have the most potent sodium channel 
blocking effects. 
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Figure 15. Class IC anti-arrhythmic drugs cause a major decrease in Vmax. 
 
 
Class IC agents are propafenone, flecainide, cibenzoline, encainide and moricizine. 
 
9.1.2 Class II agents 
Class II anti-arrhythmic drugs are classified as beta reptor blockers. Beta receptors can be 
separated into those that affect predominantly the heart (beta1) or the bronchi and those that 
affect blood vessels (beta2). In low doses, Class II anti-antiarrhythmic drugs decrease the 
sympathetic activity on the heart by selectively blocking the effect of catecholamines and 
beta1- adrenergic receptors. In high doses, the selective beta1 blockers also block beta2 
receptors. 
Frequently used class II anti-arrhythmic drugs include propranolol, esmolol and metoprolol. 
 
9.1.3 Class III agents 
The class III anti-arrhythmic drugs predominantly block the K+-channels resulting in a 
prolongation of the action potential. These agents have less effect on the Na+-channels, 
therefore conduction velocity is not changed (Figure 16). 
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Figure 16. Class III anti-arrhythmic drugs increase the cardiac action potential duration by blocking the K+ 
channels. 
 
By maintaining the normal conduction velocity and increasing the refractory period, class III 
anti-arrhythmic drugs may prevent or terminate re-entry arrhythmias. 
Class III agents include amiodarone, azimilide, bretylium, dofetilide, tedisamil, ibutilide, 
sematilide and sotalol. 
 
9.1.4 Class IV agents 
These agents have a blocking effect on the Ca²+-channels which control calcium influx into 
vascular smooth muscle cells and myocytes. As such they shorten phase 2 of the cardiac 
action potential and play a major role in the excitation-contraction cycle, the sino-atrial 
pacemaker activity and AV conduction. All these interactions lead to a reduction in heart rate.  
Class IV drugs are verapamil and diltiazem. 
 
9.1.5 Class V agents 
Because some important anti-arrhythmic drugs could not be classified based on their main 
property in the previous described classes, a new group has been developed in the ‘Vaughan-
Williams’ classification. This class includes digoxin and adenosine.  
Digoxin inhibits the Na+/K+ pump which lead to increased Na+ levels. This in turn slows 
down the extrusion of Ca2+ via the Na+/Ca2+ pump. This effect causes an increase in the 
length of phase 4 and phase 0 of the ventricular action potential. This effect together with an 
increase of the vagal activity via its central action on the central nervous system leads to a 
decrease of the ventricular rate.  
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Adenosine enhances the K+ efflux and inhibits the Ca²+ influx. It produces AV block and an 
indirect effect on the refractory period of atrial tissue. 
 
Human data 
In human medicine class IC is the first choice anti-arrhythmic drug for atrial fibrillation 
whereby a success rate of 90% has been described. However, success rate decreases with the 
duration of AF. Also class III seems to be very effective in the treatment of atrial fibrillation 
and flutter. In contrast class II and IV are described as being less valuable in atrial fibrillation. 
Class IV drugs are more used to control ventricular frequency than for conversion to sinus 
rhythm (Crijns et al., 1999; Kerin et al., 1996; Van Gelder et al., 1999).  
 
Equine data 
Quinidine sulphate (QS), a class IA drug, is the “gold” standard treatment of atrial fibrillation 
in horses. However, the duration of AF and the presence of underlying cardiac disease do 
have an important effect on success rate. For recent-onset AF (less than 2 weeks), quinidine 
gluconate has been recommended whereby boluses of 1-2.2 mg/kg are administered 
intravenously every 10 minutes until effect or until a maximum of 12 mg/kg is reached. 
However, compared to the oral administration, the intravenous administration of quinidine 
has been associated with a higher risk for toxic side-effects. Oral QS medication is the 
pharmacological treatment of choice for AF in horses: QS is administered at 22 mg/kg via 
nasogastric intubation every 2 hours until conversion to sinus rhythm or observation of side 
effects. The therapeutic plasma concentration is 2 to 5 µg/ml. If plasma concentration is more 
than 4.0 µg/ml, treatment intervals should be prolonged up to every 6 hours (Reef, 1999).  
QS treatment has an efficacy of 85% in horses with an AF duration of less than 2 months and 
without detectable cardiac disease (Deem and Fregin, 1982; Reef et al., 1988). Nevertheless, 
in up to 76% of treated horses, side effects including urticaria, nasal oedema, colic, diarrhoea, 
laminitis, anaphylactic shock, hypotension, decreased cardiac contractility, increase in QRS 
duration, tachycardia, ventricular arrhythmias, syncope or sudden death may appear (Reef et 
al., 1988, 1995). When significant side effects occur, QS administration should be 
discontinued. Hypotension can be treated with phenylephrine (0.1-0.2 µg/kg/min to effect) 
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while sustained supraventricular or ventricular tachycardia (< 100 beats/min) is generally 
treated with digoxin (0.0022 mg/kg) but one must be aware that digoxin increases quinidine 
plasma levels. When toxic quinidine signs are observed, intravenous sodium bicarbonate 
should be administered to bind free quinidine. 
 
Intravenous propranolol (0.03 mg/kg), lignocaine (20-50 µg/kg/min) or magnesium sulphate 
(1-2.5 g/450 kg/min) can also be used in horses with quinidine-induced tachycardia to control 
heart rate (Reef, 1999). 
Despite the high success rate, quinidine’s toxicity and the fact that in several countries the 
drug becomes difficult to obtain have stimulated research into alternative therapies.  
 
Intravenous cibenzoline (0.1 mg/kg/min), a class IC drug (with additional class III and IV 
properties), was unsuccessful in a horse with AF and was associated with severe ventricular 
pro-arrhythmia (van Loon, 2003). Intravenous flecainide (2 mg/ kg at 0.2 mg/kg/min), a class 
IC drug, was reported to be effective in horses with acute, experimental AF (Ohmura et al., 
2000) but failed to convert horses with naturally-occurring chronic AF. Horses from the latter 
group even developed potentially dangerous ventricular dysrhythmias (Figure 17) (van Loon 
et al., 2004). 
Figure 17. Continuous ECG recording from a horse showing ventricular dysrhythmia during flecainide 
treatment.  
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Sotalol, a class III drug, has been used in three horses with AF (0.75-1.25 mg/kg IV infusion 
over 15 minutes) and was not associated with side-effects. However, sinus rhythm could not 
be restored (van Loon, 2003). 
Recently, the use of diltiazem (0.125-1.125 mg/kg over 2 minutes), a class IV drug, was 
investigated in healthy horses. The drug induced a dose-dependent suppression of the sino-
atrial node and a decrease in atrial blood pressure, resulting in a slower ventricular response to 
experimentally applied atrial stimuli. The authors of this study hypothesized that the drug 
might be used in horses that show quinidine-induced supraventricular tachycardia 
(Schwarzwald et al., 2005, 2007a) but so far no data are available.  
 
9.2 Non-pharmacological approaches to AF 
In human medicine, the mainstay of managing AF is drug therapy. However, when drug 
therapy is ineffective or not tolerated, a non-pharmacological approach is available whereby 
general anaesthesia is usually required (Scheinman and Morady, 2001). 
 
9.2.1 External electrical cardioversion 
Human data 
Electrical cardioversion is used as treatment of cardiac arrhythmias such as AF, ventricular 
tachycardia, and ventricular fibrillation. The purpose of the direct current shock delivery is to 
depolarize the whole myocardium, bringing it into a refractory state, thereby interrupting re-
entry circuits and thus terminating the arrhythmia. The term ‘defibrillation’ is used for shock 
delivery during ventricular fibrillation. The term ‘cardioversion’ is used for shock delivery 
during atrial fibrillation or ventricular tachycardia. Since some kind of ventricular rhythm is 
still present during cardioversion, shock delivery should be synchronized with the R wave of 
the QRS complex. Indeed shock delivery onto a T wave could induce ventricular fibrillation. 
During external cardioversion the electrical shock is delivered through the chest using two 
paddles or electrodes placed on the skin. One paddle is positioned at the right side of the 
sternum at the level of the first or the second rib while the other paddle is placed at the infra-
clavicular region at the left side of the vertebrae (Figure 18) (Botto et al., 1999). 
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Figure 18. Paddle placement for external electrical cardioversion. One paddle is positioned at the right side of the 
sternum at the level of the first or the second rib and the other paddle is placed at the infra-clavicular region at 
the left side of the vertebrae. 
 
Success rate of external electrical cardioversion for chronic atrial fibrillation ranges from 70-
90% but depends mainly on the transthoracic impedance. As transthoracic impedance is 
correlated with body weight, cardioversion success rate is lower in obese patients (Lévy et al., 
1992). In these patients internal cardioversion is recommended.  
Although the success rate is high, recurrence of AF within 2 weeks after cardioversion is a 
common problem (Tieleman et al., 1998). Therefore, a pre-treatment with an anti-arrhythmic 
drug is recommended because it lowers the vulnerability of the atria. Amiodarone has been 
proven to be successful in preventing immediate recurrence of atrial fibrillation after 
successful electrical cardioversion (Capuci et al., 2000; Crijns et al., 1999; Gorenek et al., 
2006). 
Equine data 
Frye et al. (2002) attempted to use external electrical cardioversion in 2 horses with AF. 
Several attempts were unsuccessful and, finally, only the smallest horse (393 kg), with the 
shortest AF duration (3 weeks), could be converted with a 200 J shock, but this only after pre-
treatment with quinidine sulphate. 
9.2.2 Internal electrical cardioversion 
Human data 
Besides external cardioversion, human patients can be treated with internal, usually 
transvenous, electrical cardioversion. During this procedure, one cardioversion catheter is 
placed high in the right atrium (RA) against the atrial wall and a second is positioned in the 
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coronary sinus (CS) or the left pulmonary artery, which is in close contact with the left 
atrium. Low energy (up to 30 J), R wave synchronized shocks, with one catheter in the RA 
and one catheter in the CS, result in restoration of sinus rhythm in the majority of patients. 
Similar to the external approach, early recurrences of AF (Duytschaever et al., 2000, 2002; 
Lévy et al, 1997; Ricard et al., 2003; Timmermans et al., 1998; Van Noord et al., 2002) can 
be minimized by pre-treatment with anti-arrhythmic drugs such as amiodarone.  
 
Equine data 
Successful internal cardioversion under general anaesthesia has been described in horses 
(McGurrin et al., 2003, 2005; van Loon, 2001). Placement of the catheters, into the right 
atrium and left pulmonary artery, was performed in the standing, sedated animal. Mean 
cardioversion energy was 162.2+/-10.2 joule. Despite the importance of early recurrence of 
AF in human patients, this problem has not been reported in horses yet. This might be 
explained by the fact that during conventional QS treatment, the therapeutic drug level at the 
time of conversion prevents AF to reoccur. 
 
9.2.3 Ablation of AF  
Human data 
Ablation is defined as the removal of material of the surface of an object by vaporization, 
chipping or other erosive processes. Ablation therapy using radiofrequency waves in the heart 
is used to cure cardiac arrhythmias. In this context, the term ablation is often used as laser 
ablation, a process by which the molecular bonds of a material are dissolved by a laser. 
In human patients catheter ablation is used for both rate and rhythm control of AF. The 
procedure can usually be performed using sedatives and local anaesthetics. 
 
9.2.4 Atrioventricular junction ablation 
With this procedure, an ablation catheter is transvenously inserted and positioned at the 
atrioventricular node using fluoroscopy. Using radiofrequency energy, the atrioventricular 
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junction is destroyed resulting in atrioventricular block. Consequently, a permanent 
pacemaker is required to maintain a normal ventricular function. This procedure does not 
terminate atrial fibrillation, but is a form of rate control. This procedure is used in 
symptomatic patients with AF who are refractory to treatment with several anti-arrhythmic 
drugs and have an uncontrolled ventricular rate (Scheinman and Morady 2001). 
 
9.2.5 Linear catheter ablation 
This technique has been developed based upon the re-entry theory and attempts to decrease 
the number of wavelets by decreasing the amount of continuous, vulnerable atrial tissue. 
Linear interruptions are made in the right or left atrial myocardium (Scheinman and Morady, 
2001). However, success rate only ranges from 0 to 58% (Ernst et al., 1999; Haissaguerre et 
al., 1996; Pappone et al. 1999). 
 
9.2.6 Focal catheter ablation 
In a similar way multiple electrode catheters can be inserted in the atria to register the 
activation patterns. These are used to check for ectopic foci in the atria that are responsible for 
initiation of AF. Once an ectopic focus is determined, this site is ablated to prevent further 
discharge and thus AF. In 95% of the cases the focus is located within the pulmonary vein but 
other sites include right atrium, left atrium, coronary sinus, superior vena cava or vein of 
Marshall (Shah et al., 1999). Success rate ranges between 62 and 86% and in 7 to 75% of the 
cases a second or third attempt of ablation is required (Chen et al., 1999; Haissaguerre et al., 
1998) because of the presence of multiple foci (Scheinman and Morady, 2001).  
 
9.2.7 Segmental or total pulmonary vein ablation 
Ectopic foci are located in the pulmonary veins in 95% of the patients, therefore total or 
partial ablation of the ostia of the pulmonary veins is performed (Figure 19). This ablation 
around the entrance site of the pulmonary vein into the left atrium prevents the electrical 
pulses, coming from an ectopic focus in the pulmonary vein, to be transferred to the atrial 
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myocardium. Success rate ranges from 67 and 90% for patients with paroxysmal AF and 60 to 
67% for patients with chronic AF (Natale et al., 2000; Lau et al., 1999). 
Figure 19. Illustration of pulmonary vein ablation.  
 
RA: right atrium. VC: vena cava. SN: sinus node. AVN: atrio-ventricular node. LA: left atrium. LV: left 
ventricle. PV: pulmonary veins; AC: ablation catheter. TV: tricuspid valves. MV: mitral valves. 
 
 
 
Equine data 
Ablation requires very precise positioning of a catheter in the heart. Due to technical 
limitation and the large equine thorax, fluoroscopy does seldom allow such accurate 
positioning. Overlying lung tissue and the fact that apical echocardiographic views cannot be 
obtained in mature horses, hamper an ultrasound-guided approach. In addition, for the same 
reasons, an ectopic focus cannot be localised in horses. Therefore, catheter ablation cannot be 
performed in horses with AF, at present. 
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SCIENTIFIC AIMS 
 
 
Despite the importance of atrial fibrillation (AF) in horses and extensive research about 
electrical and contractile remodeling in goats and dogs, little is know about AF 
pathophysiology in horses. Indeed, when horses are referred to clinic, the exact duration of 
AF is usually unknown. In addition, the presence of predisposing factors cannot fully be ruled 
out by the clinical exam, serum biochemistry and cardiac ultrasound. As such, studying AF 
pathophysiology in horses with natural AF development is difficult because many unknown 
factors might be present. These inconveniences can be overcome by studying healthy horses 
in which AF is experimentally induced and maintained. As such, an exact AF duration can be 
chosen, and baseline values can be compared with values during maintained AF and after 
restoration of sinus rhythm. Acute AF-associated remodeling provides information about the 
acute phase of AF and could be applicable to paroxysmal AF. More long-term remodeling is 
important to understand alterations that occur with chronic AF and especially to investigate 
the reverse remodeling process after restoration of sinus rhythm. This information is 
important, not only for diagnosis and treatment, but especially for prognosis and aftercare 
after cardioversion.  
 
Therefore, the first aim of our study (Section 1) was to study the electrical and contractile 
remodeling associated with AF in healthy horses, as a result of both an acute (Chapter 1) and 
a chronic (Chapter 2) AF episode. 
 
Because ‘lone’ AF horses have a good prognosis after conversion of AF allowing them to 
return to full competition, rhythm control is indicated in most horses. Nevertheless, the most 
commonly used drug for AF treatment in horses, quinidine sulphate, is becoming difficult to 
obtain in many countries. In addition, toxic side effects are commonly encountered during 
quinidine treatment. In human medicine, quinidine has almost completely disappeared as 
pharmacological treatment. Many other less toxic but still effective drugs for rhythm control 
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are nowadays available. In addition, especially in drug refractory AF human patients, 
electrical cardioversion of AF has become a mainstay in the treatment of AF.  
 
As such, the second aim of our study was to investigate new pharmacological (Section 2) and 
non-pharmacological (Section 3) approaches for the treatment of AF in horses. Drugs used in 
human medicine, such as propafenone (Chapter 3) and amiodarone (Chapter 4, 5 and 6) were 
evaluated as pharmacological treatment of AF in horses. Finally, custom-made cardioversion 
catheters were developed to achieve transvenous electrical cardioversion of AF in horses 
(Chapter 7). 
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In human medicine, paroxysmal atrial fibrillation (AF) induces electrical, contractile and 
structural remodeling leading to AF stabilisation. Little is known about atrial remodeling 
during AF in horses. The hypothesis was that induced AF produces rapid atrial electrical and 
contractile remodeling in horses. 
In six horses a pacemaker and a neurostimulator were implanted. With the latter burst pacing 
was used to induce AF for 7 days, the pacemaker was used to study atrial and ventricular 
electrophysiology (atrial fibrillation cycle length [AFCL], AF duration and atrial and 
ventricular effective refractory period [AERP and VERP] at different pacing cycle lengths 
[PCL]). Contractile remodeling of atrium and ventricle were assessed with calculation of 
fractional shortening (FS). Measurements were performed at baseline, a 7-day AF-period and 
a 2-day recovery period.  
Within 4 and 12 hours, AF resulted in atrial electrical and contractile remodelling. During the 
AF period a progressive shortening of the AERP (261±39ms to 171±18ms at a PCL of 
1000ms, p<0.0001), an attenuation of the AERP rate adaptation and a decrease in AFCL 
(239±39ms to 194±7ms, p<0.0001) occurred. AF duration increased progressively and 
became persistent in two animals. VERP did not change significantly. AF resulted in a 
progressive decrease in atrial FS occurred (12±3% to 0±2%, p<0.05). Upon restoration of 
sinus rhythm, values returned to baseline within 48 hours. 
Atrial electrical and contractile remodeling appears rapidly. Reverse remodeling occurred 
within 2 days. These observations suggest that early conversion of AF might be beneficial for 
success rate and early returning to training. 
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Introduction 
In human patients the natural history of atrial fibrillation (AF) is characterized by an evolution 
from short self terminating episodes of AF (paroxysmal AF) to longstanding episodes of AF 
requiring pharmacological or electrical cardioversion (persistent AF). If no attempts to restore 
sinus rhythm are made, AF becomes permanent (Fuster et al., 2006).  Epidemiological data 
suggest that 29% of the patients with paroxysmal AF without underlying heart disease 
progressed to permanent AF within 15-30 years (Jahangir et al., 2007).  This evolution from 
paroxysmal to permanent AF is caused by electrical, contractile and structural changes and 
their interaction (Allessie et al., 2002; Morillo et al., 1995; Schotten and Allessie, 2001; 
Schotten et al., 2003; van Loon et al., 2001a; 2001b; Wijffels et al. 1995). Human data and 
experimental work in dogs, goats and ponies, has shown that AF results in shortening of the 
atrial effective refractory period (AERP), attenuation of the AERP rate adaptation and 
reduction of the atrial contractile function (Morillo et al., 1995; van Loon et al., 2001; 
Wijffels et al., 1997). Schwarzwald and co-workers (2007), described that contractile 
remodeling also occurs in horses with chronic naturally-occurring AF. van Loon et al. (2001) 
described that, after 6 months of experimentally induced AF in ponies, electrical and 
contractile reverse remodeling occurred after 10 days and 1-2 months, respectively. 
In human patients and in dog and goat models of AF, structural changes such as alterations in 
gap-junctions, myolysis, disruption of the sarcoplasmatic reticulum, accumulation of glycogen 
or evidence of apoptosis and fibrosis, might occur if AF exists for more than 5 weeks 
(Ausman et al., 1997; Elvan et al., 1997; Li et al., 1999). Light and electron microscopic 
results of transvenously taken atrial biopsies of ponies with 6 months of experimentally 
maintained AF revealed no structural changes such as myolis (van Loon et al., 2002a). 
In a hospitalized population the prevalence of AF with unknown duration approaches 2.5% 
(Else and Holmes, 1971). The prevalence of paroxysmal AF in finishing racehorses is 0.29% 
while it is 1.39% in slow finishing and non-finishing racehorses (Ohmura et al., 2003). 
Whether repeated bouts of paroxysmal AF in horses promote persistence of the arrhythmia by 
atrial remodeling is yet unknown. Although it has been suggested that AF duration influences 
cardioversion success rate and quinidine associated side effects (Reef et al., 1988; Reef et al., 
1995), little is known about AF remodeling and its time-course.  
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We hypothesize that, in horses, AF results in rapid electrical and contractile remodeling. In 
horses with naturally-occurring AF the exact duration of the arrhythmia is generally unknown 
and distinct underlying pathology cannot be ruled out. Therefore, in the current study, an 
experimental AF model in healthy horses was used to allow baseline measurements, to know 
exact AF duration, to make repeated measurements during the AF period and to rule out 
underlying disease. As such, the observed alterations were attributable to AF. 
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Material and Methods 
The study was performed at the University of Ghent (Belgium) and was supported by the 
Special Research Fund, Ghent University (Belgium). This research was approved by the 
Ethics Committee of the Faculty Veterinary Medicine, Ghent University (Belgium). 
Animals and study protocol 
Six healthy trotter horses with a mean±SD age of 4.0±0.8 years, a mean weight of 473±32 kg 
and a mean height at the withers of 157±2 cm, were studied. A clinical examination, a 
complete blood analysis, electrocardiography and echocardiography including two-
dimensional, M-mode and Colour Flow Doppler were performed to exclude animals with 
underlying heart disease. 
In all horses, a dual chamber pacemaker (Thera D(R), Medtronic), a neurostimulator 
(SoletraTM 7426, Medtronic) and leads (Fineline® II, Guidant) were implanted as previously 
described by van Loon et al. (2002b). With the neurostimulator, intermittent burst pacing (1 
second; 3 times threshold, 20 Hz, every 2 seconds) was applied to induce bouts of AF. The 
dual chamber pacemaker was used to study atrial and ventricular electrophysiology. 
The study consisted of 3 study periods: a baseline period, a 7-day AF-period and a 2-day 
recovery-period. In each period repeated electrophysiological and echocardiographic 
measurements were performed in the unsedated horse within 20 minutes after spontaneous 
restoration of sinus rhythm. For the latter, under continuous telemetric ECG monitoring, the 
neurostimulator was temporarily switched off to allow sinus rhythm to restore spontaneously. 
After these measurements, the pulse generator was immediately switched on for further 
maintenance of AF. 
At the end of the 7-day AF-period, the pulse generator was permanently switched off to allow 
permanent restoration of sinus rhythm. If spontaneous conversion to sinus rhythm did not 
occur within 3 days, flecainide (Tambocor®, 150 mg/15mL, Meda Pharma) was administered 
at 0.2 mg/kg/min up to a maximum total dose of 2 mg/kg (Ohmura et al., 2000). Before, 
during and up to 6 hours after drug administration, clinical status, intra-atrial and surface 
electrocardiograms were monitored. Prior to the pharmacological treatment, haematological 
and biochemical blood analysis was performed and electrolyte concentrations were 
determined.  
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After the administration of intravenous flecainide, all data collected within the first 6 hours, 
which is the elimination half-life of flecainide, were excluded from the study to avoid 
pharmacological interference.  
 
Electrophysiological measurements 
At baseline, during the AF-period and during the recovery-period, atrial effective refractory 
period (AERP) and ventricular effective refractory period (VERP) were measured at three 
times threshold amplitude. During pacing with a fixed pacing interval (S1-S1) an extra 
stimulus (S2) was introduced with a coupling interval (S1-S2) below the expected refractory 
period. The coupling interval was then increased in steps of 8 ms until capture of the extra 
stimulus occurred (the atrial or ventricular S2 was followed by a P wave or QRS complex on 
the surface ECG, respectively). The longest S1-S2 interval without capture was taken as the 
effective refractory period. AERP was measured at pacing cycle lengths (PCL) of 1000ms (60 
beats/min), 800ms (75 beats/min), 500ms (120 beats/min) and 333ms (180 beats/min). VERP 
was measured at PCL of 1000ms, 800ms and 500ms. A 2-minute adaptation was allowed at 
each pacing cycle length.  AERP and VERP were always determined 3 times to obtain a mean 
value. The heart rate was measured during AF and after restoration of sinus rhythm.  
AF duration was measured as the time between disabling the neurostimulator and spontaneous 
conversion to sinus rhythm. The AFCL was measured as an average time between two 
successive atrial depolarisation waves during a 10s atrial intracardiac electrogram obtained 
from the pacemaker (Morillo et al., 1995).  
Time points of all measurements, before, during the AF-period and during the recovery period 
are illustrated on Figures 3-6.  
 
Echocardiographic views and measurements 
Echocardiographic views were obtained using standardised imaging techniques with a 2.5 
MHz sector transducer with a maximal depth of penetration of 30 cm (GE Vingmed CFM 800 
SV). A single-lead electrocardiogram was recorded simultaneously. Recordings were stored 
on digital MO-disks and on video tape for retrospective analysis. 
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Every echocardiographic variable was determined from 5 different cardiac cycles to obtain a 
mean value. All echocardiographic measurements were performed on 5 different days at 
baseline and after 12, 24, 36, 48, 60, 72, 96 and 168 hours of maintained AF (both during AF 
and during sinus rhythm) and after 12, 24, 36, and 48 hours after termination of the AF-
period. Cycles during and immediately after a second-degree atrioventricular block or a 
spontaneous atrial premature beat were excluded from analysis. During AF, cardiac cycles 
with an RR interval between 1333 to 1090 ms (45 to 55 beats/min) were selected. 
Left atrial (LA) internal diameters (LAD) and LA cross-sectional area (LAA) were measured 
from a right parasternal long-axis view. LAD was measured from the interatrial septum, close 
to the mitral annulus to the atrial free wall (Figure 1). For every cardiac cycle 4 time points 
were determined to perform these measurements: point “p” was at the onset of the P wave; 
point “a” was during maximal atrial contraction, point “d” was at the end of the ventricular 
diastole and point “s” was at the end of ventricular systole. Due to the absence of an atrial 
contraction, point “p” and “a” could not be determined during AF. 
Left atrial fractional shortening (LA-FS) was calculated as suggested by Piotrowski et al. 
(2000) with the following formula:  
100
LADp
LADa - LADp
FS%-LA ×=  
Left atrial fractional area change (LA-FAC) was calculated as suggested by Piotrowski et al. 
(2000) with the following formula:  
100
LAAp
LAAa - LAApFAC%-LA ×=  
On the right parasternal short-axis view of the LA and aorta, internal diameters of the LA and 
the aorta were obtained (Figure 2). For the internal short-axis diameter of the LA (LAsx) 
callipers were placed in a line extending from and parallel to the commissure between the 
noncoronary and left coronary aortic valve cusps to the distant margin of the left atrium. For 
the internal short-axis diameter of the aorta at valvular level (AODV), callipers were placed 
along the commissure between the noncoronary and right coronary aortic valve cusps. For 
each time point (p, a, d, s) during the cardiac cycle the ratio LAsx/AODV was calculated 
(Young, 2004).  
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On a standard M-mode of the ventricles the left ventricular internal diameter, the 
interventricular septal thickness and the left ventricular free wall thickness were measured in 
diastole and systole and the left ventricular FS was calculated. 
Colour Flow Doppler examinations of the mitral, tricuspid, aortic and pulmonic valves were 
performed.  
 
Statistical analysis 
Data are shown as mean ± standard deviation. All analyses were based on the mixed model 
with horse as random effect and time as categorical fixed effect. All time points were 
compared with the baseline value at time zero, using Dunnett’s method to adjust for multiple 
comparisons and a global significance level of 5%.  
Chapter 1: Remodeling and reverse remodeling associated with short-term AF 
 
53 
Figure 1. On the right parasternal long-axis view, latero-lateral left atrial diameter (LAD) was measured from the 
lateral free wall to the interatrial septum. The circular line represents the left atrial cross-sectional area (LAA). 
RA: right atrium. RV: right ventricle. TV: tricuspid valve. LA: left atrium. LV: left ventricle. MV: mitral valve. 
IVS: interventricular septum 
 
Figure 2. A right parasternal short-axis view of the left atrium and aorta. The diameter of the left atrium (LAsx) 
and aorta (AODV) were obtained. To measure the internal short-axis diameter of the aorta calipers were placed 
along the commissure between the noncoronary and right coronary aortic valve cusps. To obtain the internal 
short-axis diameter of the left atrium (LAsx), calipers were placed in a line extending from and parallel to the 
commissure between the noncoronary and left coronary aortic valve cusps to the distant margin of the left 
atrium.  
 
RA: right atrium. RV: right ventricle. TV: tricuspid valve. LA: left atrium. RC: right coronary aortic cusp. LC: 
left coronary aortic cusp. NC: non-coronary aortic cusp.   
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Results 
In all horses, AF could be successfully induced and maintained using the intermittent burst 
pacing protocol.  During the AF period, when spontaneous restoration of sinus rhythm was 
temporarily allowed, two horses showed occasional atrial premature beats. These premature 
beats were no longer encountered after 4 to 5 days of recovery. 
At the end of the AF period 2 horses were in persistent AF. Blood analysis and electrolyte 
concentrations were within normal reference ranges. In one horse sinus rhythm could be 
restored without any side effects after administration of 1 mg/kg flecainide intravenously. In 
the other horse sinus rhythm did not be restored after 2 mg/kg flecainide IV. Five minutes 
after termination of the flecainide infusion, without any preceding signs, this horse suddenly 
developed wide-QRS tachycardia, which degenerated to ventricular fibrillation and resulted in 
sudden death of the animal. As such, no data from the recovery period of this horse were 
available. 
 
Electrophysiological measurements 
In each horse, threshold for stimulation remained similar throughout the study.  During the AF 
period a slight but significant increase in heart rate (p<0.01) was observed (both during AF 
and during sinus rhythm) compared to baseline (Figure 3).   
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Figure 3. Mean (±SD) heart rate (beats/min), echocardiographic and contractile parameters at baseline (n=6), 
during the atrial fibrillation period ( ) (n=6) and during the recovery period ( ) (n=5) in horses. 
Echocardiographic parameters are measured at time points p (the onset of the atrial contraction) and a (during 
maximal atrial contraction). 
 SR: measurements taken during (temporarily restored) sinus rhythm. AF: measurements taken when atrial 
fibrillation is present. LAD: left atrial diameter. LAA: left atrial cross-sectional area. LA-FS: left atrial fractional 
shortening. LA-FAC: left atrial fractional area change. * significantly different from baseline value (p<0.05). 
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Atrial fibrillation 
AF duration varied substantially but increased progressively during the AF period and 
progressed into persistent AF in two horses (Figure 4). After 4 hours of maintained AF, AFCL 
was 239±39 ms and decreased to 194±7 ms after 7 days of AF (p<0.0001) (Figure 5).  
 
Figure 4. Atrial fibrillation (AF) duration (s) of each horse (n=6) after switching off the neurostimulator during 
the AF period. AF duration varied substantially but increased progressively during the AF period. 
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Figure 5. Mean (±SD) atrial fibrillation cycle length (AFCL) of horses (n=6) during the AF-period ( ). ( ) 
recovery-period. * significantly different from first measured value (p<0.05). 
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Atrial electrophysiology 
Results are given in Figure 6. At baseline, AERP was 261±39 ms, 260±38 ms, 253±28 ms and 
233±25ms at a PCL of 1000, 800, 500 and 333 ms, respectively. During the maintained AF-
period the AERP at a PCL of 1000, 800, 500 and 333 ms shortened significantly from 12 
(p<0.001), 4 (p<0.01), 8 (p<0.01), and 32 (p<0.05) hours onwards, respectively. After seven 
days of maintained AF, AERP had decreased to 172±18 ms, 167±11 ms, 171±11 ms and 
156±9 ms at a PCL of 1000, 800, 500 and 333ms, respectively (Figure 6 A, B and D). A 
decrease in rate adaptation could be observed (Figure 6 D). Normalisation of AERP was 
observed within 24 hours after permanent restoration of sinus rhythm (Figure 6 A, B and D). 
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Figure 6. Mean (±SD) atrial effective refractory period (AERP) at a pacing cycle length of 333 (-O-), 800 ms 
(-▼-) (A) and 1000 (-■-), 500 ms (-∆-) (B) and ventricular refractory period (VERP) at a pacing cycle length of 
500 (--), 800 (-+-) and 1000 ms (-X-) (C) at baseline (n=6), during the AF-period ( ) (n=6) and during the 
recovery-period ( ) (n=5) in horses. An attenuation in rate adaptation occurs as a result of atrial fibrillation (D). 
The first two points during the recovery period were obtained from 4 horses to avoid interference of flecainide 
treatment in the fifth horse. 
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*Significantly different from baseline value (p<0.05). 
. 
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Ventricular electrophysiology  
The VERP was 377±32 ms, 340±24 ms and 263±20 ms for a PCL of 1000, 800 and 500 ms, 
respectively. During the AF-period, a mild shortening in VERP was observed (Figure 6C). 
VERP measurement was never associated with repeated ventricular responses.  
 
Echocardiographic measurements 
Atrial diameters, cross-sectional, atrial FS, atrial FAC at baseline, during the AF period and 
during the recovery period are shown in Figure 3 and 7. 
The LA-FS and LA-FAC decreased significantly within 12 to 24 hours of maintained AF 
(P<0.05). After 7 days of AF, LA-FS and LA-FAC had both decreased with 100% or more, 
whereby sometimes negative values were obtained (Figure 3).  Within 48 hours of recovery 
measurements attained mean values close to the baseline value. 
End-diastolic (d) measurements of LA diameter and AODV showed no significant differences 
throughout the study. A significant decrease (P<0.01) of all LA measurements at time point 
“s” was observed from 12 hours of AF onwards and  normalised between 24 to 48 hours after 
restoration to sinus rhythm. 
The ratio LAsx/AOD measured at each time point during the cardiac cycle remained below 1.2 
(Young, 2004). 
No significant changes were detected in the interventricular septum thickness, left ventricular 
free wall thickness, left ventricular internal diameters and left ventricular fractional 
shortening. 
Colour Flow Doppler of all valves revealed no differences compared to baseline. 
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Figure 7. Mean (±SD) echocardiographic parameters at baseline (n=6), during the atrial fibrillation (AF) period 
( ) (n=6) and during the recovery period ( ) (n=5) in horses. Echocardiographic parameters are measured at 
time points d (at the end of ventricular diastole) and s (during maximal ventricular contraction). During the AF-
period parameters are determined both in sinus rhythm (SR) and in AF (AF). 
 
LAD: left atrial diameter. LAA: left atrial cross-sectional area. * significantly different from baseline value 
(p<0.05). 
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Discussion 
The major findings of the study are as follows: (1) a short period of AF in horses (>12 hours) 
results in atrial electrical and contractile remodeling; (2) AFCL decreases more slowly and 
more time is required to develop persistent AF; (3) electrical reverse remodeling is complete 
within 24 hours while contractile reverse remodeling occurs more slowly.  
 
The atrial burst pacing model of AF 
The burst pacing protocol proved to be feasible and effective to induce and maintain AF in 
horses and was supposed to mimic naturally-occurring AF because of a similar degree in atrial 
contractile dysfunction (Schwarzwald et al., 2007). Besides measurements obtained during 
AF, the spontaneous restoration of sinus rhythm after induction of AF allows making both 
electrophysiological and echocardiographic measurements during normal sinus rhythm. In 
addition, all measurements can be performed in the unsedated horse so any drug interference 
can be avoided. Furthermore, in contrast to humans, dogs and goats, atrial fibrillation in 
horses is accompanied with only a slight increase in heart rate most likely related to a high 
vagal tone (Hnatkova et al., 1998; King et al., 2002; Miller et al., 1999; Silbauer and Sulke, 
2007). 
 
AF induced electrical remodeling 
Similar to humans, dogs, goats and ponies, AF resulted in a shortening of the AERP and an 
attenuation of the AERP rate adaptation (Morillo et al., 1995; van Loon et al., 2001b; Wijffels 
et al., 1995). These changes increase the propensity to develop persistent AF as was observed 
in two horses. Different theories have been proposed to explain the mechanism of AF 
primarily based upon ectopic foci, the presence of multiple re-entry waves, the leading circle 
concept or the presence of rotors and spiral waves (Allessie et al., 1973; Engelman et al., 
1986; Jalife et al., 2002; Lewis et al., 1912; Moe, 1962). The sustainability of AF might 
depend on the possibility of the atrium to maintain a critical number of re-entry circuits (Moe, 
1962). This in turn is dependent on (1) the atrial dimensions and on (2) the size of the reentry 
circuits. The size of the circuit is expressed as the wavelength (WL) and is defined by the 
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product of the AERP and the conduction velocity (CV) (WL=AERP • CV). It is known that if 
AERP decreases, wavelength decreases and AF will more easily become sustained (Allessie 
et al., 1985). This phenomenon is amplified by the larger atrial dimensions of the horse 
compared to goats and ponies. Interestingly the two horses that developed persistent AF had 
the largest atria.  
During this short-term AF protocol, a decrease in AFCL was observed. This decrease might 
be explained by the shortening of the AERP with the duration of AF or due to a slowing of 
conduction. Recent data by Allessie (personal communication) however suggest that even 
during chronic AF, conduction velocity during AF is not decreased. 
In the present study we did not investigate the underlying mechanism leading to electrical 
remodeling but this is most probably related to an increase in intracellular calcium 
concentration resulting in a reduction of the action potential duration and refractory period 
(Courtemanche et al., 1998; Allessie et al., 2002).  
 
AF induced contractile remodeling 
Twelve hours of maintained AF resulted already in a significant reduction of atrial contractile 
function that further decreased during the following 7 days. The initial decrease in LA 
diameter and area at time point “s” might be explained by the small increase in heart rate 
resulting in a reduced atrial filling time. However, it is unlikely that this phenomenon is 
completely responsible for a reduction in atrial contractile function (due to reduced filling) 
since during the next days a further decrease in contractile function is present without further 
increase in heart rate.   
After a short period of induced AF the different LAsx1/AODV ratio’s stayed within normal 
references (<1.2) (Young, 2004). The influence of long standing AF on these ratio’s remains 
to be investigated but data in humans and ponies suggest that chronic AF results in an increase 
in left atrial size (Sanfilippo et al 1990, van Loon et al., 2001b)  
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AF induced ventricular remodeling 
A short period of atrial fibrillation did not influence ventricular contractile function or 
ventricular electrophysiology. The latter can be explained by the fact that, in horses, the 
increase in ventricular rate during AF was very small compared to most other species. Indeed, 
in human patients, it has been suggested that AF-associated ventricular electrical remodeling 
was caused by changes in ventricular rate, not by the arrhythmia per se (Manios et al. 2005).  
 
Conclusions and clinical implications 
In an experimental short-term (1week) AF model, AF leads to rapid electrophysiological and 
contractile remodeling that might result into self-sustaining, persistent AF in some horses. 
Upon restoration of sinus rhythm, reverse remodeling occurs within a few days. These 
observations suggest that early conversion of AF might be beneficial for success rate and 
early returning to training. However,, in clinical cases, additional factors, such as individual 
variation or subtle myocardial disease (fibrosis), might complicate the course of AF. 
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Summary 
A previous study has shown that a brief episode (<7 days) of atrial fibrillation (AF) in horses 
is associated with electrical and contractile remodeling. Reverse remodeling was complete 
within 2 days. However, little is known about remodeling and reverse remodeling after long-
term AF in horses.  
In four healthy horses a pacemaker and neurostimulator were implanted. AF was induced with 
the neurostimulator and maintained by applying intermittent burst pacing for 4 months. 
Before, during and after the 4-month AF-period, atrial electrophysiology and atrial contractile 
function were studied.  
Significant atrial electrical and contractile remodeling was observed starting from 24-48 hours 
respectively. Upon restoration of sinus rhythm after 4 months of AF, atrial electrical reverse 
remodeling was complete within 3 weeks. In contrast, atrial contractility and left atrial 
diameter only normalized after 2 months.  
Four months of pacing-induced AF results in completely reversible electrical and contractile 
remodeling. However, 2 months are necessary for full recovery of atrial contractile function. 
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Introduction 
Atrial fibrillation (AF) is the most clinically important supraventricular arrhythmia in horses 
(Deem and Fregin 1982; Reef et al. 1988; Reef and McGuirk 2002). This arrhythmia is 
frequently detected as an incidental finding because symptoms are not always obvious, 
especially in pleasure horses, although a history of exercise intolerance, exercise-induced 
epistaxis, respiratory disease, weakness or syncope may be present (Deem and Fregin 1982, 
Reef and McGuirck 2002). In many cases, AF exists already for several weeks or months 
before horses are treated. AF duration has been reported to influence the success rate of 
treatment (Reef et al. 1988). In human literature, it is described that AF is a self-promoting 
electrical disease because of electrical and contractile remodeling, and that successful 
pharmacological or electrical treatment becomes more difficult the longer AF exists (Gold et 
al. 1986; Allessie et al. 2002; Schotten et al. 2003). However, little information is available 
about electrophysiological and contractile changes in horses with chronic AF.  
Recent information about electrophysiological and contractile remodeling and reverse 
remodeling of short-term AF (7 days) in healthy horses has been described (De Clercq et al. 
2008). In this study, significant atrial electrical and contractile remodeling was observed from 
4 and 12 hours onwards, respectively. After restoration of sinus rhythm reverse remodeling 
was completed within 2 days. This study suggested that horses successfully treated for recent-
onset AF only require a short resting period before returning to training. However, because in 
clinical circumstances many horses suffer from an AF-duration of more than 7 days, 
information is needed about electrical and contractile remodeling and reverse remodeling of 
long-term AF. In general, knowledge about AF in horses is gathered from equines with 
naturally occurring AF. The exact duration of the arrhythmia is usually not known and it is 
not always clear if these horses have distinct underlying cardiac pathology.  
The purpose of the study was to investigate atrial electrophysiological changes and 
echocardiographic alterations and recovery in healthy horses during a 4-month lasting period 
of pacing-induced AF and after permanent restoration of sinus rhythm. 
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Materials and methods 
The study was performed at Ghent University (Belgium) and was supported by the Special 
Research Fund, Ghent University (Belgium). This research was approved by the Ethics 
Committee of the Faculty Veterinary Medicine, Ghent University (Belgium). 
 
Animal and study protocol 
Four healthy trotter horses with a mean age of 4.5±0.6 years, a mean weight of 482±22 kg and 
a mean height at the withers of 156±3 cm, were studied. A clinical examination, a complete 
blood analysis, electrocardiography and echocardiography including two-dimensional, M-
mode and Colour Flow Doppler, were performed to exclude animals with underlying heart 
disease. 
In all horses, a dual chamber pacemaker and a pulse generator were implanted as previously 
described by van Loon et al. (2002). After implantation a recovery period of 2 months was 
respected before starting the study.  
With the pulse generator, intermittent burst pacing (3 times threshold, 20 Hz, 1s every 2 
seconds) was performed to induce bouts of AF. The dual chamber pacemaker allowed 
studying atrial and ventricular electrophysiology. 
The study consisted of 3 study periods: a baseline period, a 4-month lasting AF-period and a 
2-month lasting recovery-period. Throughout the study measurements were performed in the 
unsedated horse. If needed, a temporary pacing catheter was introduced through an introducer 
sheath (De Clercq et al., 2008b).  
During the AF-period, measurements were performed during AF, but also during sinus 
rhythm. For the latter, under continuous telemetric ECG monitoring, the pulse generator was 
temporarily switched off to allow sinus rhythm to restore spontaneously. Within 20 minutes 
after spontaneous restoration of sinus rhythm measurements during sinus rhythm were 
performed. After termination of the examination, the pulse generator was immediately 
switched on again for further maintenance of AF. 
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However, atrial fibrillation became persistent in all horses during the 4-month maintained AF-
period. As such, switching off the pulse generator did no longer result in spontaneous 
restoration of sinus rhythm. The pulse generator was permanently switched off from the time 
that permanent AF was present. In order to terminate AF at the end of the 4-month AF-period 
each horse was treated with quinidine sulphate (QS) orally (22 mg/kg by nasogastric 
intubation every 2 hours) until sinus rhythm occurred, until adverse side effects appeared or 
when a maximum daily dose of 132 mg/kg was reached. 
 
Electrophysiological measurements 
To study the atrial and ventricular effective refractory period (AERP, VERP) a programmed 
electrical stimulation study was performed at 3 times the baseline threshold amplitude for 
stimulation. During pacing with a fixed pacing interval (S1-S1) an extra stimulus (S2) was 
introduced with a coupling interval (S1-S2) below the expected refractory period. The 
coupling interval was then prolonged in steps of 8 ms until capture of the extra stimulus 
occurred, i.e. the atrial or ventricular S2 was followed by a P wave or QRS complex on the 
surface ECG. The longest S1-S2 interval without capture was taken as the AERP or VERP. 
AERP was measured at pacing cycle lengths (PCL) of 1000 ms (60 beats/min), 800 ms (75 
beats/min), 500 ms (120 beats/min) and 333 ms (180 beats/min). VERP was measured at PCL 
of 1000ms, 800ms and 500ms. A 2-minute interval was respected between each measurement 
at each pacing cycle length. Refractory periods were measured on 10 separate days during the 
baseline period, after 1, 2, 3, 4, 7, 14, 21, 45, 60, 90 and 120 days of AF during the AF-period, 
directly after conversion to sinus rhythm with QS and after 1, 2, 3, 4, 7, 10, 14, 21, 30, 45 and 
60 days of the recovery-period.  
At the same time intervals before, during and after the AF-period, heart rate and atrial 
fibrillation cycle length (AFCL) were measured. The AFCL is the time between two 
successive atrial depolarization waves and was measured from a 10s atrial electrogram.  
AF duration was measured as the time between disabling the neurostimulator and spontaneous 
conversion to sinus rhythm. 
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Echocardiographic views and measurements 
Echocardiographic views were obtained using standardized imaging techniques with a 2.5 
MHz sector transducer at a depth of 30 cm (GE Vingmed CFM 800 SV). A single-lead 
electrocardiogram was recorded simultaneously. Recordings were stored on digital MO-disks 
and on video tape for retrospective analysis. 
Every echocardiographic variable was determined from 5 cardiac cycles to obtain a mean 
value. All echocardiographic measurements were performed on 5 different days at baseline 
and after and after 1, 2, 4, 7, 14, 21, 30, 45, 60, 92, 120 days of maintained AF (both during 
AF and during sinus rhythm) and after 1, 2, 3, 4, 7, 14, 21, 30, 45 and 60 days after 
termination of the AF-period. Cycles during and immediately after a second-degree 
atrioventricular block or a spontaneous atrial premature beat were excluded from analysis. 
During AF, cardiac cycles with an RR interval between 1333 to 1090 ms (45 to 55 beats/min) 
were selected to make ultrasonographic measurements. 
Left atrial (LA) internal diameters (LAD) and LA surface (LAS) were measured from a right 
parasternal long-axis view. LAD was measured from the interatrial wall, close to the mitral 
annulus to the atrial free wall (Figure 1). For every cardiac cycle 4 time points were 
determined to perform these measurements: point “p” was at the onset of the P wave; point 
“a” was during maximal atrial contraction, point “d” was at the end of the ventricular diastole 
and point “s” was at the end of ventricular systole. Due to the absence of an atrial contraction, 
point “p” and “a” could not be determined during AF. 
The percentage of left atrial fractional shortening (LA-FS)(%) was calculated with the 
following formula:  
100
LADp
LADa - LADpFS-LA ×=  
The percentage of left atrial fractional area change (LA-FAC)(%) was calculated with the 
following formula:  
100
LASp
LASa - LASpFAC-LA ×=  
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On the right parasternal short-axis view of the LA and aorta, internal diameters of the LA and 
the aorta were obtained. For the internal short-axis diameter of the LA (LAsx) calipers were 
placed along a line extending from and parallel to the commissure between the noncoronary 
and left coronary aortic valve cusps to the distant margin of the left atrium. For the internal 
short-axis diameter of the aorta (AOD), calipers were placed along the commissure between 
the noncoronary and right coronary aortic valve cusps. Atrial and aortic measurements 
performed on the right parasternal short-axis view are illustrated on Figure 2. For each time 
point (p, a, d, s) during the cardiac cycle the ratio LAsx/AOD was calculated (Young, 2004).  
Colour Flow Doppler examinations of the mitral, tricuspid, aortic and pulmonic valves were 
performed.  
 
Statistical analysis 
Data are shown as mean ± standard deviation. All analyses were based on the mixed model 
with horse as random effect and time as categorical fixed effect. All timepoints were 
compared with the baseline value at time zero, using Dunnett’s method to adjust for multiple 
comparisons, and a global significance level of 5%. 
Chapter 2: Remodeling and reverse remodeling associated with long-term AF. 
 
76 
Figure 1. On the right parasternal long-axis view of a horse, latero-lateral left atrial diameter (LAD) was 
measured from the lateral free wall to the interatrial septum. The circular line represents the left atrial surface 
area (LAS). RA: right atrium.  
 
RV: right ventricle. TV: tricuspid valve. LA: left atrium. LV: left ventricle. MV: mitral valve. IVS: 
interventricular septum. 
 
Figure 2. A right parasternal short-axis view of the left atrium and aorta of a horse. The diameter of the left 
atrium (LAsx) and aorta (AOD) was obtained. To measure the internal short-axis diameter of the aorta calipers 
were placed along the commissure between the noncoronary and right coronary aortic valve cusps. To obtain the 
internal short-axis diameter of the left atrium (LAsx), calipers were placed along a line extending from and 
parallel to the commissure between the noncoronary and left coronary aortic valve cusps to the distant margin of 
the left atrium.  
 
RV: right ventricle. TV: tricuspid valve. LA: left atrium. RC: right coronary aortic cusp. LC: left coronary aortic 
cusp. NC: non-coronary aortic cusp. 
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Results 
In all horses, AF could be successfully induced and maintained using the intermittent burst 
pacing protocol. In each horse, threshold for stimulation remained below the upper 
stimulation capacity (amplitude and duration) of the pacemaker except for horse 2.  In this 
horse, atrial electrical measurements during the recovery period were performed with a 
temporary pacing catheter (Bipolar Intracardiac Electrode, USCI) introduced trough an 8.5F 
introducer sheath (Intro-Flex, Baxter), placed in the lower half of the jugular vein. 
Programmed electrical stimulation was performed with an external pacemaker and the 
pacemaker programmer.  At the end of AF period all horses were successfully converted to 
sinus rhythm after a total of 2 or 3 doses of QS. One horse (horse 2) showed widening of the 
QRS complex and tachycardia after the 2nd dose of QS. 
  
Electrophysiological measurements 
Atrial fibrillation 
Atrial vulnerability and AF duration were very variable but increased progressively during the 
AF period and progressed into persistent AF in all horses. AF became persistent after 1 (horse 
1 and 3), 4 (horse 2) and 6 (horse 4) weeks of maintained AF (Figure 3). After 4 hours of 
maintained AF, AFCL was 243±13ms and decreased to 151±13 ms after 4 months of AF 
(Figure 4). 
There was a significant increase in heart rate during the first week of AF (Table 1).
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Figure 3: Mean±SD atrial fibrillation duration (in seconds) after switching off the neurostimulator during the 
atrial fibrillation study (log scale) of 4 horses. 
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Figure 4: Mean (±SD) atrial fibrillation cycle length (AFCL) during the AF-period ( ) of 4 horses.  
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Table 1. Mean (±SD) atrial and ventricular electrophysiological and echocardiographic measurements before, 
and during the AF-period, and after restoration to sinus rhythm of 4 horses.  
BASELINE AFTER 4 MONTHS OF AF* MEAN INCREASE %*    BACK TO BASELINE
TIME (days) VALUE
Heart rate (bpm) 40±3 53±9 33 3 34±5ˆ
Electrophysiological measurements
Right atrium
AERP1000 (ms) 256±24 219±16 ‐ 14 21 255±13°
AERP800 (ms) 256±25 224±30 - 12 21 255±11°
AERP500 (ms) 249±26 248±30 - 0.5 0 248±30°
AERP333 (ms) 226±24 148±8 - 35 21 225±12°
Right ventricle
VERP1000 (ms) 358±16 387±35 8 0 387±35°
VERP800 (ms) 321±19 372±32 16 14 339±17°
VERP500 (ms) 250±17 276±36 10 1 251±16°
Echocardiographic measurements
Right parasternal long-axis view
LA-FS (%) 12.2±2.5 0.7±2.0 - 94 14 11.2±3.4°
LA-FAC (%) 18.9±6.4 -1.6±4.2 - 108 14 17.4±6.2°
LADd (cm) 8.7±0.5 9.1±0.8 5 7 8.6±0.6°
LASd (cm²) 41.4±6.4 50.0±10.7 21 60 41.6±7.6°
LADs (cm) 9.7±0.6 9.8±0.7 1 2 9.7±0.7°
LASs (cm²) 55.0±6.4 58.9±9.9 7 7 55.0±6.8°
LV-FS (%) 35.4±3.7 33.7±4.3 5 2 35.7±4.3°  
AERP: atrial effective refractory period. VERP: ventricular effective refractory period. LAD: left atrial diameter 
measured on the right parasternal long-axis view. FS: fractional shortening. FAC: fractional area change. LAS: 
left atrial surface of the right parasternal long-axis view. d: measurements during ventricular diastole. s: 
measurements during ventricular systole. LV-FS: left ventricular fractional shortening. *: data obtained after 
quinidine sulphate treatment. °: data differ less than 10% of baseline value. ^ data differ more than 10% of 
baseline value. 
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Atrial and ventricular electrophysiology 
Results are given in Table 1 and Figure 5. At baseline, AERP was 256±24 ms, 256±25 ms, 
249±26 ms and 226±24 ms at a pacing CL of 1000, 800, 500 and 333 ms, respectively (Table 
1and Figure 5 A and B). During the maintained AF-period the AERP shorted significantly 
from 24 hours onwards for each pacing CL (1000, 800, 500 and 333ms). After seven days of 
maintained AF, mean±SD AERP had decreased to 163±20, 168±19, 171±22 and 165±24 ms 
at a pacing CL of 1000, 800, 500 and 333ms, respectively. A decrease in rate adaptation could 
also be observed (Figure 5C). After pharmacological restoration to sinus rhythm a period of 3 
weeks was necessary to achieve AERP baseline values (Table 1).  
No significant changes were observed in VERP (Figure 5D) 
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Figure 5. Mean (±SD) atrial effective refractory period (AERP) at a pacing cycle length of 333 (-O-), 800 ms 
(-▼-) (A) and 1000 (-■-), 500 ms (-∆-) (B) and ventricular refractory period (VERP) at pacing cycle length of 
500 (-׀-), 800 (-+-) and 1000 ms (-X-) (D) at baseline, during the AF-period ( ) and during the recovery-time 
( ) in 4 horses. Rate adaptation curves of the AERP at different time points during the study (C). 
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*Data obtained after conversion to sinus rhythm with quinidine sulphate. 
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Echocardiographic measurements 
Results are given in Table 1 and Figure 6. There were no significant differences between 
measurements performed during atrial fibrillation and during sinus rhythm in the AF-period. 
Left atrial FS and FAC decreased significantly within 1 or 2 days of maintained AF 
(p<0.0001). Atrial contractile function was completely lost within 1 to 4 weeks of maintained 
AF: a maximum decrease was observed of 94% and 108% compared to baseline for LA-FS 
and LA-FAC, respectively (Table 1). Both values returned progressively to baseline values 
but this required 2 months of normal sinus rhythm.  
LADd, LADs, LASd and LASs had increased after 4 months of AF with 5%, 1%, 20% and 
7%, respectively. All values returned back to baseline values within 2 months. The ratio 
LAsx1/AODsx measured at each time point during the cardiac cycle remained below 1.2 
(Young 2004). A significant increase for LAsxa/AODsxa and LADsx1d/AODsxd was observed 
during the 4-month AF-period. Both values returned back to normal within 7 days of the 
recovery-period. No significant changes were detected in aortic diameter.  
Colour Flow Doppler of all valves revealed no differences compared to baseline. 
 
 
Figure 6. Course of the overall left atrial fractional shortening (FS%) (mean±SD) at baseline, during the AF-
period ( ) and during the recovery-time ( ) (n=6). 
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Discussion 
The present study evaluates electrical and contractile remodeling during chronic maintained 
AF in horses without underlying structural heart disease. This study population can be 
considered to be representative for those horses presented with lone subacute or chronic atrial 
fibrillation. The burst pacing protocol was effective to induce and maintain AF. Besides the 
measurements made during AF, brief periods of spontaneously restored sinus rhythm allowed 
making electrophysiological measurements during normal sinus rhythm without any 
administration of drugs. However, in all horses persistent AF developed after 7, 28, 7 and 42 
days for horse 1, 2, 3 and 4, respectively. Therefore, measurements made during the brief 
periods of spontaneously restored sinus rhythm could only be followed for a short period (7 to 
42 days). After 4 months of AF none of the horses converted spontaneously to normal sinus 
rhythm. We choose for the pharmacological treatment with QS because until now this is still 
the “gold” standard treatment for chronic atrial fibrillation in horses. The relatively short half-
life of quinidine was thought to be beneficial to continue measurements during the recovery 
period. Horses were not electrically cardioverted because this might influence atrial 
contractile function (Harjai et al., 1997) and because of the chance for immediate recurrence 
of AF (De Clercq et al., 2008c). 
First of all, the AF study period confirmed the observation made previously: a rather short 
episode of AF results in (1) electrical remodeling expressed as a decrease in AERP and a 
depressed AERP rate adaptation curve and (2) contractile remodeling expressed as a decrease 
in atrial fractional shortening. Atrial contractile dysfunction has also been found in horses 
with naturally occurring AF (Schwarzwald et al., 2007). Our study also demonstrated that a 
prolonged period of AF was associated with a minimal increase in atrial size in 4 horses. 
Despite this increase in diameter, the ratio’s LAsx1/AODsx stayed within the normal references 
(<1.2) (Young 2004). Besides the shortening of the AERP, a large atrial diameter was more 
likely to be associated with the development of persistent atrial fibrillation: the two horses 
that developed persistent atrial fibrillation after one week of maintained AF had the largest 
atria at baseline (results not shown). 
Upon restoration of sinus rhythm rapid electrical reverse remodeling was present but a 
normalization of atrial contractility and left atrial diameter was only reached after 2 months. 
These observations are in contrast to the findings made after short episodes of atrial 
fibrillation (<7 days) where normalization of atrial contractile function is more rapid. These 
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suggest that after cardioversion of chronic atrial fibrillation in horses a long resting period is 
required before returning to training.   
In summary, the results of this study indicate that AF induces, in healthy horses, a rapid 
electrical and contractile remodeling and a slow increase in left atrial diameter. In each horse, 
persistent AF developed after 1 to 6 weeks of intermittent burst pacing. After pharmacological 
restoration to sinus rhythm, a rapid electrical reverse remodeling and a slower normalization 
of atrial contractility and left atrial diameter was observed. 
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PHARMACOLOGICAL TREATMENT
 
 
Until now, quinidine sulphate (QS), a class I anti-arrhythmic drug, has been the drug of 
choice for pharmacological treatment of atrial fibrillation (AF) in horses. It has an efficacy of 
85% in horses where AF duration is less than 2 months and where no detectable cardiac 
disease is present. However, in up to 76% of treated horses this drug is associated with serious 
cardiac or non-cardiac side effects including urticaria, nasal edema, colic, diarrhea, laminitis, 
polymorphic ventricular tachycardia, anaphylactic shock, syncope or sudden death. Recently, 
QS is no longer available in some countries.  
In human medicine, a wide range of anti-arrhythmic drugs to treat acute or chronic 
supraventricular or ventricular arrhythmias. Propafenone, a class I anti-arrhythmic drug, is 
used for treatment of supraventricular and ventricular arrhythmias and several studies describe 
that this drug is more or as efficient as QS and other class I or class III anti-arrhythmic drugs 
for prevention and suppression of arrhythmias. Amiodarone, a class III anti-arrhythmic drug, 
is an efficacious and safe anti-arrhythmic drug used in humans to treat AF, atrial flutter and 
ventricular fibrillation. 
Because in horses, intravenous propafenone has already been described for treatment of 
ventricular arrhythmias, the use of this drug in horses with chronic AF was studied in Chapter 
3. In Chapters 4 to 6, the use of amiodarone in horses with chronic AF was investigated. 
Both studies were performed in horses with chronic AF as most clinical patients are supposed 
to suffer from chronic AF which is supposed to be more resistant to medical treatment than 
recent-onset AF. 
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Summary 
The objective of this study was to investigate the effects of intravenous propafenone in horses 
with naturally-occurring and experimentally-induced chronic atrial fibrillation (AF). The 
study was performed on two horses with naturally-occurring chronic (6 to 12 months) AF and 
4 horses with pacing induced chronic (4 months) AF. The mean duration of spontaneous self-
sustained AF in the latter group, was 3 months. 
All horses received a 2 mg/kg propafenone bolus IV over 15 minutes. If AF persisted after 20 
minutes, a continuous infusion of 7 mcg/kg/min of propafenone was given for 120 minutes. 
Before, during and after the treatment protocol, propafenone concentrations, haematological 
and biochemical analyses and electrolyte concentrations were determined and clinical signs 
were monitored. At regular intervals surface electrocardiograms, for determination of heart 
rate, f wave interval, QRS duration and QT interval, and intra-atrial electrograms, for 
measurement of atrial fibrillation cycle length (AFCL) were recorded. If propafenone 
treatment failed, quinidine sulphate was administered. 
All horses received both the bolus and continuous infusion with minimal adverse effects. 
During the 15-minute bolus a slight increase in heart rate was observed and horses appeared 
more sensitive to external stimuli. Throughout the treatment, no significant changes were 
observed in respiratory rate, QRS or QT duration and blood analysis remained within normal 
references. Although a highly significant (p<0.001) increase in f wave interval and AFCL was 
observed and propafenone concentrations (569-1268 ng/mL) reached the human therapeutic 
level (64-1044 ng/mL), none of the horses cardioverted to sinus rhythm. Sinus rhythm could 
be restored in all horses with a standard, oral QS treatment. 
Although the current propafenone treatment resulted in therapeutic propafenone 
concentrations without important side effects, this drug failed to restore sinus rhythm in any 
horse with chronic AF.  
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Introduction 
Atrial fibrillation (AF) is the most important arrhythmia in horses. Treatment is recommended 
in horses with AF in the absence of underlying heart disease because the horse’s performance 
generally returns to the previous level after restoration to sinus rhythm. In horses, atrial 
fibrillation may be detected as an incidental finding because symptoms are not always 
obvious, especially in pleasure horses. However, a history of exercise intolerance, exercise-
induced epistaxis, respiratory disease, weakness or syncope may be present (Deem and 
Fregin, 1982; Reef and McGuirck, 2002). In many cases, history suggests that AF is already 
present for several weeks or even months before horses are presented for cardioversion. It has 
been suggested that when AF persists for >3-6 months or when atrial dilatation is present 
because of mitral valve regurgitation or AF per se, treatment is less effective (Reef et al., 
1988; van Loon et al., 2001a;2001b). 
Oral quinidine sulphate, a class I anti-arrhythmic drug, is the drug of choice for 
pharmacological treatment of acute and chronic AF in horses. An efficacy of 85%  in horses 
with an AF duration of < 2 months and without the presence of detectable cardiac disease has 
been reported (Deem and Fregin, 1982; Reef et al. 1988). Nevertheless, in up to 76% of 
treated horses this drug can yield serious cardiac and non-cardiac side effects including 
urticaria, nasal oedema, colic, diarrhea, laminitis, polymorphic ventricular tachycardia, 
anaphylactic shock, syncope or sudden death (Reef et al., 1988; 1995). In addition, in some 
countries quinidine sulphate is no longer available. 
Although intravenous flecainide, a class I anti-arrhythmic drug, was originally reported to be 
efficacious in acute (experimentally induced) AF (Ohmura et al., 2000), life threatening and 
even lethal ventricular dysrhythmias have been reported in both acute (unpublished results) 
and chronic AF horses (van Loon et al., 2004). Intravenous cibenzoline (0.1 mg/kg/min), a 
class I anti-arrhythmic drug (with additional class III and IV properties), was unsuccessful in 
2 horses with AF and was associated with severe ventricular pro-arrhythmia (van Loon, 
2003).  
Sotalol, a class III drug, has been used in three horses with AF (0.75-1.25 mg/kg IV infusion 
over 15 minutes) and was not associated with side-effects. However, sinus rhythm could not 
be restored (van Loon, 2003).  
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Intravenous amiodarone, a class III anti-arrhythmic drug, has been described in horses with 
chronic atrial fibrillation but with a moderate success rate of 50-67% and occurrence of 
important side effects, especially with prolonged (> 36 hours) protocols (De Clercq et al., 
2006, 2007a). 
Successful electrical cardioversion has been described for horses with AF (Deem and Fregin, 
1982; van Loon, 2001b; Frye et al., 2002; McGurrin et al., 2003, 2005a, 2005b; van Loon et 
al., 2005; De Clercq et al., 2007b). However, this technique requires general anaesthesia, 
special equipment and expertise which may make the process more expensive.  
Further research for alternative pharmacological treatment options might be necessary and 
useful. Kochiadakis et al. (1999) reported that propafenone appeared to be safe and 
moderately effective for the treatment of chronic atrial fibrillation in humans. 
This article describes the effects of an intravenous propafenone treatment in horses with 
naturally-occurring or experimentally-induced chronic AF. 
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Material and Methods 
The study was performed at Ghent University (Belgium) and was supported by the Special 
Research Fund, Ghent University (Belgium). This research was approved by the Ethics 
Committee of the Faculty Veterinary Medicine, Ghent University. 
Cases 
Six trotter horses with a mean age, body weight and height at the withers of 5.6±2.1 years, 
517±65 kg and 158±7 cm, respectively, were studied. Two of the six trotter horses (Horse 1 
and 2) had a history of exercise intolerance and naturally-occurring AF of duration of six 
months and one year. In the 4 other horses (horse 3-6), AF had been experimentally induced 
and maintained as described by van Loon et al. (2001) during a 4 month period. In these 
horses a transvenous screw-in electrode was implanted in the right atrium and connected with 
a pacemaker to deliver repeated bursts of electrical stimuli to the atrium. Initially, cessation of 
burst pacing resulted in relative short episodes of AF. As burst pacing was continued, the 
induced AF episodes increased and became self-sustained in all horses. At the time of 
propafenone treatment, the mean duration of spontaneous, self-sustained AF was 3 months. 
At that time AFCL was 138±15 ms, compared to 138±6 ms in the horses with naturally-
occurring AF. 
Treatment regime  
Horses received 2 mg/kg of propafenone (Rhytmonorm®, 70 mg/20mL, Abbott) IV over 15 
minutes. If AF persisted 20 minutes after this bolus, a continuous infusion of 7 mcg/kg/min of 
propafenone was given for 120 minutes. Infusion was discontinued when conversion was 
achieved, when any side effects were observed or the 120-minute infusion was completed. 
Recorded data  
Before propafenone treatment clinical examination, a base-apex electrocardiogram and 
echocardiography were performed in all horses. Echocardiography included two-dimensional, 
M-mode and colour flow Doppler. The two-dimensional and M-mode measurements from the 
left cardiac window included left atrial diameter during ventricular diastole and systole and, 
from the right cardiac window, aortic diameter in diastole, left ventricular internal diameter in 
diastole and systole, interventricular septum thickness in diastole and systole and left 
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ventricular fractional shortening. Measurements were performed by one observer before and 
at 2.5, 5, 7.5, 10, 12.5, 15, 35, 60, 90, 120, 150 and 180 minutes of the study protocol. Before, 
during and after propafenone treatment clinical signs were monitored and intra-atrial 
electrograms and surface ECG’s were recorded. From the surface ECG heart rate (HR), f-
wave interval (ms), QRS duration (ms) and corrected QT interval (ms) were measured. The 
atrial fibrillation cycle length (AFCL) was measured with a pacemaker and a pacemaker 
programmer (Programmer 9790, Medtronic) as described by van Loon et al. (2000). In these 
horses a transvenous screw-in electrode had previously been implanted in the right atrium and 
was connected to an implantable pacemaker. The pacemaker programmer allowed us to 
measure directly the AFCL on an intra-atrial electrogram. In the non-instrumented horses an 
8.5F introducer sheath (Intro-Flex, Baxter) was placed in the lower half of the jugular vein. In 
the standing and non-sedated animal, a temporary pacing/sensing catheter (U.S.C.I., Bard, 
Ireland) was introduced through the introducer sheath and placed under echocardiographic 
guidance in the right atrium. Atrial endocardomyocardial contact of the temporary pacing 
sensing catheter resulted in rapid atrial deflections on the intra-atrial electrogram. The mean 
interval between the f waves and the AFCL were measured from a 2 to 10 s window. 
Blood samples for retrospective propafenone concentrations were taken at baseline and at 2.5, 
5, 7.5, 10, 12.5, 15, 35, 60, 90, 120, 150, 180, 480, 720 and 1440 minutes of the protocol. The 
plasma concentrations were analyzed by a validated high performance liquid chromatography 
combined with UV detection (Verbesselt et al., 1991). A limit of quantification of 5 ng/mL 
was obtained. 
Blood samples for haematological and biochemical analyses including white blood cell count, 
differential analysis, total bilirubin, creatinine, total protein, urea nitrogen, alkaline 
phosphatase, aspartate aminotransferase, creatinine kinase, gamma-glutamyl transferase, 
lactate dehydrogenase, and electrolyte concentrations were taken at baseline, after the 15-
minute bolus and 24 hours after cessation of the propafenone treatment. 
Statistical analysis 
Effects of the propafenone treatment on respiratory rate, heart rate, AFCL, f wave interval, 
QRS duration and corrected QT interval were analysed using single-factor ANOVA. A 
Dunnett’s test was performed to detect possible significant differences compared to baseline 
values (p<0.05). 
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Results 
All electrolyte concentrations and haematological, biochemical parameters were within 
normal references. Cardiac evaluation performed by auscultation, echocardiography (2D and 
M-mode) and Colour Flow Doppler were normal, except for horse 2 which had a mild mitral 
valve regurgitation. Left atrial diameters during diastole and systole were within the reference 
ranges (Patteson et al., 1995). 
Every horse received the full treatment protocol. During the 15-minute bolus each horse was 
more sensitive to external stimuli. No other cardiac or non-cardiac adverse effects were 
observed. This minimal excitation disappeared gradually within 30 minutes after termination 
of the 15-minute bolus. Cardioversion to sinus rhythm could not be achieved. 
From the numerical description of the data for respiratory rate, HR, AFCL, f wave interval, 
QRS duration and corrected QT interval as well as from the error bar graphs, it was concluded 
that the condition of equality of variances was satisfied. For the respiratory rate, HR, QRS 
duration and corrected QT interval, statistical analysis did not reveal significantly differences 
(p<0.05). However, a very slight increase in heart rate was observed (Figure 1). The ANOVA 
revealed a significant difference in the mean values over time for AFCL and f wave interval 
from 7.5 and 10 minutes onwards (P<0.05), respectively, and a highly significant difference 
from 10 and 12.5 (P<0.01), respectively (Figure 1). However, although an increase in AFCL 
could be observed in all horses, no cardioversion could be achieved.  
Propafenone concentrations (ng/mL) during and after the treatment are displayed in Figure 1. 
Two plasma samples (at 120 and 480 minutes) of horse 6 were destroyed during 
centrifugation and no data of these time points were available. 
Haematological and biochemical parameters remained within normal limits after the 15 
minute bolus and twenty four hours after cessation of the propafenone treatment. 
One week after propafenone treatment the four instrumented horses and one horse (horse 1) 
with naturally occurring AF were treated with oral QS. Each horse converted successfully to 
sinus rhythm after 2 or 3 doses of QS. One horse showed tachycardia and QRS widening. 
Thirty minutes before restoration to sinus rhythm, the mean (±SD) f wave interval was 376 
(±46) ms and QRS duration was 108 (±11) ms. 
Chapter 3: Propafenone in horses with atrial fibrillation 
 
102 
Figure 1. Mean (±SD) atrial fibrillation cycle length (AFCL), f wave interval, heart rate (HR), propafenone 
concentrations, QRS duration and corrected QT interval (n=6) before, during and after the propafenone 
treatment.  
 
* significantly different from baseline value.  
° data obtained from 5 horses. 
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Discussion 
Propafenone, a class I anti-arrhythmic drug is used successfully to convert atrial fibrillation of 
recent onset in humans with a success rate of up to 83% (Khan et al., 2001; Fuster et al., 
2006). As with other conventional anti-arrhythmic drugs, it’s efficacy in long lasting AF is 
lower. For different species a great intersubject variability in elimination half-life of 
propafenone is described. The elimination half-life after a single intravenous propafenone 
bolus is about 150, 83 and 120 minutes for humans, dogs and horses, respectively (Arboix et 
al., 1985; Connolly et al., 1983; Hollmann et al., 1983; Puigdemont et al., 1987; 1990). Based 
upon these observations we investigated the potential of intravenous administration of 
propafenone at a dose of 2 mg/kg to treat horses with chronic AF. At the time of propafenone 
treatment, the mean duration of spontaneous self-sustained AF in the instrumented horses was 
3 months. For the horses with experimentally-induced AF, AF induction by burst pacing was 
only applied for a few weeks. For the remainder of time, AF continued spontaneously without 
any further intervention. AS such, AF in these horses was thought to resemble naturally-
occurring chronic AF. In addition, AFCL in both groups was similar (138±15 versus 138±6). 
In contrast to humans, in our study none of the animals converted to sinus rhythm. 
The doses used in our treatment protocol were those described for humans adapted to the 
weight of a horse (Capucci et al., 1992; Kochiadakis et al., 1999; Lavanga et al., 1991).  
In humans, therapeutic propafenone plasma concentration is very variable and ranges between 
20-60 ng/mL (Steurer et al., 1991), 50-200 ng/mL (Chan et al., 1989) and 64-1044 ng/mL 
(Connolly et al., 1983). Steurer and co-workers (1991) and Karagueuzian and co-workers 
(1982), described a decreased propafenone efficacy at a plasma concentration below 20 
ng/mL in humans and below 500 ng/mL in dogs. In humans, ranges above 4180 ng/mL are 
described as being lethal (Clarot et al., 2003). However, intersubject variability in therapeutic 
concentration emphasizes the need to individualize therapy to the patient (Connolly et al., 
1983). A pharmacokinetic study of propafenone in horses described a rapid elimination half-
life (1-2 hours) after a single bolus of 2 mg/kg (Puigdemont et al., 1990). However, injection 
rate was not mentioned and clinical signs, surface electrocardiograms or other values were not 
followed. Because of the rapid decline in plasma concentrations, these authors suggested the 
use of a continuous infusion for administration of the drug without mentioning a dose 
protocol (Puigdemont et al., 1990). With our treatment protocol (2 mg/kg), a dosage higher 
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than suggested for the management of ventricular arrhythmia (Reef, 1999), horses reached the 
human lower therapeutic level of 20-500 ng/mL.  
However, this resulted in a highly significant prolongation of AFCL (p<0.001), suggesting a 
significant slowing of conduction at the atrial level at this propafenone concentration. This 
effect was obtained without significant adverse reactions. The administration of a higher 
dosage of propafenone could result in a further increase of AFCL but with a higher risk of 
major side effects. Flecainide, another class Ic anti-arrhythmic drug, induced a prolongation 
of the AFCL to a median of 200 ms and a prolongation of the QRS complex to 130 ms. This 
was associated with the development of serious potentially life-threatening ventricular 
arrhythmia (van Loon et al., 2004). Furthermore we observed in one horse (unpublished data) 
the development of ventricular tachycardia with very wide QRS complexes leading to 
ventricular fibrillation and asystole in a dosage of flecainide of 2 mg/kg. The preceding QRS 
duration was 140 ms and AFCL was 286 ms. Based upon these observations we limited the 
dosage of propafenone to 2 mg/kg in order to avoid QRS prolongation, an early marker for 
the development of ventricular proarrhythmia. 
In contrast to propafenone, quinidine sulphate treatment resulted in the termination of AF in 
all our horses. The degree of AFCL prolongation was much more pronounced after quinidine 
compared to propafenone. This results in an increased reduction of the average number of 
fibrillation waves increasing the statistical change of termination of AF (Allessie et al., 1998). 
In human medicine, side effects due to acute or chronic doses of propafenone are cardiac, 
hepatic, cholestatic, dermatologic or nervous disorders (Cocozzella et al., 2003; Gandolfi et 
al., 2001; Huang et al., 2005; Odeh et al., 2000; Spinler et al., 1992; Wiesfeld et al., 2006). In 
case of cardiac adverse reactions, some authors described successful therapy with 
administration of alkalinising solutions (e.g. bicarbonate) or rifampicine in order to increase 
the metabolism of propafenone (Brubacher, 2004; Stancak et al., 2004; Unal et al., 2007). We 
did not observe any significant side effect of propafenone in the given dose in these horses.  
In conclusion, an IV propafenone treatment in horses with naturally-occurring or induced 
chronic AF resulted in significant electrophysiological right atrial changes but failed to 
reverse AF into sinus rhythm. Overall, the value of class Ic anti-arrhythmic drug in the 
termination of AF in horses seems limited. 
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Summary 
Six horses without underlying cardiac disease were presented because of atrial fibrillation of 
between 5 and 12 months duration. These horses received an intravenous amiodarone 
treatment of 5 mg/kg/h for 1 h followed by 0.83 mg/kg/h for 23 h and subsequently 1.9 
mg/kg/h for 30 h. During treatment, clinical signs were monitored and a surface ECG and an 
intra-atrial electrogram were recorded. Infusion was discontinued when sinus rhythm or side 
effects occurred. Four horses successfully cardioverted, of which one showed symptoms of 
hind limb weakness and weight shifting. Two horses did not cardiovert and showed similar 
side effects. In all horses, side effects disappeared within 6 hours after termination of 
treatment. Cardiac side effects, such as pro-arrhythmia, were not seen in any of the horses. 
Total bilirubin slightly increased in 3 horses and normalized within 4 days. It was concluded 
that amiodarone has the potential to treat naturally-occurring chronic atrial fibrillation in 
horses, although further research is needed to refine the infusion protocol. 
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Introduction 
Atrial fibrillation (AF) is the most important cardiac arrhythmia in horses. Although some 
horses have a history of exercise intolerance, exercise-induced epistaxis, respiratory disease, 
weakness or syncope, AF may be detected as an incidental finding in an otherwise normal 
horse (Deem and Fregin, 1982, Reef et al., 1988 and Reef and McGuirk, 2002). Horses are 
predisposed to AF because they have a high resting vagal tone and a large atrium. In contrast 
to humans and dogs, horses usually have no macroscopic underlying cardiac pathology. This 
means that after successful medical treatment these animals can return to their previous 
athletic ability (Reef et al., 1988). 
Quinidine sulphate (QS) is used worldwide to treat AF in horses but may result in 
anaphylactic shock, colic, diarrhea, laminitis, tachycardia or sudden death (Deem and Fregin, 
1982; Marr et al., 1995; Reef et al., 1988; Reef et al., 1995; Reef and McGuirk, 2002). 
Because QS becomes increasingly difficult to obtain, and is expensive, there is a need to find 
an alternative and preferably less toxic treatment for chronic AF in horses (McGurrin et al., 
2003). Flecainide, a Na+-channel blocker has been shown to be efficacious in horses with 
acute AF (Ohmura et al., 2000) but not in horses with chronic AF. It can induce potentially 
dangerous ventricular dysrhythmias (van Loon et al., 2004). 
In this report the use of intravenous (IV) amiodarone (AD), mainly a potassium-channel 
blocker, as a treatment of chronic AF in horses is described. The drug is considered as a class 
III compound in the “Vaughan–William” classification: but in addition it blocks sodium-, 
calcium-channels and β-adrenoreceptors, therefore it prolongs repolarization and increases the 
duration of the action potential (Gill et al., 1992). 
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Materials and methods 
Cases 
Five Warmblood horses and one Standardbred (horse 1) were referred for arrhythmia (horses 
4 and 6), exercise intolerance (horse 1), epistaxis (horse 5), colic (horse 2) and castration 
(horse 3), and were each diagnosed with AF. Their mean age, body weight and height at the 
withers were 11 years (3.5–17.0 years), 602 kg (520–647 kg) and 170 cm (153–180 cm). All 
horses, except horse 3, were used for trotting, jumping or pleasure riding and all except horse 
3 had a history of exercise intolerance, respiratory symptoms or nose bleeding. Based upon 
history and clinical examination, the duration of atrial fibrillation was thought to have been 
present chronically for between 5 and 12 months. Horse 6 had been treated 4 weeks 
previously with QS but after 4 doses the horse had shown severe colic symptoms that 
necessitated termination of treatment. 
A clinical examination and a complete blood analysis (Spotchem SP-4420) were performed. 
A full cardiac evaluation, including auscultation, ECG, two-dimensional, M-mode and Colour 
Flow Doppler echocardiography (GE Vingmed CFM 800 SV), was also undertaken (Table 1). 
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Table 1. Auscultation of the heart, echocardiographic (2D, M-mode and Colour Flow Doppler) and intra-atrial 
measurements before treatment in 6 horses. 
Horse 1 Horse 2 Horse 3 Horse 4 Horse 5 Horse 6
Auscultation
auscultation no murmurs
1/6 holosystolic 
over TV
1/6 holosystolic 
over MV
no murmurs 
1/6 holosystolic 
over TV
no murmurs
Echocardiography (2D and M-mode)
LADd (cm) 11.30 13.31 14.41 15.66 14.43 15.25
LADs (cm) 12.33 13.74 14.77 15.99 14.96 15.55
Ao (cm) 6.24 6.18 6.17 6.97 7.15 7.02
LVIDd (cm) 12.07 10.80 12.64 13.10 12.07 11.15
LVIDs (cm) 7.93 6.21 8.85 7.93 7.51 7.47
FS (%) 34.29 42.55 30.00 39.47 37.78 32.99
Colour Flow Doppler
mitral valve no no trivial no no trivial
aortic valve no no no no no trivial
pulmonary valve no no no no no moderate
tricuspid valve no trivial no no  trivial no
Intra-atrial electrogram
AFCL (ms) 167 160 148 143 182 174  
LADd: left atrial diameter in diastole. LADs: left atrial diameter in systole. Ao: aortic diameter. 
LVIDd: left ventricular internal diameter in diastole. LVIDs: left ventricular internal diameter in systole. 
FS: left ventricular fractional shortening. AFCL: atrial fibrillation cycle length. no: no insufficiency. 
TV: tricuspid valve area. MV: mitral valve area. 
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Treatment regimen 
Horses received 5 mg/kg/h AD (Cordarone®, 150 mg/3 mL, Sanofi-Synthélabo) IV over 1 
hour followed by 0.83 mg/kg/h AD IV for 23 hours and then 1.9 mg/kg/h AD IV for the 
following 30 hours. Infusion was discontinued when conversion was achieved or when any 
side effects were observed. Horses that failed to convert to normal sinus rhythm with AD IV 
were treated after 1 week with 22 mg/kg quinidine sulphate (QS) administered by nasogastric 
intubation every 2 hours until sinus rhythm occurred, or adverse side effects appeared, or until 
a maximum daily dose of 132 mg/kg was administered. 
 
Recorded data 
Two-dimensional and M-mode echocardiographic measurements included left atrial diameter 
in diastole and systole measured from the left cardiac window, aortic diameter in diastole, left 
ventricular internal diameter in diastole and systole and left ventricular fractional shortening 
from the right cardiac window (Patteson et al., 1995; Patteson, 1999). Colour Flow Doppler 
echocardiography was used to identify valvular regurgitation. 
Before and during amiodarone treatment clinical signs were monitored and ECGs were 
recorded. From the surface ECG heart rate, the interval between f waves (ms), QRS duration 
(ms) and QT duration (ms) were measured. With a temporary pacing catheter (USCI, Bard) 
placed in the right atrium, the local atrial electrogram was recorded using a pacemaker (Thera 
D, Medtronic) and a pacemaker programmer (Programmer 9790, Medtronic). From this 
electrogram the atrial fibrillation cycle length (AFCL), which is the time between two 
successive atrial depolarization waves, was recorded (van Loon et al., 1998). The mean 
interval between the f waves and AFCL were estimated from a 2 to 10 s window (Figure 1 
and Table 2). 
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Figure 1. Mean atrial fibrillation cycle length (AFCL, n=6) in ms, amiodarone (AD, n=5) and 
desethylamiodarone (DAD, n=5) plasma concentration (μg/mL) with standard deviation, in the different patients 
during treatment.  
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Table 2. Measurements on the surface ECG (f wave interval) and intra-atrial electrogram (AFCL) and 
amiodarone (AD) and desethylamiodarone (DAD) plasma concentrations for each horse. 
 
Time (hours) AD (µg/mL) DAD (µg/mL) AFCL (ms)
f wave interval 
(ms)
0 / / 167 180
0.5 / / 190 180
1 / / 222 180
2 / / 222 180
6 / / 222 200
Horse 1 12 / / 222 200
24 / / 250 220
28 / / 267 240
36 / / 286 260
48 / / 400 260
54 / / 400 260
69 / / SR SR
0 0 0 160 160
0.5 1.93 < LOQ 211 160
1 1.60 < LOQ 236 200
2 0.80 0.07 267 200
6 0.84 0.07 267 240
Horse 2 12 0.90 0.10 286 240
24 1.06 0.12 250 200
28 1.90 0.16 333 320
32 2.30 0.19 400 400
36 2.48 0.22 400 440
40 1.42 0.22 SR SR
0 0 0 148 140
0.5 3.39 < LOQ 200 180
1 3.37 < LOQ 222 220
2 1.79 0.16 235 200
Horse 3 6 1.78 0.17 235 200
12 1.97 0.20 250 200
24 2.45 0.29 286 240
28 3.93 0.32 334 300
32 4.78 0.36 SR SR
0 0 0 143 120
0.5 0.49 < LOQ 160 160
1 3.57 0.07 174 160
2 1.39 0.12 182 160
6 1.44 0.11 190 200
Horse 4 12 1.59 0.15 190 160
24 1.74 0.19 222 200
28 2.03 0.23 250 200
32 3.15 0.25 286 240
36 2.65 0.28 286 240
40 3.21 0.28 286 244
44 4.36 0.25 SN SN
0 0 0 182 160
0.5 2.12 < LOQ 222 180
1 2.21 0.07 250 200
2 1.01 0.13 250 200
Horse 5 6 0.96 0.12 250 240
12 0.88 0.15 286 240
24 1.11 0.20 308 252
28 1.91 0.22 364 340
32 2.25 0.25 364 340
36 2.20 0.26 400 400
38 1.61 0.25 SN SN
0 0 0 174 160
0.5 2.61 < LOQ 222 204
1 3.22 < LOQ 250 216
2 1.23 0.08 261 240
6 1.14 0.08 273 256
Horse 6 12 1.37 0.11 267 272
24 1.41 0.14 286 296
28 2.35 0.18 364 320
32 2.73 0.18 375 328
36 2.75 0.18 400 332
40 3.02 0.20 SN SN
56 0.68 0.23 SR SR  
LOQ: limit of quantification is 0.05 µg/ml for both components. SR: sinus rhythm. SN: symptoms. During the 
first hour the patient received an amiodarone perfusion at a rate of 5 mg/kg/h followed for the next 23 hours at a 
rate of 0.83 mg/kg/h and then continued by a perfusion rate of 1.9 mg/kg/h.   Horses that converted to sinus 
rhythm with the intravenous amiodarone treatment.  Horses that did not converted with the amiodarone 
treatment. /: blood samples were not performed due to technical reasons. 
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Blood samples were taken for hematological and biochemical analysis at baseline, 1 and 4 
days after termination of treatment. Blood samples for retrospective analysis of AD and 
desethylamiodarone (DAD) levels were taken at 0, 0.5, 1, 2, 6, 12, 24 h followed by every 4 
hours until sinus rhythm or side effects appeared. These samples were analyzed by a validated 
high-performance liquid chromatography (HPLC) method with ultraviolet detection adapted 
from the method of Huy et al. (1991). All validation parameters met the criteria of the EC 
guidelines (Anonymous, 2002) and a limit of quantification of 0.05 μg/mL was obtained for 
both components. Due to technical reasons AD and DAD blood samples were not analyzed 
for horse 1. 
 
Statistical analysis 
The data on the effect of the treatment over time were analyzed using single-factor ANOVA. 
A post hoc Scheffé test was performed to detect possible significant differences among the 
means. 
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Results 
All hematological and biochemical parameters were within normal limits. The results of 
cardiac evaluation performed before treatment by auscultation, echocardiography (2D and M-
mode), Colour Flow Doppler and intra-atrial ECG are reported in Table 1. All 
echocardiographic measurements were within normal references except for horses 4 and 6, 
where the left atrial diameter in diastole was 15.66 and 15.25 cm (reference 11.3–14.52 cm) 
and for horses 3, 4, 5 and 6 where the left atrial diameter in systole was 14.77, 15.99, 14.96 
and 15.55 cm, respectively (reference 11.22–14.48 cm)(Patteson et al., 1995). 
Four out of 6 horses were successfully converted to sinus rhythm with the IV AD treatment. 
In three horses (1, 2 and 3), cardioversion was achieved without side effects. Horse 1 received 
the full treatment during 54 hours and converted 15 hours after termination of the treatment. 
Horses 2 and 3 converted after 40 and 32 hours of treatment, respectively. In the fourth horse 
(horse 6) AD treatment was discontinued after 49 hours of treatment because of the 
occurrence of hind limb weakness and weight shifting. 
Sixteen hours after termination of the AD administration this horse converted to sinus rhythm. 
In horses 4 and 5, similar side effects of hind limb weakness occurred after 44 and 38 hours of 
treatment, respectively, and the AD infusion was terminated. These 2 horses did not convert 
to sinus rhythm. In all 3 animals with side effects of hind limb weakness, symptoms gradually 
disappeared 4–6 hours after termination of treatment. 
In the first horse, AD and DAD levels were not determined. In the second and third horses, at 
the time of conversion, AD/DAD levels were 1.42/0.22 and 4.78/0.36 μg/mL, respectively. 
Upon occurrence of side-effects, AD/DAD levels in horses 4, 5 and 6 were 4.36/0.25, 
1.61/0.25 and 3.66/0.27 μg/mL, respectively. The time of conversion of horse 6 was 16 hours 
after termination of the AD infusion. At that time AD/DAD levels were 0.68/0.23 μg/mL. 
From the numerical and graphical description of the data for the AFCL and f wave intervals, 
it was seen that the condition of equality of variances was not suitable for statistical analyses 
for AFCL and f wave interval. Therefore, the ANOVA was performed on the ln-transformed 
data for AFCL and f waves, and revealed a highly significant difference in the mean values 
over time (P < 0.001). When compared to baseline value, the post hoc Scheffé test showed a 
significant difference from 2 hours for AFCL and from 24 hours for f wave interval (0.01 < P 
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< 0.05). For the other parameters studied, i.e., QT, QRS and HR, the Scheffé test did not 
reveal any differences between the mean measured values (P > 0.05). 
Twenty four hours after cessation of AD treatment hematological and biochemical parameters 
remained within normal limits, except for total bilirubin which was slightly increased in 
horses 4, 5 and 6. The horses showed no clinical abnormalities and 4 days after cessation of 
treatment total bilirubin had returned to normal values. 
One week after AD treatment horses 4 and 5 were treated with oral QS. At that time both 
horses showed an AFCL that was longer than at the start of the AD treatment (horse 4: 160 
ms versus 143 ms; horse 5: 267 ms versus 182 ms). 
After a total of 11 doses of QS, in horse 4, treatment was terminated because of adverse side 
effects (>25% widening of the QRS complex, tachycardia). Conversion to sinus rhythm was 
not achieved. Horse 5 converted successfully to sinus rhythm after two doses of QS. During 
the treatment this horse showed a mild abdominal discomfort. 
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Discussion 
Amiodarone, a K+- channel blocker, is an efficacious and safe anti-arrhythmic drug used in 
humans to treat atrial fibrillation, atrial flutter and ventricular fibrillation (Anderson, 1995; 
Kerin et al., 1996; Kodama et al., 1997; Podrid, 1995; Singh, 1995). By inhibiting outward 
potassium currents, AD prolongs the repolarization which may lead to AF termination 
(Sugiyama et al., 2001). 
The dose for the first 24 h of AD infusion was extrapolated to the weight of a horse from 
reported human doses (Kerin et al., 1996; Kochiadakis et al., 1999a; Kochiadakis et al., 
1999b; Vardas et al., 2000). In humans, after a 24-hour infusion, treatment is usually 
continued orally (Canada et al., 1983; Kochiadakis et al., 1999a; Kochiadakis et al., 1999b). 
However, we used an IV treatment because preliminary pharmacokinetic results in horses had 
indicated a low bioavailability of orally administered AD (D. De Clercq unpublished data). 
In the human condition, conversion occurred at a plasma AD concentration between 0.6 and 
3.0 μg/mL with a mean of 2.541±1.321 μg/mL (Canada et al., 1983; Vardas et al., 2000). 
Tieleman et al. (1997) calculated that a conversion was unlikely to occur at plasma AD 
concentration less than 1.2 μg/mL. The average plasma concentration of DAD was 
0.34±0.241 μg/mL (Vardas et al., 2000) and 1.4±0.7 μg/mL (Tieleman et al., 1997). However, 
Rotmensch et al. (1984) described a weak or even an absent concentration-effect correlation. 
Some studies describe that for conversion of AF concentrations of DAD was more important 
than those of AD (Balser et al., 1991; Nattel et al., 1988). A delayed therapeutic effect after 
withdrawal of therapy is described (Latini et al., 1984). 
Despite the fact that none of the horses showed significant atrioventricular valve 
regurgitation, left atrial dimensions were out with the normal limit in four horses (Patteson et 
al., 1995). This might be explained, at least in part, by the fact that references for 
Thoroughbreds were used while our horses were Warmbloods. 
Although in horse 5 only a slightly enlarged left atrium and a long baseline AFCL were 
found, AD treatment failed. The fact that in the following week, only 2 doses of QS were 
needed to cardiovert this horse could be explained by a synergistic effect of both drugs. AD is 
known to have a long half-life in humans (15–47 days) (Canada et al., 1983; Chow, 1996) and 
ponies (Trachsel et al., 2004) and at the onset of the QS treatment the AFCL (267 ms) was 
substantially longer than at the baseline (182 ms) (Pandozi et al., 2003; Sager, 2000). A 
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longer AFCL means that less fibrillation waves can coexist in the atria and that AF 
termination is more likely (Wijffels et al., 1995). 
Horse 4 could not be converted at all. This could be explained by the fact that this animal had 
the longest AF duration, the largest atrial size and also the shortest AFCL, all factors leading 
to an increased AF stability (van Loon et al., 2000; 2001; Vardas et al., 2000; Wijffels et al., 
1995). 
In human medicine, adverse effects due to chronic doses of AD are thyroid, pulmonary, 
hepatic, gastrointestinal, ocular and dermatological disturbances and rarely epididymitis or 
nerve disorders (Gill et al., 1992). High doses of AD may also slow down the sensory and 
motor nerve conduction velocities of the legs because of a toxic effect on the axons in the 
peripheral nerves (Besser et al., 1994). However, variability in blood–nerve barrier efficacy 
between individuals has been suggested in man (Santoro et al., 1992). These findings might 
explain the hind leg weakness and weight shifting observed in some of our horses. Toxic side 
effects with a short term AD treatment are rather rare. A few cases of acute hepatotoxicity due 
to IV AD administration have been reported in humans (Agozzino et al., 2002; Gonzalez et 
al., 2002). Three of our horses had a slightly increased total bilirubin but showed no clinical 
abnormalities. 
The present paper describes an IV AD treatment in horses with naturally occurring chronic 
AF. While QS and flecaïnide can result in life threatening proarrhythmia (wide QRS 
tachycardia, torsades de pointes), the current AD protocol did not result in cardiac side effects 
which was considered as a major advantage. In addition non-cardiac side effects were mild 
and disappeared spontaneously after termination of treatment. 
In order to increase success rate and decrease adverse drug effects, AD treatment regimen 
should be further adapted based upon pharmacokinetic and pharmacodynamic studies in 
horses. 
 
  
Chapter 4 : Intravenous amiodarone in horses
 
124 
References 
Agozzino, F., Picca, M., Pelosi, G., 2002. Acute hepatitis complicating intravenous amiodarone 
treatment. Journal of the Italian Heart 3, 686-688. 
Anderson, J.L., 1995. Contemporary clinical trials in ventricular tachycardia and fibrillation: 
Implications of ESVEM, CASCADE, and CASH for clinical management. Journal of 
Cardiovascular Electrophysiology 6, 880-886. 
Anonymous, 2002. Commission Decision of 12 August 2002, implementing Council Directive 
96/23/EC concerning the performance of analytical methods and the interpretation of results, 
2002/657/EC, Official Journal of the European Community, L221/8. 
Balser, J.R., Bennett, P.B., Hondeghem, L.M., Roden, D.M., 1991. Suppression of time-dependent 
outward current in guinea pig ventricular myocytes. Actions of quinidine and amiodarone. 
Circulation Research 69, 519-529. 
Besser, R., Treese, N., Bohl, J., Goebel, H.H., 1994. Clinical, neurophysiologic and biopsy findings in 
neurotoxic amiodarone syndrome. Medizinische Klinik 89, 367-372. 
Canada, A.T., Lesko, L.J., Haffajee, C.I., Johnson, B., Asdourian, G.K., 1983. Amiodarone for 
tachyarrhytmias: pharmacology, kinetics, and efficacy. Drug Intelligence and Clinical 
Pharmacy 17, 100-104. 
Chow, M.S., 1996. Intravenous amiodarone: pharmacology, pharmacokinetics, and clinical use. 
Annals of Pharmacotherapy 30, 637-643. 
Deem, D.A., Fregin, G.F., 1982. Atrial fibrillation in horses: a review of 106 clinical cases, with 
consideration of prevalence, clinical signs, and prognosis. Journal of the American Veterinary 
Medical Association 180, 261-265. 
Gill, J., Heel, R.C., Fitton, A., 1992. Amiodarone. An overview of its Pharmacological Properties, and 
Review of its Therapeutic Use in Cardiac Arrhythmias. Drugs 43, 69-110. 
Gonzalez, G.A., Garcia, S.M.V., La Mata, G.M., Mino, F.G., 2002. Early-onset acute toxic hepatitis 
induced by intravenous amiodarone administration. Gastroenterologia y Hepatologia 25, 392-
394. 
Huy, C.P., Costa, S., Nany, S., Claude, J.R., Hamon, M., 1991. Rapid microdetermination of 
amiodarone and its metabolite N-desethylamiodarone in plasma by high-performance liquid 
chromatography. Analytical Letters 24, 603-623. 
Kerin, N.Z., Faitel, K., Naini, M., 1996. The efficacy of intravenous amiodarone for conversion of 
chronic atrial fibrillation. Amiodarone vs quinidine for conversion of atrial fibrillation. 
Archives Internal Medicine 156, 49-53. 
Kochiadakis, G.E., Igoumenidis, N.E., Parthenakis, F.I., Chlouverakis, G.I., Vardas, P.E., 1999a. 
Amiodarone versus propafenone for conversion of chronic atrial fibrillation: results of a 
randomized, controlled study. Journal of the American College of Cardiology 33, 966-971. 
Kochiadakis, G.E., Igoumenidis, N.E, Solomou, M.C., Kaleboubas, M.D., Chlouverakis, G.I., Vardas, 
P.E., 1999b. Efficacy of amiodarone for the termination of persistent atrial fibrillation. 
American Journal of Cardiology 83, 58-61. 
Kodama, I., Kamiya, K., Toyama, J., 1997. Cellular electropharmacology of amiodarone. 
Cardiovascular Research 35, 13-29. 
Latini, R., Tognoni, G., Kates, R.E., 1984. Clinical pharmacokinetics of amiodarone. Clinical 
Pharmacokinetics 9, 136-156. 
Marr, C., Reef, V.B., Reimer, J.M., Sweeney, R.W., Reid, S.W., 1995. An echocardiographic study of 
atrial fibrillation in horses: before and after conversion to sinus rhythm. Journal of Veterinary 
Internal Medicine 9, 336-340. 
McGurrin, K.M.J., Physick-Sheard, P.W., Kenney, D.G., Kerr, C., Hanna, W.J.B., Neto, F.T., Weese, 
J.S., 2003. Transvenous electrical cardioversion in equine atrial fibrillation: technique and 
successful treatment of 3 horses. Journal of Veterinary Internal Medicine 5, 715–718. 
Nattel, S., Davies, M., Quantz, M., 1988. The antiarrhythmic efficacy of amiodarone and 
desethylamiodarone, alone and in combination, in dogs with acute myocardial infarction. 
Circulation 77, 200-208. 
Chapter 4 : Intravenous amiodarone in horses
 
125 
Ohmura, H., Nukada, T., Mizuno, Y., Yamaya, Y., Nakayama, T., Amada, A., 2000. Safe and 
efficacious dosage of flecainide acetate for treating equine atrial fibrillation. Journal of 
Veterinary Medicine Science 262, 711-715. 
Pandozi, C., Gentilucci, G., Calo, L., Castro, A., Lamberti, F., Loricchio, M.L., Santini, L., Magris, B., 
Bulava, A., Peichl, P., Santini, M., 2003. Relations between monophasic action potential 
duration and refractoriness after cardioversion of persistent atrial fibrillation: results in wash-
out and amiodarone-treated patients. Journal of the Italian Heart 4, 257-263. 
Patteson, M.W., Gibbs, C., Wotton, P.R., Cripps, P.J., 1995. Echocardiographic measurements of 
cardiac dimensions and indices of cardiac function in normal adult thoroughbred horses. The 
Equine Veterinary Journal Supplement 19, 18-27 
Patteson, M., 1996. Two-dimensional and M-mode echocardiography. In Cardiology of the horse, pp. 
93-116. 
Podrid, P.J., 1995. Amiodarone: Reevaluation of an old drug. Annals of Internal Medicine 122, 689-
700. 
Reef, V.B., Levitan, C.W., Spencer, P.A., 1988. Factors affecting prognosis and conversion in equine 
atrial fibrillation. Journal of Veterinary Internal Medicine 2, 1-6. 
Reef, V.B., McGuirk, S.M., 2002. Diseases of the cardiovascular system. Atrial fibrillation. In Large 
Animal Internal Medicine, third ed, pp. 471-474. 
Reef, V.B., Reimer, J.M., Spencer, P.A., 1995. Treatment of atrial fibrillation in horses: new 
perspectives. Journal of Veterinary Internal Medicine 9, 57-67. 
Rotmensch, H.H., Belhassen, B., Swanson, B.N., Shoshani, D., Spielman, S.R., Greenspon, A.J., 
Greenspan, A.M., Vlasses, P.H., Horowitz, L.M.N., 1984. Steady-state plasma amiodarone 
concentrations: relationship with antiarrhythmic efficacy and toxicity. Annals of Internal 
Medicine 101, 624-649. 
Sager, P.T., 2000. New advances in class III antiarrhythmic drug therapy. Current Opinion in 
Cardiology 15, 41-53. 
Santoro, L., Barbieri, F., Nucciotti, R., Battaglia, F., Crispi, F., Ragno, M., Greco, P., Caruso, G., 
1992. Amiodarone-induced experimental acute neuropathy in rats. Muscle Nerve 15, 788-795. 
Singh, B.N., 1995. Expanding indications for the use of Class III agents in patients at high risk for 
sudden death. Journal of Cardiovascular Electrophysiology 6, 887-900. 
Sugiyama, A., Satoh, Y., Hashimoto, K., 2001. Acute electropharmacological effects of intravenously 
administered amiodarone assessed in the vivo canine model. Japanese Journal of 
Pharmacology 87, 74-82. 
Tieleman, R.G., Gosselink, A.T., Crijns, H.J., Van Gelder, I.C., Van Den Berg, M.P., De Kam, P.J., 
Van Gilst, W.H., Lie, K.I., 1997. Efficacy, safety, and determinants of conversion of atrial 
fibrillation and flutter with oral amiodarone. The American Journal of Cardiology 79, 53-57. 
Trachsel, D., Tschudi, P., Portier, C.J., Kuhn, M., Thormann, W., Scholtysik, G., Mevissen, M., 2004. 
Pharmacokinetics and pharmacodynamic effects of amiodarone in plasma of ponies after 
single intravenous administration. Toxicology and Applied Pharmacology 195, 113-125. 
van Loon, G., Blissitt, K.J., Keen, J.A., Young, L.E., 2004. Use of intravenous flecainide in horses 
with naturally-occurring atrial fibrillation. The Equine Veterinary Journal 36, 609-614. 
van Loon, G., Duytschaever, M., Tavernier, R., Fonteyne, W., Jordaens, L., Deprez, P., 2002. An 
equine model of chronic atrial fibrillation: methodology. The Veterinary Journal 164, 142-
150. 
van Loon, G., Jordaens, L., Muylle, E., Nollet, H., Sustronck, B., 1998. Intracardiac overdrive pacing 
as a treatment of atrial flutter in a horse. The Veterinary Record 142, 301-303. 
van Loon, G., Tavernier, R., Duytschaever, M., Fonteyne, W., Deprez, P., 2000. Pacing induced 
sustained atrial fibrillation in a pony. Canadian Journal Veterinary Research 64, 254-258. 
Vardas, P.E., Kochiadakis, G.E., Igoumenidis, N.I., Tsatsakis, A.M., Simantirakis, E.N., Chlouverakis, 
G.I., 2000. Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial 
fibrillation: A randomized, controlled study. Chest 117, 1538-1545. 
Wijffels, M.C., Kirchhof, C.J., Dorland, R., Allessie, M.A., 1995. Atrial fibrillation begets atrial 
fibrillation. A study in awake chronically instrumented goats. Circulation 92, 1954-1968. 
 

 127 
 
 
 
 
CHAPTER 5 
 
 
PHARMACOKINETICS AND 
BIOAVAILABILITY OF INTRAVENOUSLY 
AND ORALLY ADMINISTERED 
AMIODARONE IN HORSES 
  
 129 
EVALUATION OF THE PHARMACOKINETICS AND 
BIOAVAILABILITY OF INTRAVENOUSLY AND ORALLY 
ADMINISTERED AMIODARONE IN HORSES 
Dominique De Clercqa, Kris Baertb, Siska Croubelsb, Gunther van Loona, An Maesb, Rene 
Tavernierc, Piet Depreza, Patrick De Backerb 
 
 
aDepartment of Large Animal Internal Medicine, Ghent University, Salisburylaan 133, B-9820 Merelbeke, 
Belgium 
bDepartment of Pharmacology, Pharmacy, and Toxicology, Ghent University, Salisburylaan 133, B-9820 
Merelbeke, Belgium 
cDepartment of Cardiology, University Hospital Ghent, De Pintelaan 185, B-9000 Ghent, Belgium  
 
 
 
 
 
 
 
 
 
Adapted from: De Clercq, D., Baert, K., Croubels, S., van Loon, G., Maes, A., Tavernier, R., 
Deprez, P., De Backer, P., 2006. Evaluation of the pharmacokinetics and bioavailability of 
intravenously and orally administered amiodarone in horses. American Journal of Veterinary 
Research 67, 448-454. 
Chapter 5 : Pharmacokinetics of amiodarone in horses
 
130 
Summary 
The objective of the study was to determine the clinical effects and pharmacokinetics of 
amiodarone after single doses of 5 mg/kg administered orally or intravenously.  
In a cross over study, clinical signs and electrocardiographic variables were monitored and 
plasma and urine samples were collected. A liquid chromatography–mass spectrometry 
method was used to determine the percentage of protein binding and to measure plasma and 
urine concentrations of amiodarone and the active metabolite desethylamiodarone.  
No adverse clinical signs were observed. After IV administration, median terminal 
elimination half-lives of amiodarone and desethylamiodarone were 51.1 and 75.3 hours, 
respectively. Clearance was 0.35 [L/h]/kg, and the apparent volume of distribution for 
amiodarone was 31.1 L/kg. The peak plasma desethylamiodarone concentration of 0.08 
µg/mL was attained 2.7 hours after IV administration. Neither parent drug nor metabolite was 
detected in urine, and protein binding of amiodarone was 96%. After oral administration of 
amiodarone, absorption of amiodarone was slow and variable; bioavailability ranged from 
6.0% to 33.7%. The peak plasma amiodarone concentration of 0.14 µg/mL was attained 7.0 
hours after oral administration and the peak plasma desethylamiodarone concentration of 0.03 
µg/mL was attained 8.0 hours after administration. Median elimination half-lives of 
amiodarone and desethylamiodarone were 24.1 and 58.6 hours, respectively.  
Results indicate that the pharmacokinetic distribution of amiodarone is multicompartmental. 
This information is useful for determining treatment regimens for horses with arrhythmias. 
Amiodarone has low bioavailability after oral administration, does not undergo renal 
excretion, and is highly protein-bound in horses.  
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Introduction 
Amiodarone (AD) is a benzofuran-derived drug that was developed more than 35 years ago 
for management of myocardial ischemia in humans (Singh, 1983). Although the 
antiarrhythmic and preventative effects of AD on atrial flutter and atrial fibrillation (AF) have 
been known since the early 1980s, the drug has been used most extensively for treatment of 
ventricular arrhythmias (Siddoway, 2003). Because of its potency as an antiarrhythmic drug, 
AD is receiving renewed attention for potential use in treatment and prevention of AF (Pollak 
and Shafer, 2004).  
AD has high lipid solubility and is taken up extensively by tissues, resulting in a high volume 
of distribution and prolonged elimination half-life (t1/2). Estimates of elimination t1/2 vary, 
depending on study design and sensitivity of the analytic methods used (Gill et al., 1992; 
Pollak and Shafer, 2004). A model for estimating pharmacokinetic variables of AD in ponies 
has been described (Trachsel et al., 2004). As is true in humans, AF is one of the most 
common cardiac arrhythmias in horses (Reef et al., 1988; Tsikouris and Cox, 2001). The 
major clinical sign in horses is exercise intolerance. The prognosis for return to normal sinus 
rhythm is influenced by the duration for which the arrhythmia has persisted and by atrial 
diameter; duration of the arrhythmia for longer than 6 months or development of the 
arrhythmia in association with atrial dilatation is associated with a poor prognosis for 
successful cardioversion. Atrial dilatation can be caused by mitral valve regurgitation and can 
also result from AF (Reef et al., 1988; Stadler et al., 1994; van Loon et al., 2001). In many 
horses with AF, no underlying cardiac disease is detected and treatment is often successful. 
After cardioversion, horses generally return to the previous level of athletic ability (Reef et 
al., 1988).  
The standard treatment for AF is administration of quinidine sulphate (QS), although up to 
76% of treated horses develop 1 or more adverse effects, including urticaria, nasal mucosal 
edema, colic, diarrhea, laminitis, tachycardia, anaphylactic shock, syncope, or sudden death 
(Marr et al., 1995; Muir et al., 1990; Reef et al., 1988; 1995; 2002; Stadler et al., 1994). In 
some countries, QS has become difficult to obtain and will likely become more expensive 
(McGurrin et al., 2003). These factors have stimulated the search for an alternative and less 
toxic drug for treatment of chronic AF in horses.  
Multiple antiarrhythmic drugs are used for treatment of AF in humans, some of which have 
already been investigated for use in horses (Boriani et al., 2004). Intravenously administered 
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flecainide (a class IC antiarrhythmic drug) and AD (a class III antiarrhythmic drug) have been 
used for treatment of horses with AF (De Clercq et al., 2006; van Loon et al., 2004). The use 
of flecainide in horses appeared promising for treatment of acute AF in 1 study, but it was not 
useful in horses with chronic AF because of elicitation of ventricular dysrhythmias (Ohmura 
et al., 2000; van Loon et al., 2004). In another study, 4 of 6 horses were converted to sinus 
rhythm after IV administration of AD. In that study, horses received 5 mg of AD/kg per hour 
for 1 hour followed by 0.83 mg/kg/h for 23 hours and 1.9 mg/kg/h for 30 hours. Infusion was 
discontinued when conversion was achieved or when adverse effects were observed (De 
Clercq et al., 2006). Because AD appeared to be potentially useful for treatment of chronic 
AF in horses, the present study was undertaken to investigate the pharmacokinetics of orally 
and IV administered AD in horses.  
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Materials and Methods  
The experimental protocol was approved by the Ethics Committee of the Faculty Veterinary 
Medicine at Ghent University.  
Study design 
In a cross-over format, the first phase of the study involved IV administration of a single dose 
(5 mg/kg) of AD (Cordarone 150mg/3mL, Sanofi-Synthélabo) to 3 healthy Standardbred 
mares with mean±SD age, body weight, and height at the withers of 9.8±3.5 years, 
491.7±19.8 kg, and 156.3±8.9 cm, respectively, that had not been withheld from feed. Horses 
received the dose of AD as a bolus in the right jugular vein over a period of 2 minutes. Three 
other horses received an orally administered dose (5 mg/kg) of crushed tablets by means of 
nasogastric intubation after being withheld from feed for 12 hours. Four hours after receiving 
the oral treatment, horses were given hay ad libitum. Blood was withdrawn from the left 
jugular vein in heparinized polyethylene tubes just before drug administration; 5, 15, 30, 45, 
60, 90, 120, 180, 240, 300, 360, 480, and 720 minutes after administration; and every 12 
hours after that until 7 days after administration. Blood samples were centrifuged at 3,000 X g 
immediately after collection to obtain plasma. In 3 horses that received AD IV, total urine 
samples were collected 0, 1, 2, 3, 4, 6, 8, and 12 hours after treatment. Plasma and urine 
samples were frozen and stored at –18°C until drug assay. Clinical signs, respiratory rate, and 
an ECG were recorded at each blood sampling time until 6 hours after drug administration. 
Information collected from ECG included heart rate, PR interval, QRS wave duration, and QT 
interval. Immediately before and 7 days after drug administration, complete hematologic and 
biochemical blood analyses were performed.  
In the second phase of the study, which was initiated 60 days after the first phase, the same 
sampling protocol was followed. Horses that had received AD IV in the first phase were 
treated orally and vice versa.  
Plasma and urine analyses 
AD and desethylamiodarone (DAD) concentrations were measured by use of a validated high-
performance liquid chromatography (HPLC) method and tandem mass spectrometry. In brief, 
100 µL of a solution of the internal standard tamoxifen (concentration, 10 µg/mL) was added 
to a 1,000-µL aliquot of plasma or urine. After mixing for 15 seconds, 25 µL of glacial acetic 
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acid was added to deproteinize the mixture and the tube was centrifuged at 9,500 x g for 10 
minutes. Thereafter, solid-phase extraction and clean up were performed by use of strong-
cation–exchange cartridges (Sopachem) that had been previously conditioned with 1 mL of 
methanol solution and 1 mL of water. After application of the supernatant, cartridges were 
sequentially washed with 1 mL of 0.1M hydrochloric acid and 1 mL of methanol. Analytes 
were eluted with 2 mL of a methylene chloride-isopropanol-ammonia solution (78/20/2 
[vol/vol/vol]). The elution liquid was evaporated at 40°C under a gentle nitrogen stream. The 
dry residue was dissolved in 250 µL of 0.1% formic acid in a water-methanol solution (20/80 
[vol/vol]). A 100-µL aliquot of that mixture was injected onto the liquid chromatography 
system combined with an ion-trap mass spectrometer operating in the electrospray positive-
ionization mode (Thermo Finnigan). For chromatographic separation, a C18 column (Thermo 
Finnigan, 5 µm; 100 X 2.1 mm internal diameter) with a guard column of the same type (5 
µm; 10 X 2.1 mm internal diameter) were used. An isocratic run of 5 minutes was performed 
with a mobile phase of acetonitrile (A) and 0.1% formic acid in water (B; ratio, 80A:20B 
[vol/vol]) at a flow rate of 0.2 mL/min. Quantification was performed by use of ion transitions 
with mass-over-charge ratios of 646.1 > 572.8 for amiodarone and 618.2 > 546.8 for DAD.  
The analytical method was validated for linearity, within-and between-day trueness and 
precision, limit of quantification (LOQ), and limit of detection (LOD) according to the 
European Community guidelines for analytical methods (Commission Decision, 2002). 
Calibration curves were prepared by adding AD or DAD to pooled blank plasma and urine 
samples at concentrations of 0.005, 0.010, 0.025, 0.050, 0.100, 0.500, 1.000, and 0 µg/mL. 
The trueness (i.e., recovery or the difference between the mean detected and fortified 
concentrations) and within-day precision of the method were determined by use of 6 blank 
samples to which known quantities of drug were added at 0.010 and 0.050 µg/mL for plasma 
and 0.025 and 0.500 µg/mL for urine. The trueness for AD in plasma was –23.9% and –
10.7% for the 0.010 and 0.050 µg/mL samples, respectively, and for DAD, values of 7.5% 
and –1.6% were obtained for the 0.025 and 0.500 µg/mL samples, respectively. For urine 
samples, values were 1.0% and –0.8% for AD and –12.3% and –0.6% for DAD at 
concentrations of 0.025 and 0.500 µg/mL, respectively. All values were within the acceptance 
range of –30% to +10% for concentrations ≤ 0.010 µg/mL and –20% to 10% for 
concentrations > 0.010 µg/mL (Yamaoko et al., 1978). The precision also fell within the 
maximum relative SD values of 21.3%, 18.6%, 11.8%, and 16.7% for concentrations of 
0.010, 0.025, 0.050, and 0.500 µg/mL, respectively. The between-day trueness and precision 
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were determined by use of samples of plasma with a drug concentration of 0.010 µg/mL and 
were used for quality control during analyses of the collected samples. Those values were in 
the specified maximum ranges. The LOQs for plasma and urine were established by analyzing 
6 blank samples to which AD and DAD (concentration, 0.005 µg/mL) had been added. The 
LOD was calculated by means of the criterion of a signal-to-noise ratio of 3:1. This 
corresponded to LODs of 0.0001 and 0.00004 µg/mL, respectively, for AD and DAD in 
plasma and of 0.00016 and 0.00009 µg/mL, respectively, in urine.  
Protein binding was determined in plasma samples (n = 6) to which drug had been added at a 
concentration of 2 µg/mL and allowed to equilibrate for 30 minutes at 37°C. One milliliter of 
that solution was centrifuged at 9,500 x g for 10 minutes through a filter of 30.000 molecular-
weight cutoff. The filtrate was analyzed similarly to plasma samples.  
 
Pharmacokinetic data analysis 
The plasma concentration-time curves for data obtained after IV administration of AD in each 
horse were fitted by use of a nonlinear least-squares regression-fitting program (M/W Pharm, 
version 3.60). The model was determined for best fit on the basis of a smaller value for the 
Akaike information criterion (Yamaoko et al., 1978). The plasma concentration-time curves 
for those data best fit the 3-compartmental model. The following equation was used to 
describe the concentration-time curves: Cp = Ae–αt + Be–βt+ Ce–γt , where Cp is the plasma 
concentration; A, B, and C are zero-time intercepts; e is the base of natural logarithms (ln); t 
is time; and α, β, and γ are hybrid constants dependent on first-order rate constants. Values for 
AUC0–inf, Cl, apparent Vd, and t1/2el were calculated according to standard pharmacokinetic 
equations (Gibaldi and Perrier, 1975).  
For AD data obtained after oral administration and DAD data obtained after IV and oral 
administration (of AD), noncompartmental methods were used because standard fitting 
procedures resulted in poor correlations. The AUC0–inf  value was calculated via the 
trapezoidal method. The variables Cmax and Tmax were observed directly from the plasma 
concentration time plots. Absolute bioavailability (F) was calculated from the following 
equation:  
F = (AUC0–inf oral/AUC0–inf IV) X 100  
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Statistical analysis 
Pharmacokinetic variables were reported as median values except for t1/2el, for which a 
harmonic mean was calculated. Respiratory rate, heart rate, P-R interval, QRS duration, and 
Q-T interval over time were analyzed by use of single-factor ANOVA. The mean measured 
values were compared with values obtained before treatment. For all comparisons, values of p 
< 0.05 were considered significant. 
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Results  
Administration of AD via IV and oral routes was tolerated well by all horses. Values for 
hematologic and serum biochemical variables remained within reference ranges for the first 
(i.e., immediately before administration) and second (i.e., 7 days after administration) blood 
samples (Carlson, 2002). Numeric and graphic descriptions of data for respiratory rate, heart 
rate, PR interval, QRS duration, and QT interval indicated that the condition of equality of 
variances was satisfied. Results of single-factor ANOVA did not reveal significant differences 
between mean values for the variables. Although increased heart rate was observed after IV 
administration of AD, the change was not significant. Pharmacokinetic variables for AD and 
DAD were given as median and range values and summarized (Tables 1 and 2). Mean±SD 
plasma concentrations of AD and DAD after IV and oral administration were plotted (Figures 
1 and 2). In horses in the IV administration group, plasma concentrations of AD and DAD 
were quantifiable from 5 and 15 minutes, respectively, after administration until 168 hours 
after administration. In the oral administration group, AD and DAD concentrations were 
quantified in plasma from 30 and 90 minutes, respectively, after administration until 96 and 
120 hours after administration. After IV administration, plasma concentrations of AD 
decreased rapidly in the first phase of the 3-compartment model. The second phase was 
characterized by a slower decline in concentration and was followed by a very slow decline in 
concentration in the third phase. In 2 horses, there was a small increase (50 and 100 µg/mL) 
in plasma AD concentration at 8 and 12 hours, respectively (Figure 3). The plasma 
concentration curves after oral administration of the drug were variable, and absorption was 
slow and incomplete. Protein binding of AD as analyzed at 2 µg/mL was 96%. No AD or 
DAD could be detected in the urine samples collected until 12 hours after IV administration.  
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 Table 1. Median and range values of pharmacokinetic variables after a single IV or orally administered dose (5 
mg/kg) of amiodarone (AD) in 6 healthy horses.  
 
Pharmacokinetic parameters of Pharmacokinetic parameters of
AD after 5 mg AD/kg bodyweight IV AD after 5 mg AD/kg bodyweight PO
median range median range
Cmax (µg/ml) NA NA 0.14 0.04 - 0.17
Tmax (h) NA NA 7.0 3.0 - 12.0
AUC (µg.h/ml) 14.5 11.0 - 19.6 2.5 1.2 - 5.1
Cl ([L/h]/kg) 0.35 0.27 - 0.45 NA NA
Vd (L/kg) 31.1 14.9 - 64.5 NA NA
T1/2el (h) 51.1* 38.2 - 84.0 24.1* 18.7 - 36.1
F (%) NA NA 19.4 6.0 - 33.7  
IV: intravenous. PO: per oral. Cmax: maximum concentration obtained after bolus. Tmax: time to reach Cmax. 
AUC: area under the curve. Cl: clearance. Vd: volume of distribution. T1/2el: terminal elimination half-life. F: 
absolute bioavailability. NA: not applicable. * harmonic mean. 
 
 
 
Table 2. Median and range values of pharmacokinetic variables for desethylamiodarone (DAD) after a single IV 
or orally administered dose (5 mg/kg) of amiodarone (AD) in the same 6 horses as in Table 1.  
 
  Pharmacokinetic parameters of Pharmacokinetic parameters of
DAD after 5 mg AD/kg bodyweight IV DAD after 5 mg AD/kg bodyweight PO
median range median range
Cmax (µg/ml) 0.08 0.05 - 0.11 0.03 0.02 - 0.06
Tmax (h) 1.5 0.7 - 8.0 8.0 6.0 - 14.0
AUC (µg.h/ml) 7.3 4.2 - 10.3 2.1 1.2 - 6.7
T 1/2el (h) 75.3* 53.8 - 127.1 58.6* 48.0 - 100.8  
IV: intravenous. PO: per oral. Cmax: maximum concentration obtained after bolus. Tmax: time to reach Cmax. 
AUC: area under the curve. T1/2el: terminal elimination half-life. * harmonic mean. 
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Figure 1. Mean ± SD plasma concentrations of amiodarone and desethylamiodarone after a single IV 
administered dose (5 mg of amiodarone/kg) in 6 healthy horses. The concentration axis is expressed in a semi-
logarithmic scale. 
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Figure 2. Mean ± SD plasma concentrations of amiodarone and desethylamiodarone after a single orally 
administered dose (5 mg/kg) of amiodarone in the same horses as Figure 1. The concentration axis is expressed 
in a semi-logarithmic scale. 
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Discussion  
The dose (5 mg/kg) of AD used in the present study was chosen on the basis of doses 
described in pharmacokinetic studies in other species. In this study, there were no changes in 
respiratory rate, P-R interval, QRS duration, or QT interval and no arrhythmias developed 
after the single IV dose of AD, findings that corroborated with those from a study in humans 
(Chow, 1996). Substantial prolongation of the QT interval without torsades de pointes, 
however, has been described after administration of several doses of AD in humans and dogs 
and has also been reported after a single IV dose in ponies (Hohnloser et al., 1991; van Opstal 
et al., 2001; Trachsel et al., 2004). Horses in the present study had a moderate increase in 
heart rate after IV administration of AD, a finding that has also been reported in ponies and 
humans; in contrast, a decrease in heart rate after a single dose of AD has been described in 
dogs (Connolly et al., 1984; Trachsel et al., 2004; Wellens et al., 1984). As hypothetized in 
human medicine, the higher heart rate may be explained by the development of hypotension 
after IV administration (Gill et al., 1992; Vardas et al., 2000; Wellens et al., 1984).  
Pharmacokinetic variables reported for AD vary. This is likely a result of the length of time 
during which samples were collected in the experiments and the sensitivity of the assays 
(Pollak et al., 2000; Weiss et al., 1999). In the present study, bolus-dose administration and 
sampling times of 7 days were used to determine bioavailability and calculate standard 2-
stage compartmental pharmacokinetic variables. The method of analysis was a liquid 
chromatography–tandem mass spectrometry method performed on an ion-trap mass 
spectrometer. These methods yielded an LOQ of 0.005 µg/mL in the plasma and urine 
samples. Other investigators obtained lower LOQ values by use of either another tandem 
mass spectrometer system with a more sensitive triple-quadrupole instrument or techniques 
involving the use of radiolabeled AD (Meng et al., 2001). With the latter methods, the 
terminal elimination phase can be better characterized and a better estimate of elimination t1/2 
can be obtained. In humans studies, investigators described a terminal elimination phase of 
100 days and an elimination t1/2 of 58 days after a single dose of AD (Meng et al., 2001; 
Pollak et al., 2000), findings that were in accordance with values reported after long-term 
administration or use of radiolabeled drug (Broekhuyzen et al., 1969). A drawback in methods 
involving the use of radiolabeled drug is that it is not always possible to differentiate between 
parent drug and metabolites. Comparison of pharmacokinetic variables should, therefore, be 
performed with data collected under the same circumstances, including similar sampling 
times and sensitivity of analytic methods.  
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The concentration-versus-time curves for data obtained after IV administration were fitted to 
a 3-compartment model. Values for mean Vd (31.1 L/kg), Cl (0.35 [L/h]/kg), and t1/2 (38 to 84 
hours) were calculated. Compared with our value, a much longer t1/2 of 16.3 days was 
calculated in ponies treated with AD by another group (Trachsel et al., 2004). This difference 
may be explained because a mathematical based pharmacokinetic model was used to estimate 
pharmacokinetic parameters in that study.  
As has been reported in studies in humans, the plasma concentration-time curves in these 
horses after oral administration did not have a good fit for the curve on the basis of 
compartmental modeling (Andreasen et al., 1981; Haffajee et al., 1983). A delay (0.5 hours) 
in the appearance of AD in plasma was observed in these horses. In humans, mean lag times 
of 0.5 to 1.4 hours have been reported (Canada et al., 1983, Haffajee et al., 1983; Plomp et al., 
1984). Maximum plasma AD concentrations were attained 7.0 hours after administration in 
our horses, whereas mean±SD values of 7.3±2.9 hours, 5.2±0.6 hours and 4.8±2 hours have 
been reported in humans (Andreasen et al., 1981; Canada et al., 1983, Haffajee et al., 1983). 
A lower median Cmax (0.14 µg/mL) was observed in our horses, compared with values of 0.5 
µg/mL, 1.7 µg/mL, and 0.37±0.22 µg/mL reported in humans (Andreasen et al., 1981; 
Haffajee et al., 1983; Plomp et al., 1984). Median bioavailability in the nonfed horses (19.4%) 
was < 50%, a value that has been reported in dogs and rats, whereas in humans, values of 
22% to 86% have been reported (Andreasen et al., 1981; Broekhuyzen et al., 1969; Canada et 
al., 1983; Holt et al., 1983; Plomp et al., 1984; Riva et al., 1982). The large variability in 
absorption observed in the present study was in agreement with findings from 
pharmacokinetic studies in humans. Such low and variable bioavailability may be attributed 
to incomplete absorption of the drug and first-pass metabolism in the intestine or liver (Plomp 
et al., 1984). Concurrent ingestion of food has a positive influence on bioavailability of AD in 
humans; investigators in that study concluded that AD has dissolution–rate-limited absorption 
and the effects of food and bile result in the improved bioavailability (Meng et al., 2001). 
Whether food intake also increases bioavailability of orally administered AD in horses 
remains to be investigated.  
A secondary peak in plasma concentration 8 to 12 hours after IV administration was observed 
in 2 horses and may have been a result of entero-hepatic cycling (Andreasen et al., 1981). The 
fact that the highest bioavailability for AD was observed in those 2 horses supports this 
theory.  
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Plasma concentrations of DAD were measured simultaneously in each sample. This 
metabolite is important because it has pharmacologic potency and toxicity equal to the parent 
drug (Gill et al., 1992). After administration of the drug in our study, median maximum DAD 
concentrations were 80 and 29 µg/L after IV and oral administration, respectively. The t1/2 of 
DAD was longer than the t1/2 of amiodarone, a finding that was in accordance with data in 
humans (Plomp et al., 1984). In an earlier study in which AD was given as an IV infusion, 
plasma DAD concentrations remained low and did not exceed 360 µg/L, a fraction of the 
amiodarone concentration (De Clercq et al., 2006). This observation has also been made in 
rats (Wyss et al., 1990). These findings are different from those reported in a study in which 
chronic AD administration in humans yielded plasma DAD concentrations nearly equal to AD 
concentrations (Pollak et al., 2000). This may indicate that there is a species-dependent 
difference in metabolism, with N-dealkylation being a less important metabolic pathway in 
horses than in humans. However, long-term administration studies should be performed, with 
analysis of plasma and liver tissue for AD and DAD concentrations, and in vitro experiments 
with microsomes obtained from equine liver tissue could be performed to confirm this 
hypothesis.  
We observed 96% protein binding for AD in the in vitro ultrafiltration experiments. The 
protein binding was investigated at 2 µg/mL since that concentration appears to be a 
pharmacologically important plasma concentration (Canada et al., 1983; Vardas et al., 2000). 
Some investigators have questioned the reliability of the ultrafiltration technique for 
quantification of AD protein binding because of adherence of drug molecules to the filtration 
devices, but those experiments were conducted with radiolabeled AD; other researchers 
reported no interference when using analytic-grade AD (Ujhelyi et al., 1996; Veronese et al., 
1988). The high protein binding we observed was in agreement with findings in other species 
(Andreasen et al., 1981; Latini et al., 1984; Veronese et al., 1988). 
No AD or DAD was detected in urine of horses during the 12 hours following IV 
administration. Because glucuronide conjugates have been detected in urine of treated 
humans, urine samples in the present study were combined with sodium hydroxide to 
deglucuronidate the samples, but neither AD nor DAD was detected. Similar results have 
been described in humans and rats (Haffajee et al., 1983; Latini et al., 1984; Plomp et al., 
1984; Wyss et al., 1990). In a study involving rats, little unchanged AD or DAD was 
eliminated in feces or urine (Wyss et al., 1990). In that study, 94% and 1.7% of a dose of 
radiolabeled drug was eliminated in feces and urine, respectively, primarily as other 
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nonspecified radioactive metabolites formed from AD and DAD (Wyss et al., 1990). This 
finding is in contrast to those predicted by the mathematical model used in an earlier study, in 
which 96% of AD was eliminated as DAD in the urine of ponies (Trachsel et al., 2004). These 
results indicate that metabolism of AD into other compounds is the primary form of 
elimination. The metabolic fates of AD and DAD are unclear. The metabolism of AD and 
DAD in several species, including humans, rats, and rabbits, has been reviewed (Ha and 
Follath, 2004). AD is dealkylated to DAD in the liver and intestine, primarily in hepatic 
microsomes. A hydroxylation step in the metabolism of AD has been proposed (Ha and 
Follath, 2004). DAD may be hydroxylated, dealkylated, and deaminated. Involvement of 
cytochrome P450 enzymes and species-dependent metabolic steps have been proposed (Ha 
and Follath, 2004). Deiodination of AD has also been observed, 1 result of which is excretion 
of free iodide in the urine (Rao et al., 1986).  
The toxicity of AD has already been known for a long period of time. In the early 1980s, 
physicians were reluctant to prescribe AD because of adverse effects associated with chronic 
administration (Pollak et al., 2000). The uncommon pharmacokinetic features of AD and 
DAD (i.e., slow filling of the third compartment of the 3-compartment model and a gradual 
increase in plasma concentrations toward steady state) are partly responsible for the 
reluctance to administer AD. In this study, no clinically important adverse effects or changes 
in results of serum biochemical analyses were observed. In human medicine, acute adverse 
effects associated with IV administration of AD are rare. Hypotension is the most common 
reaction and develops as a result of the vasodilatory and negative inotropic effects of AD. The 
vasodilatory effect is caused by the solvent (polysorbate 80) in which the drug is suspended 
and can be managed with dose reduction or routine pressure-supportive measures (Chow, 
1996). Development of acute hepatotoxicosis after IV administration of AD has been reported 
in humans (Agozzino et al., 2002; Gonzalez et al., 2002).  
Adverse effects associated with chronic (eg, months to years) administration of AD are more 
frequent and involve the lungs, liver, heart, thyroid gland, gastrointestinal tract, eyes, skin, 
nerves, and, rarely, the epididymis (Gill et al., 1992). Gastrointestinal adverse effects in 
humans include nausea, anorexia, and constipation. Neurologic adverse effects include ataxia, 
paresthesia, and development of tremors. In general, clinical signs of toxicosis are dose-
related and disappear after withdrawal of treatment. Guidelines for treating adverse reactions 
have been described (Siddoway, 2003).  
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The purpose of the present study was to determine the pharmacokinetics of AD in horses to 
facilitate development of treatment protocols for horses with acute-onset or chronic AF. An 
oral treatment protocol could be developed, but associated disadvantages include drug 
bioavailability that is low and variable among individuals and the long delay between 
initiation of treatment and onset of suppression of the arrhythmia. Therefore, several weeks 
may be required to achieve steady-state plasma concentrations and drug costs may be 
prohibitive. Moreover, failure of long-term AD treatment (65 mg/kg, q 24 hours for 30 days) 
to resolve AF has been reported in 2 horses (Guglielmini et al., 2003).  
AD may be more useful if administered according to a continuous IV infusion protocol. This 
method of administration has the advantage of rapid filling of the deep compartments and 
possibly a more rapid onset of action that could lead to cardioversion. Disadvantages 
associated with this treatment method are that the treatment must be administered in a clinical 
setting and that, depending on the dose, a higher risk of adverse effects may exist. One 
protocol for IV infusion of AD has been published; mild signs of hind limb weakness and 
weight shifting were reported (De Clercq et al., 2006). A serial IV dosing schedule, as was 
proposed by 1 group of investigators, would be easier to implement in practice, but no clinical 
data from horses treated via this protocol have been published (Trachsel et al., 2004). Another 
possibility would be a treatment protocol combining IV and oral dosing, in which the IV dose 
could be administered in a clinic setting and plasma drug concentrations could be measured. 
Use of such a protocol would potentially permit slower increases in plasma drug 
concentrations toward the desired steady-state concentration with fewer adverse effects but 
would have the disadvantage of increased treatment costs.  
Results of the present study confirm that the pharmacokinetics of AD and DAD in horses are 
multicompartmental. The drug is poorly bioavailable after oral administration, does not 
undergo renal excretion, and is highly protein-bound, similar to findings in other species. 
However, further pharmacokinetic and pharmacodynamic studies are needed to develop a safe 
treatment protocol for AD in horses. Studies of long-term dosing and clinical effects and use 
of more sensitive analytic techniques are needed before AD can feasibly be administered to 
horses with chronic AF. 
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Summary 
Good results have been obtained with a human amiodarone (AD) IV protocol in horses with 
chronic atrial fibrillation (AF). A pharmacokinetic study of AD in horses revealed an adapted 
IV AD treatment protocol for horses.  
Six horses with chronic AF were treated with an adapted AD infusion protocol. The protocol 
consisted of 2 phases with a loading dose followed by a maintenance infusion. In the first 
phase, horses received an infusion of 6.52 mg AD/kg/h for 1 hour followed by 1.1 mg/kg/h 
for 47 hours. In the second phase, horses received a second loading dose of 3.74 mg AD/kg/h 
for 1 hour followed by 1.31 mg/kg/h for 47 hours. Clinical signs were monitored, a surface 
ECG and an intra-atrial electrogram were recorded. AD treatment was discontinued when 
conversion or any side effects were observed.  
Three of the six horses cardioverted successfully without side effects. The other three horses 
did not convert and showed adverse effects, including diarrhea. In the latter, there were no 
important circulatory problems, but the diarrhea continued for 10-14 days. The third horse 
had to be subjected to euthanasia because a concomitant Salmonella infection worsened the 
clinical signs.  
The applied treatment protocol based upon pharmacokinetic data achieved clinically relevant 
concentrations of AD and desethylamiodarone. Intravenous AD has the potential to be an 
alternative pharmacological treatment for AF in horses, although AD may lead to adverse 
drug effects, particularly with cumulative dosing.  
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Introduction  
Atrial fibrillation (AF) is the most common pathological cardiac arrhythmia in horses. Some 
horses may have a history of exercise intolerance, exercise-induced epistaxis, respiratory 
disease, weakness or syncope. In pleasure horses, it may be diagnosed by coincidence during 
clinical examination for a completely different purpose (Deem and Fregin, 1982; Reef and 
McGuirck, 2002).  
AF often occurs in horses without underlying macroscopic cardiac pathology (Deem and 
Fregin, 1982; Reef et al., 1988). These animals have a good prognosis for cardioversion and 
generally return to their previous level of athletic performance after successful treatment. 
However, when AF persists for >3–6 months or when atrial dilatation is present because of 
mitral valve regurgitation or AF per se, treatment becomes more difficult and AF recurrence 
is more common (Reef et al., 1988; van Loon et al., 2001).  
For many years, quinidine sulphate (QS) has been used as the standard treatment for AF and 
has an efficacy of 85% in horses with AF of duration <2 months and without the presence of a 
detectable cardiac disease (Deem and Fregin, 1982; Reef et al., 1988). Nevertheless, in up to 
76% of treated horses this anti-arrhythmic drug can yield serious cardiac and noncardiac side 
effects including urticaria, nasal edema, colic, diarrhea, laminitis, polymorphic ventricular 
tachycardia, anaphylactic shock, syncope or sudden death (Reef et al., 1995, 1988).  
Because QS has become more difficult to obtain and is expensive, alternative 
pharmacological anti-arrhythmic treatments for AF in horses have been investigated recently 
(McGurrin et al., 2003). After encouraging results in experimental, acute AF in horses 
(Ohmura et al., 2000), flecainide, a class I anti-arrhythmic drug, showed little potential in 
clinical cases, and was associated with important ventricular pro-arrhythmia (van Loon et al., 
2004).  
Recently, the use of amiodarone (AD) IV, a class III anti-arrhythmic drug, has been described 
in horses suffering from chronic AF (De Clercq et al., 2006a). Horses received 5 mg AD/kg/h 
for 1 hour followed by 0.83 mg/kg/h for 23 hours and, subsequently, 1.9 mg/kg/h for 30 
hours. With this protocol, four out of six horses successfully converted into sinus rhythm. 
However, three of the six horses showed adverse effects of hindlimb weakness that 
disappeared completely within 4-6 hours after termination of the IV AD treatment. One week 
after the AD treatment, the 2 horses that had not converted to sinus rhythm were treated with 
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QS per os. One horse successfully converted to sinus rhythm but, in the other, QS treatment 
had to be terminated because of adverse side effects (>25% widening of the QRS complex, 
tachycardia). Subsequently, this horse was used as a broodmare.  
 The current study was undertaken with the aim of assessing whether a pharmacokinetic-
based treatment protocol of IV AD in horses with chronic AF had improved efficacy and 
decreased adverse drug rate. In these protocols, a loading dose and a maintenance dose was 
used to achieve a rapid steady state concentration. When using only a maintenance dose, the 
time to reach 90% of the steady state concentration was 3.32 half-lives (Shargel and Yu 1993) 
or, with the pharmacokinetic data of AD used in this study, about 40 hours. 
This report describes the results of a pharmacokinetic-based treatment protocol of IV AD in 
horses with chronic AF. 
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Materials and methods  
Cases  
Five Warmblood horses and one Standardbred (horse 6) were referred for exercise intolerance 
(horses 1, 5 and 6), epistaxis (horses 1, 2, 3 and 5) or arrhythmia (horses 4 and 6) and 
diagnosed with AF. Mean±SD age, bodyweight and height at the withers were 10.3±4.4 years 
(2–15 years), 582.0±93.4 kg (436–720 kg) and 168.3±11.7 cm (155–190 cm), respectively. 
All horses were used for trotting, jumping or pleasure riding. Based upon history and clinical 
examination, AF duration was estimated to be between 1 and 8 months. The clinical 
examination, hematology and full cardiac evaluation were within normal references. 
Echocardiography included auscultation, surface ECG, 2-dimensional, M-mode and Colour 
Flow Doppler. The 2-dimensional and M-mode measurements from the left cardiac window 
included left atrial diameter during ventricular diastole and systole and, from the right cardiac 
window, aortic diameter in diastole, left ventricular internal diameter in diastole and systole, 
interventricular septum thickness in diastole and systole and left ventricular fractional 
shortening (Patteson et al. 1995) (Table 1).  
Two weeks previously, horse 6 had converted with 9 doses of QS (22 mg/kg), but relapsed in 
AF after one week.  
 
Adapted treatment regimen based on pharmacokinetic parameters  
Based on the results of a previous study, where a steady state concentration of 1.0 µg/ml was 
found (De Clercq et al., 2006a) and the literature concerning the therapeutic window of AD 
(Haffajee et al., 1983), a decision was made to aim for a steady state of 2.0 µg/ml of AD in a 
first phase of 2 days and a steady state of 2.5 µg/ml of AD in the second phase of 2 days. This 
adjustment was based on the pharmacokinetic parameters that were found after a bolus 
administration of 5 mg/kg (De Clercq et al., 2006b) in test horses. The parameters used were 
obtained after analysis of a 2-compartment model until the 24-hour point. The following 
formula was used to calculate the loading and maintenance doses to obtain a steady state 
concentration of 2.0 and 2.5 µg/ml in these horses (Shargel and Yu, 1993):  
 ⎥⎦
⎤⎢⎣
⎡ ⎟⎠
⎞⎜⎝
⎛
−
−−⎟⎠
⎞⎜⎝
⎛
−
−−= −− btat
p
e
ba
kae
ba
bk
kV
RCp 1  
Chapter 6 : Adapted intravenous amiodarone protocol in horses
 
156 
In this formula, Cp is the plasma concentration, R is the rate of infusion, Vp is the volume of 
distribution of the central compartment, k is the elimination rate constant, a and b are hybrid 
constants and t is time. These individual results were averaged and used in the following 
protocols:  
In the first phase, horses received a loading dose of 6.52 mg AD/kg/h IV (Cordarone 150 
mg/3 mL, Sanofi-Synthélabo) for 1 hour, followed by 1.1 mg/kg/h IV for 47 hours. In the 
second phase, horses received a second loading dose of 3.74 mg of AD/kg/h IV for 1 hour 
followed by 1.31 mg/kg/h for 47 hours. Infusion was discontinued if conversion to sinus 
rhythm was achieved or side effects observed.  
 
Recorded data  
Before treatment and at regular time intervals, clinical signs and surface ECG were 
monitored. From the latter, heart rate (HR), mean interval between f waves (ms), QRS 
duration (ms) and QT interval (ms) were measured. The atrial fibrillation cycle length 
(AFCL) was recorded from an intra-atrial electrogram. With a temporary pacing catheter 
placed in the right atrium, the local atrial electrogram was recorded using a pacemaker (Thera 
D, Medtronic) and a pacemaker programmer (Programmer 9790, Medtronic). From this 
electrogram the AFCL, the time between 2 successive atrial depolarization waves, was 
recorded (van Loon et al., 1998). The mean interval between the f waves and AFCL were 
estimated from 2-10 s.  
Before and at regular time intervals during treatment, plasma was collected and stored at -
18°C for later AD and desethylamiodarone (DAD) analysis. Plasma was collected just before 
AD administration and at 0.5, 1, 2, 4, 6, 12, 24 and 36 hours (first phase) and at 48, 48.5, 49, 
50, 54, 60, 72 hours (second phase) or until sinus rhythm or adverse effects appeared. After 
termination of the infusion protocol, plasma was collected daily for 5 days for AD and DAD 
plasma concentrations.  
Plasma levels were analyzed by a validated high performance liquid chromatography 
combined with UV detection (Maes et al. 2006). A limit of quantification of 0.05 µg/ml was 
obtained for both components.  
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Haematological and biochemical blood analysis were performed before drug administration 
and at 24 hours and 7 days after cessation of treatment.  
 
Statistical analysis  
The effect of the treatment over time on electrocardiographic variables was analyzed using 
single-factor ANOVA. A Dunnet’s test was performed to detect possible significant 
differences among baseline values.  
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Results  
The results of cardiac evaluation by auscultation, echocardiography (2D and M-mode) and 
Colour Flow Doppler are presented in Table 1. The f-wave interval, AFCL, AD and DAD 
plasma concentrations during treatment are shown in Table 2, Figures 1 and 2.  
Three of the 6 horses were converted successfully to sinus rhythm without side effects at 24 
hours (Horses 2 and 3) and at 46 hours (Horse 1). In the other 3 horses, AD treatment was 
discontinued because of the occurrence of diarrhea with clinical signs of depression and poor 
appetite during 48 (horse 5), 54 (horse 4) and 72 hours (horse 6) of AD treatment. None of 
these 3 horses converted to sinus rhythm and they were treated with fluid administration, 
antimicrobial drugs IV, flunixin meglumine IV (1.1 mg/kg), vitamin E per os (6000 iu) and 
fecal transfaunations for 10-14 days. Clinical signs disappeared gradually in horses 4 and 5 
within 10 and 14 days, respectively; 3 fecal samples for culture did not reveal Salmonella or 
Clostridium infection. However, 2 days after termination of AD treatment, horse 6’s general 
condition suddenly deteriorated. This animal showed severe clinical signs of anorexia, 
toxemia, dehydration and laminitis because of a concomitant Salmonella infection. Despite 
intensive treatment, the horse had to be subjected to euthanasia 10 days after AD treatment.  
After 24 hours, the mean±SD AD plasma level was 2.01±0.33 µg/mL (n = 6). At the end of 
the first phase, the mean±SD AD level was 2.64±0.58 µg/mL (n = 4). Two out of 6 horses 
reached the second phase and at the end of infusion, the concentrations were 2.51 and 2.57 
µg/mL. At the time of conversion, AD/DAD plasma concentrations were 2.02/0.38 µg/mL, 
2.17/0.16 µg/mL and 1.77/0.15 µg/mL in horses 1, 2 and 3, respectively. At the time of the 
occurrence of side effects AD/DAD plasma concentrations were 2.51/0.34, 3.43/0.26 and 
2.57/0.45 µg/mL in horses 4, 5 and 6, respectively.  
Plasma AD and DAD concentrations decreased gradually after cessation of the treatment. 
Five days after termination, AD/DAD plasma concentrations were 0.23/0.30 µg/mL (horse 1), 
0.20/0.12 µg/mL (horse 2), 0.15/0.12 µg/mL (horse 3), 0.21/0.25 µg/mL (horse 4), 0.43/0.12 
µg/mL (horse 5) and 0.90/0.40 µg/mL (horse 6).  
From the numerical description of the data for AFCL, f wave interval, QRS, QT and HR as 
well as from the error bar graphs, it was concluded that the condition of equality of variances 
was satisfied. The ANOVA revealed a highly significant difference in the mean values over 
time for AFCL and f wave interval (p<0.001). When compared to baseline value, the 
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Dunnett’s test showed a significant increase in difference for both parameters from 1 h and 
further (p<0.05). For QT interval, QRS duration and HR, the Dunnett’s test did not reveal any 
differences over time between the mean measured values (p>0.05).  
Haematological and biochemical parameters remained within normal limits 24 h after 
cessation of AD treatment, except that the serum total bilirubin concentration was slightly 
increased in horses 4 and 6. Seven days after cessation of treatment, the serum total bilirubin 
had returned to within the reference range in horse 4 but remained slightly increased in horse 
6.  
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Table 1. Clinical characteristics of the study population (6 horses). 
Horse 1 Horse 2 Horse 3 Horse 4 Horse 5 Horse 6
General information
Age (years) 11 15 10 12 12 2
Height at the withers (cm) 190 165 170 164 166 155
Weight (kg) 720 608 616 526 550 436
Duration of AF (months) 5 2 1 8 3 ?
Cardiac examination
Auscultation 2/6 Holosystolic over MV
1/6 Holosystolic 
over MV
No 
murmurs
No 
murmurs
No 
murmurs
2/6 Holosystolic over MV and 
4/6 holosystolic over TV
Echographic examination
Echocardiography (2D and M-mode)
LADd (cm) 14.5 13.3 12.8 13.6 11.4 11.7
LADs (cm) 14.5 13.7 13.4 13.9 12.4 12.7
Ao (cm) 8.1 7.2 7.1 7.2 7.0 7.0
LVIDd (cm) 12.0 11.6 12.0 11.3 11.1 12.3
LVIDs (cm) 7.7 7.9 8.3 7.1 6.8 7.5
FS (%) 35.6 31.7 30.8 36.7 39.2 39.4
Colour flow Doppler
Mitral valve trivial R trivial R normal normal normal trivial R
Tricuspid valve normal normal normal normal normal moderate R  
AF: atrial fibrillation. LADd: left atrial diameter during ventricle diastole. LADs: left atrial diameter during 
ventricle systole. Ao: aortic diameter in diastole. LVIDd: left ventricular internal diameter in diastole. LVIDs: 
left ventricular internal diameter in systole. FS: left venticular fractional shortening. TV: tricuspid valve area. 
MV: mitral valve area. R: regurgitation. 
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Table 2. Amiodarone (AD) and desethylamiodarone (DAD) plasma concentrations, f wave interval and atrial 
fibrillation cycle length (AFCL) for each horse. 
 
Time    
(hours)
AD      
(µg/ml)
DAD     
(µg/ml)
AFCL      
(ms)
f wave 
interval (ms)
0 0 0 190 160
Horse 1 0.5 3.85 < LOQ 266 240
1 4.29 0.08 285 240
2 1.46 0.21 285 240
4 1.67 0.28 307 260
6 1.44 0.26 307 280
12 1.25 0.25 364 300
24 1.98 0.36 364 300
36 1.76 0.39 400 320
46 2.02 0.38 SR SR
0 0 0 167 160
Horse 2 0.5 2.99 < LOQ 200 180
1 5.25 0.07 235 208
2 2.04 0.08 250 240
4 1.52 0.06 250 240
6 1.56 0.06 250 248
12 1.99 0.11 333 260
24 2.17 0.16 SR SR
0 0 0 167 160
Horse 3 0.5 2.4 < LOQ 250 180
1 2.88 0.06 267 220
2 1.16 0.10 308 220
4 1.56 0.09 286 260
6 2.18 0.09 286 260
12 1.74 0.13 286 260
24 1.77 0.15 SR SR
0 0 0 160 120
0.5 2.46 0.05 211 160
1 2.91 0.09 250 220
2 1.82 0.21 250 220
4 2.11 0.17 250 220
6 1.51 0.18 267 260
12 1.12 0.19 267 260
24 1.73 0.29 267 240
36 1.58 0.31 286 240
48 2.96 0.47 308 300
48.5 4.44 0.48 308 300
49 4.31 0.49 333 300
50 2.59 0.37 333 300
54 2.51 0.34 AE AE
0 0 0 190 180
0.5 3.55 < LOQ 267 240
1 3.89 0.05 286 260
2 1.70 0.07 286 260
4 1.93 0.09 308 260
6 2.15 0.11 286 260
12 2.13 0.12 364 280
24 2.6 0.17 364 280
36 3.14 0.24 364 280
48 3.43 0.26 AE AE
0 0 0 133 120
0.5 3.08 0.06 235 180
1 3.39 0.16 267 240
2 1.4 0.20 267 240
4 1.2 0.13 267 280
6 0.94 0.19 364 320
12 1.14 0.15 364 320
24 1.81 0.27 364 320
36 2.06 0.33 364 340
48 2.15 0.36 364 340
48.5 3.73 0.35 364 340
49 2.93 0.36 400 360
50 2.06 0.32 400 360
54 2.00 0.37 400 360
60 1.94 0.32 400 360
72 2.57 0.45 AE AE
          
Horse 6
          
Horse 4
         
Horse 5
 
LOQ: limit of quantification is 0.05 µg/ml for both components. SR: sinus rhythm. AE: adverse effects. During 
the first phase an intravenous amiodarone loading dose was administered at a rate of 6.52 mg/kg/h (  ) for 1 
hour followed by an infusion at a rate of 1.1 mg/kg/h for the next 47 hours. In the second phase a second loading 
dose at a rate of 3.74 mg/kg/h (  ) for 1 hour (from hour 48 to hour 49) was followed by an infusion at a rate 
of 1.31 mg/kg/h.  Horses that converted into sinus rhythm with the intravenous amiodarone treatment.  
 Horses that did not converted into sinus rhythm with the intravenous amiodarone treatment. 
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Figure 1. Mean (+/-SD) amiodarone (AD) and desethylamiodarone (DAD) plasma concentration (µg/mL) in 
patients with (n= 3 first 48 hours, n=2 from 48 to 54 hours and n=1 from 54 to 72 hours) and without (n=3 first 
24 hours, n=1 at 36 hours) adverse effects, during treatment of a total of 6 horses. 
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During the first phase an amiodarone loading dose was administered at a rate of 6.52 mg/kg/h (  ) for 1 hour 
followed by an infusion at a rate of 1.1 mg/kg/h for the next 47 hours. In the second phase, a second loading 
dose at a rate of 3.74 mg/kg/h (  ) for 1 hour (from hour 48 to hour 49) was followed by an infusion at a rate 
of 1.31 mg/kg/h. 
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Figure 2. Mean (+/- SD) atrial fibrillation cycle length (AFCL) (ms) in horses with (n= 3 in first 48 hours, n=2 
from 48 to 54 hours and n=1 from 54 to 72 hours) and without (n=3 first 24 hours, n=1 at 36 hours) adverse 
effects, during treatment of a total of 6 horses. 
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During the first phase an amiodarone loading dose was administered at a rate of 6.52 mg/kg/h (  ) for 1 hour 
followed by an infusion at a rate of 1.1 mg/kg/h for the next 47 hours. In the second phase, a second loading 
dose at a rate of 3.74 mg/kg/h (  ) for 1 hour (from hour 48 to hour 49) was followed by an infusion at a rate 
of 1.31 mg/kg/h. 
Chapter 6 : Adapted intravenous amiodarone protocol in horses
 
164 
Discussion  
In human medicine, AD, is used to treat AF, atrial flutter and ventricular fibrillation with a 
moderate to good efficacy (Anderson, 1995; Kerin et al., 1996). This drug may terminate AF 
because it has similar actions to beta- and calcium channel blockers on the sino-atrial node, it 
increases the refractory period via sodium and potassium channel effects, and slows 
intracardiac conduction of the action potential via the sodium channel effects (Gill et al., 
1992). Desethylamiodarone is an AD metabolite with a similar pharmacodynamic potency 
and toxicity as the parent drug (Gill et al., 1992).  
Much contradictory information is available about AD and DAD plasma concentrations and 
the possibility of conversion. Some authors describe that the concentration of DAD is more 
important than that of AD (Balser et al., 1991; Nattel et al., 1988). Others described a weak or 
even absent concentration-effect correlation (Rotmensch et al., 1984). In the present study, 
there was an apparent dose-response relationship. The horses with the highest AD/DAD 
plasma level showed adverse signs including diarrhea. However, in the previous equine study 
(De Clercq et al., 2006a), this effect-concentration correlation was not observed.  
In human medicine, efficacy has been shown for AD plasma concentrations between 0.1–11.9 
µg/mL (Latini et al., 1984); and a reference value of 2-2.5 µg/ml has been suggested as safe 
treatment with AD (Boppana et al., 1983; Haffajee et al., 1983; Mostow et al., 1982). Some 
authors describe that cardioversion occurs at an AD concentrations 0.6-3.0 µg/mL with a 
mean±SD of 2.5±1.3 µg/mL (Canada et al., 1983; Vardas et al., 2000). Based upon this 
information, the results from a pharmacokinetic study were used to calculate the infusion 
protocol for horses (De Clercq et al., 2006b). After 24 hours, the mean AD plasma level was  
2.01±0.33 µg/mL (n = 6). At the end of the first phase, mean AD level was 2.64±0.58 µg/mL 
(n = 4). This rather high value was due largely to horse 5 which had a concentration of 3.43 
µg/mL at that time. Two out of 6 horses reached the second phase and at the end of infusion, 
the concentrations were 2.51 and 2.57 µg/mL. The levels obtained approached the targets of 
2.0 µg/mL AD after the first phase and 2.5 µg/mL after the second phase.  
Nevertheless, some horses exceeded this therapeutic concentration, probably because of the 
pharmacokinetic variability of AD in horses. Some horses might have a lower volume of 
distribution and therefore show a higher plasma concentration. Also, because of the multi-
compartmental pharmacokinetics of AD a prediction of plasma concentration is more difficult 
Chapter 6 : Adapted intravenous amiodarone protocol in horses
 
  165 
and the importance of drug accumulation in long term infusion protocols can become 
important when the deep compartments are being filled (De Clercq et al., 2006b).  
Some authors report no difference in AD plasma concentration between human responders 
and nonresponders (Haffajee et al., 1983). In the present study, an important difference of AD 
or DAD plasma levels during the first 24 hours of the infusion protocol was not observed 
between horses with or without development of adverse effects (Figure 1).  
Many factors, including myocardial ultrastructure, AF duration, atrial size and 
electrophysiological properties might influence the success rate of pharmacological treatment. 
Long AF duration, large atrial size and short AFCL are all factors leading to increased AF 
stability (van Loon et al., 2000; Wijffels et al., 1995). All these factors could have been 
related to failure of treatment in these 3 horses.  
In man, adverse effects due to chronic AD treatment include disturbances of the thyroid and 
pulmonary, hepatic, gastrointestinal (in particular dose related nausea), ocular, 
dermatological, epididymis and nerve effects (Gill et al., 1992). A few cases of hepatitis and 
one case report of anaphylaxis due to acute IV AD administration have been described 
(Agozzino et al., 2002; Bravo et al., 2005; Fransi and Briedis, 2004). Also, in dogs, adverse 
effects due to chronic AD treatment include hepatopathy, anorexia, lethargy, pruritis, 
neutropenia and thrombocytopenia (Calvert et al., 2000; Gilbert et al., 2000; Kraus et al., 
2005; Oyama and Prosek, 2006). In a previous equine AD study, adverse clinical signs 
included an increase of total bilirubin and weakness of the hindlimb (De Clercq et al., 2006a). 
In the present study, 2 of 6 horses also showed a slightly increased serum total bilirubin 
concentrations and 3 of 6 horses had clinical signs of diarrhea. Malabsorption syndrome with 
severe diarrhea has been described in dogs after oral administration of sublethal doses of 100 
mg of AD/kg for one month. Malabsorption syndrome was caused by partial villous atrophy 
and the accumulation of macrophages with dyslipidic inclusions (Vic et al., 1985).  
It could be possible that a similar mechanism could have been present in our horses, but the 
exact mechanism of the appearance of diarrhea during short-term AD infusion is not 
described. The clinical signs in horse 6 were worse compared to the other 2 horses because of 
a concomitant Salmonella infection, of which it may have been a carrier. The bilirubin 
increase in horse 6 one week after termination of AD treatment, can be explained by the 
anorexic state of the animal. However, it is known that IV AD has complex pharmacokinetics 
(multi-compartmental) and that all mechanisms of toxicity and adverse effects are not yet 
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completely understood (De Clercq et al., 2006b; Kowey et al., 1997). Antioxidants reduce 
lysosomal phospholipidosis, which is a potential mechanism of AD toxicity (Honegger et al., 
1995). Therefore, horses with adverse effects received vitamin E orally until relieve of the 
clinical signs.  
A delayed therapeutic effect after withdrawal of therapy has been described in man and horses 
but was not observed in the current study (De Clercq et al., 2005; Latini et al., 1984).  
AD treatment in horses with naturally-occurring chronic AF did not result in cardiac side 
effects, but noncardiac adverse effects included short-term hindlimb weakness (De Clercq et 
al., 2006a) and a 10-14 day period of diarrhea. These adverse effects only appeared in the 
horses that received an AD treatment for more than 36 hours.  
In conclusion, the applied treatment protocol based upon pharmacokinetic data achieved 
clinically relevant concentrations of AD and DAD. A clinical benefit was observed in 6 
horses based on intra-atrial electrogram and cardioversion was achieved in 3 horses. 
However, in the other 3 horses conversion was not achieved and adverse effects were 
identified. The therapeutic index of AD, based on the reported plasma levels, is likely to be 
low. Caution should be exercised in using this drug, particularly for prolonged infusions 
owing to the long half-life of the drug. In some horses conversion to sinus rhythm was 
possible, but further studies are necessary to evaluate a correct dosage regimen and the 
applicability of the drug in horses with chronic AF.  
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ELECTRICAL CARDIOVERSION
 
 
In human medicine, electrical cardioversion is highly effective to treat a wide range of 
arrhythmias, including atrial fibrillation (AF). When internal electrodes are used instead of 
external (skin) electrodes, energy requirements for successful cardioversion can be 
dramatically reduced. Because of the lower cardioversion threshold with internal 
cardioversion and because of failure of previous external cardioversion attempts in horses, the 
internal cardioversion technique to treat chronic AF in horses was further investigated in 
Chapter 7. As adapted cardioversion catheters for horses were not commercially available, 
custom-made catheters were used in this study. 
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Summary 
Pharmacological conversion of atrial fibrillation (AF) to sinus rhythm in horses can be 
difficult. The objective of this study was to investigate the feasibility of transvenous electrical 
cardioversion with custom made catheters in 8 horses, of which 3 had failed cardioversion 
using quinidine sulfate. Two cardioversion catheters and one pacing/sensing electrode were 
inserted via the right jugular vein and placed using ultrasound guidance into the left 
pulmonary artery, the right atrium and the right ventricle, respectively. Because immediate 
recurrence of AF was encountered in the second horse treated, pre-treatment with amiodarone 
was given to each of the remaining 6 horses. Induction of general anaesthesia was associated 
with dislocation of the cardioversion catheter in 3 horses, requiring a second catheterization 
procedure. During general anaesthesia, biphasic R wave synchronized shocks of up to 360 J 
were delivered between both cardioversion electrodes. 
In 6 horses (75%), including 2 which had failed quinidine sulfate treatment, sinus rhythm was 
restored with a mean energy level of 295±62 J. No side effects were observed. Blood analysis 
3 hours after cardioversion revealed normal parameters, including cardiac troponin I values. 
Transvenous electrical cardioversion of AF with custom made cardioversion catheters can be 
considered as a treatment option for AF in horses, especially when conventional drugs fail.  
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Introduction 
Atrial fibrillation (AF) is the most important clinically relevant arrhythmia in horses (Reef et 
al., 1988; Reef et al., 1995) and is known to occur because of atrial enlargement, myocarditis, 
autonomic nerve system imbalance, electrolyte or acid–base disturbances, administration of 
anesthetic drugs or tranquilizers, or for unknown causes (Reef and McGuirk, 2002). In 
contrast to humans and dogs, AF often occurs in horses without detectable cardiac pathology 
(Collatos, 1995; Deem and Fregin, 1982; Reef et al., 1988). Such horses have a rather good 
prognosis for cardioversion and they can generally return to their previous level of athletic 
performance after successful treatment. 
After initiation of AF, rapid electrophysiological changes (within 1-2 days) (De Clercq et al., 
2007a) and a decrease in atrial contractility (within 1-2 weeks) occur, leading to slight atrial 
dilatation (van Loon et al., 2001a, 2001b) and further AF stability (Allessie et al., 2002; 
Morillo et al., 1995; Schotten et al., 2003; van Loon, 2001b; Wijffels et al., 1995). In horses, 
it is generally believed that when AF persists for more than 3 months, especially when atrial 
dilatation is present, treatment becomes more difficult and AF recurrence is more common 
(Reef et al., 1988; van Loon et al., 2001a; 2001b). 
The standard treatment for equine AF is quinidine sulfate (QS), but, in some countries the oral 
form is difficult to obtain and expensive. In addition, important QS-related side-effects may 
occur during treatment (McGurrin et al., 2003; Reef et al., 1988, 1995). Intravenous flecainide 
and amiodarone (AD) have been used, but these have shown only a moderate success rate and 
their use has often been associated with significant side effects (De Clercq et al., 2006, 2007b; 
Ohmura et al., 2000; van Loon et al., 2004). Therefore, alternative treatment options should 
be pursued in AF horses that do not tolerate medication or are drug-refractory. 
In human beings, transthoracic cardioversion is highly successful in restoring sinus rhythm, 
but this procedure is difficult in horses because of the size of the thorax and the air-filled 
lungs between the cardioversion paddles. If external cardioversion fails in humans, internal 
cardioversion is an option. Here, one cardioversion catheter is generally placed in the high 
right atrium against the atrial wall and a second is positioned in the coronary sinus, which is 
in close contact with the left atrium. Low energy (<30 J) R wave synchronized shocks result 
in restoration of sinus rhythm in the majority of patients. 
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Since immediate recurrence of AF (IRAF) after successful electrical cardioversion is 
common, pre-treatment with anti-arrhythmic drugs is frequently used to prevent AF re-
initiation (Duytschaever et al., 2000, 2002; Lévy et al., 1997; Ricard et al., 2003; 
Timmermans et al., 1998; Van Noord et al., 2002). Administration of AD has proven to be 
successful in preventing IRAF in human patients (Gorenek et al., 2006). Intravenous (IV) AD 
has also been described in horses for AF treatment and has been shown to produce rapid 
changes in electrophysiological properties (De Clercq et al., 2006, 2007b). Whereas long-term 
administration of AD (>36 hours) to convert AF to sinus rhythm in horses has been associated 
with side effects, short-term administration (<36 hours) revealed no such adverse effects (De 
Clercq et al., 2006, 2007b). 
The application of electrical cardioversion to treat AF in horses has been described (Deem 
and Fregin, 1982; Frye et al., 2002; McGurrin et al., 2003, 2005a, 2005b; van Loon, 2001b; 
van Loon et al., 2005). Recently, McGurrin et al. (2005b) reported on the use of electrical 
cardioversion in a large number of horses with a success rate of 98%. Their catheter was 150 
cm in length, 2.5 mm in diameter and had a coiled wire 9.5 cm long that served as a 
cardioversion electrode. The catheter was fluid filled, allowing intracardiac pressure 
registration. However, cardioversion catheters to perform transvenous electrical cardioversion 
in horses are not commercially available yet. The present report describes the results of 
transvenous electrical cardioversion of AF in 8 horses using custom made catheters. 
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Material and methods 
Cases 
AF was diagnosed in 4 French saddle horses, 2 Warmbloods and 2 Trotters that had been 
referred for exercise intolerance (horses 1–5 and 8), colic (horse 6) and arrhythmia (horse 7). 
The mean age, bodyweight and wither height were 9±4 years, 567±57 kg and 170±6 cm, 
respectively. The horses were used for jumping, trotting or pleasure riding. The exact duration 
of AF was known in horse 4 (1.5 months), in horses 1 and 5 (2 months), in horse 3 (1 year) 
and in horse 2 (1.5 years). In the other horses, the duration of AF, based upon history and 
clinical examination, was supposed to be 3 months (horse 7) or 6 months (horses 6 and 8). 
Horse 1 had been successfully treated previously with oral QS (22 mg/kg q 2 h) some 2 years 
previously, but developed severe tachycardia during treatment. This horse presented with 
recurrence of AF, with onset 2 months prior to examination. Three other horses (horses 4, 5 
and 7) had recently been treated with QS but had failed to convert and showed obvious side 
effects including tachycardia, colic and diarrhea. 
A clinical examination and a complete blood analysis were performed, including an assay for 
the cardiac biomarker troponin I using a luminescent immunoassay with a detection limit of 
0.10 ng/mL (ADVIA centaur, Bayer Diagnostics). A full cardiac examination was undertaken 
including two-dimensional, M-mode and Colour Flow Doppler echocardiography (GE 
Vingmed CFM 800 SV) of the left atrial diameter at end-diastole and end-systole measured 
from the left cardiac window; aortic diameter in diastole; left ventricular internal diameter in 
diastole, and systole and left ventricular fractional shortening from the right cardiac window 
(Patteson et al., 1995). Colour Flow Doppler echocardiography was used to identify valvular 
regurgitation. Detailed patient information is shown in Table 1.  
The owners were given 2 treatment options, including the administration of QS and the 
electrical cardioversion technique under general anaesthesia. Information was given about the 
success rate and the potential adverse effects of QS. The owners were also informed about the 
preliminary results on electrical cardioversion, the risk of general anaesthesia and the possible 
danger associated with transvenous electrical cardioversion, and the experimental design of 
the catheter. Written consent to perform electrical cardioversion was obtained from each 
owner. 
Chapter 7: Transvenous cardioversion with custom made catheters in horses
 
182 
Table 1. General information, auscultation of the heart, echocardiographic (2D, M-mode and Colour Flow 
Doppler) measurements of 8 horses. 
 
Horse 1 2 3 4 5 6 7 8
GENERAL
breed SF trotter SF trotter SF WB WB SF
age (years) 15 7 7 5 10 15 5 12
gender gelding mare gelding stallion gelding gelding gelding mare
bodyweight (kg) 600 523 592 457 627 557 557 615
height at the withers (cm) 180 167 168 162 176 168 174 170
referral reason EI EI EI EI EI colic arrhythmia EI
duration of atrial fibrillation (months) 2 18 12 1,5 2 6? 3? 6?
PREVIOUS TREATMENTS
PT / SN / Re Yes / SVT / SR no no Yes / no / AF Yes / colic / AF no Yes / D / AF no
AUSCULTATION
pathological murmur 1/6 HS MV no no no no no no no
ECHOCARDIOGRAPHY (2D AND M-MODE)
LADd (ref. 11.3-14.52 cm)° 14.48 11.33 14.45 13.01 13.78 13.44 12.74 12.22
LADs (ref. 11.22-14.48 cm)° 14.98 12.33 14.26 13.13 13.8 13.48 13.4 12.72
AOD (ref. 6.98-8.74 cm)° 7.00 6.99 7.00 7.34 7.48 7.49 7.23 7.60
LVIDd (ref. 9.90-12.20 cm)° 12.64 12.07 12.24 11.78 11.90 12.20 12.19 10.69
LVIDs (ref.6.40-9.00 cm)° 7.70 7.93 8.12 8.99 7.24 8.80 8.11 6.44
FS (ref. 29.41-44.67%)° 39.09 34.29 32.43 31.26 39.13 34.00 40.80 39.78
COLOUR FLOW DOPPLER
mitral valve trivial normal normal trivial trivial normal trivial trivial
aortic valve trivial normal trivial trivial normal trivial normal trivial
pulmonary valve trivial normal normal trivial normal normal normal normal
tricuspid valve trivial trivial normal trivial trivial normal trivial normal  
SF: French saddle horse. WB: Warmblood horse. EI: exercise intolerance. HS: holosystolic murmur. MV: mitral 
valve area. PT: previous treatment with oral quinidine sulphate. SN: symptoms observed during quinidine 
treatment. Re: result of quinidine treatment. SVT: supraventricular tachycardia. SR: sinus rhythm. AF: atrial 
fibrillation. D: diarrhoea. LADd: left atrial diameter at end-diastole. LADs: left atrial diameter at end-systole. 
AOD: aortic diameter. LVIDd: left ventricular internal diameter in diastole. LVIDs: left ventricular internal 
diameter in systole. FS: left venticular fractional shortening. ° normal reference values according to Patteson et 
al. (1995). 
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Treatment regimen 
Because the second treated horse (horse 2) showed IRAF within 6 min of electrical 
cardioversion, it was decided to pre-treat all subsequent horses with anti-arrhythmic drugs. 
Twenty-four hours before cardioversion, 6 horses (horses 3–8) received 6.52 mg/kg/h 
amiodarone (Cordarone 150 mg/3 mL, Sanofi-synthélabo) IV over 1 hour, followed by 1.1 
mg/kg/h IV for 23 hours (De Clercq et al., 2007b). Electrocardiographs were recorded at 
baseline, 1, 2, 4, 6, 12 and 24 h. Blood was collected just before electrical shock delivery and 
the plasma analyzed for retrospective AD and its active metabolite desethylamiodarone by a 
validated high-performance liquid chromatography (HPLC) method combined with MS/MS 
detection (Maes et al., 2006). The limit of quantification for both components was 0.005 
μg/mL. 
In all horses, a 14 F introducer sheath (TriPort, Mansfield EP) was placed in the lower half of 
the right jugular vein. This introducer has three separate entrance ports, each with a 
haemostatic valve, for insertion of two custom made cardioversion catheters and one bipolar 
pacing catheter (Bipolar Intracardiac Electrode, USCI). The custom made catheter consisted 
of an insulated 0.35 mm steel wire and had a length of 180 cm. At the distal end, 12 cm of the 
insulation was removed to serve as cardioversion electrode. The distal end of the wire was 
isolated and smoothened with polyurethane in order to avoid tissue damage during catheter 
positioning (Figure 1).  
Catheters were inserted and positioned in the standing sedated animal (detomidine, 10 μg/kg, 
Domosedan®, Pfizer Animal Health) under echocardiographic guidance: one cardioversion 
catheter in the left pulmonary artery (LPA) (Figure 2), one cardioversion catheter in the right 
atrium (RA), and a bipolar pacing catheter in the right ventricular apex. The tip of the 
pulmonary cardioversion catheter was advanced into the left pulmonary artery about 20 cm 
beyond the bifurcation of the pulmonary artery. During insertion of the pacing catheter, while 
the tip of the catheter was still located in the RA, the atrial fibrillation cycle length (AFCL) 
was measured (Programmer 9790, Medtronic) (van Loon et al., 1998). The mean AFCL was 
taken as the time between two successive atrial depolarization waves, measured in a window 
of 2–10 s.  
After catheter placement in the standing horse, general anaesthesia was induced. Horses were 
pre-medicated with detomidine before induction, which was achieved with a combination of 
IV ketamine (Anesketin®, 2.2 mg/kg, Eurovet) and midazolam (Dormicum®, 0.06 mg/kg, 
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Roche). Induction was guided with webbing and horses were gently placed in left lateral 
recumbency. An orotracheal tube (30 mm diameter) was placed and isoflurane inhalant 
anaesthesia was given. Intermittent positive pressure ventilation was applied in all horses. 
Dobutamine was administered IV to maintain arterial blood pressure. A base apex ECG was 
connected to both a biphasic electrical defibrillator (Lifepak 20, Medtronic) and a pacemaker 
programmer (Programmer 9790, Medtronic). The custom made cardioversion catheters were 
connected to the defibrillator with the RA catheter as cathode and the LPA catheter as anode. 
The pacing catheter was connected to the pacemaker programmer to achieve ventricular 
pacing in case of temporary asystole (van Loon et al., 2005). 
Catheter position was verified with ultrasound and modified if necessary. Shocks were 
delivered as biphasic truncated exponential waves and were synchronized with the R wave. 
Shock energy delivered to the horses was increased from 150 to 360 J in steps of 50 J until 
sinus rhythm was restored. An arbitrary 2-5 min delay was used between successive shocks to 
assess cardiac rhythm. Cardioversion catheters were removed 5-10 min after cardioversion to 
sinus rhythm. 
After recovery, clinical status was followed and blood for complete blood analysis and 
cardiac troponin I assay was withdrawn 3 hours after the procedure. If sinus rhythm could not 
be restored during the first procedure, a second attempt at electrical cardioversion or oral QS 
treatment was made. 
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Figure 1. The distal end of the insulated (A) custom made cardioversion catheter has a cardioversion electrode 
(B) and a polyurethane-smoothened tip (C). 
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Figure 2. Right parasternal long-axis view with the right ventricular inflow-outflow of a horse. This 
echocardiogram was obtained with a 2.5 MHz sector-transducer at a displayed depth of 30 cm. The custom made 
catheter (arrows) can be observed in the main pulmonary artery (P) and is directed towards the left pulmonary 
artery (LPA). RA: right atrium, TV: tricuspid valve, RV: right ventricle, Ao: aorta, RPA: right pulmonary artery. 
 
 
 
Figure 3. Right parasternal long-axis view with the right ventricular inflow-outflow of a horse. This 
echocardiogram was obtained with a 2.5 MHz sector-transducer at a displayed depth of 30 cm. An echogenic 
linear artefact resembling a catheter (arrows) can be observed in the main pulmonary artery (P). RA: right 
atrium, TV: tricuspid valve, RV: right ventricle, Ao: aorta, LPA: left pulmonary artery, RPA: right pulmonary 
artery. 
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Results 
Before the procedure, biochemical and hematological parameters were all within normal 
reference ranges except for calcium and magnesium in two horses. Horse 3 presented a low 
magnesium level (2.0 mg/dL; ref. 2.2-2.8 mg/dL) and horse 4 had a low calcium level (10.2 
mg/dL; ref. 11.2-13.6 mg/dL) (Carlson, 2002). Both horses received IV calcium and 
magnesium supplementation. Cardiac troponin I was normal in all horses (<0.15 ng/mL; Begg 
et al., 2006). The results of the cardiac examination were within normal limits except for 
horse 1 where the left atrial diameter at end-systole was 14.98 cm (ref. 11.22-14.48 cm) and 
left ventricular internal diameter during diastole was 12.64 cm (ref. 9.90–12.20 cm)(Patteson 
et al., 1995). 
Repeated monitoring during and after AD treatment showed no adverse effects. Except for an 
occasional premature ventricular complex, no ECG abnormalities were seen during left 
pulmonary artery catheter placement. In some horses, visualization and positioning of the 
catheter in the left pulmonary artery was hampered due to echogenic linear artifacts in the 
main and right pulmonary artery. These artifacts were directed towards the right pulmonary 
artery (Figure 3). Mean (±SD) AD and desethylamiodarone concentrations (μg/mL) at the 
beginning of the shock delivery were 0.9±0.2 and 0.1±0.03, respectively.  
Details of baseline AFCL, cardioversion threshold, impedance, catheter position and total 
number of shocks delivered in each horse are shown in Table 2. In 5 of the 8 horses (horses 2-
6) sinus rhythm could be restored (Figure 4) after a total of 3-18 shocks with a mean (±SD) 
energy level of 295±62 J (range 200-360 J; Table 2). Lead impedance was between 48 and 72 
Ω. However, after cardioversion and catheter withdrawal, horse 2 presented multiple atrial 
premature complexes. Six minutes after cardioversion an atrial premature complex resulted in 
recurrence of AF.  
In 3 of the 8 horses (horses 1, 7 and 8), the cardioversion catheter from the LPA was 
displaced after induction of general anaesthesia. Several attempts to reposition the catheter 
during general anaesthesia failed, requiring termination of the cardioversion procedure. In 2 
of the 3 horses (horses 7 and 8), a second electrical cardioversion attempt was performed after 
10 days, which resulted in successful cardioversion in one horse (horse 7). No further 
cardioversion attempts were made in horse 2, the horse returned home as a broodmare. 
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Recovery from general anaesthesia was uneventful in all horses. One horse (horse 8) 
developed diarrhea and fever 4 days after the second cardioversion procedure. Three fecal 
samples were positive on Salmonella culture. The horse received IV fluid, antimicrobials and 
flunixin meglumine (Finadyne®, 1.1 mg/kg, Schering-Plough) and the diarrhea and fever 
resolved within 3 days. No further cardioversion attempts were made and the horse returned 
home as a broodmare. Haematological and biochemical parameters taken 3 hours after 
cardioversion, remained within normal ranges in all horses. 
Ten days after the unsuccessful electrical cardioversion, horse 1 was treated with oral QS (22 
mg/kg q 2 hours). After the second dose, treatment was terminated because of severe 
tachycardia (220 bpm). One hour later, cardioversion to sinus rhythm occurred. One week 
after electrical cardioversion, all converted horses were still in sinus rhythm and returned 
home. 
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Table 2. Catheter position, number of shocks, number of procedures and results are given for each horse. 
 Horse 1 2 3 4 5 6 7 8 Mean+/-SD°
AFCL (ms) 190 133 279† 214† 250† 279† 214† 200† 228+/-55
Cardioversion energy (Joule) / 300 200 250 300 360 360 360* 295+/-70
Impedance (ohm) / 72 60 48 65 60 58 54* 60+/-8
RA (cm) / 56 63 56 72 79 65 50 65+/-9
LPA (cm) / 116 143 117 165 157 135 105 138+/-20
Total number of shocks delivered 0 16 3 3 6 12 18 19 9+/-7
Number of cardioversion procedures 1 1 1 1 1 1 2 2 /
Result of 1st procedure / SR / IRAF SR SR SR SR AF AF /
Result of 2nd procedure / / / / / / SR AF /  
 Horses converted to sinus rhythm with the electrical cardioversion protocol. 
† AFCL measured after a 24-hour amiodarone infusion protocol 
* Highest energy level and impedance are given, although sinus rhythm could not be restored. 
° Values of horse 1 and 8 not included 
SR: sinus rhythm. 
RA: catheter depth in the right atrium from the lower half of the jugular vein 
LPA: catheter depth in the left pulmonary artery from the lower half of the jugular vein. 
IRAF: immediate recurrence of atrial fibrillation after successful electrical cardioversion. 
AF: atrial fibrillation. 
 
 
Figure 4. A base apex electrocardiogram during delivery of a 250 joule R wave synchronized shock (▼) in horse 
4 shows restoration of sinus rhythm (↓). Lead recording is 25 mm/s and 1mV/cm 
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Discussion 
Treatment of AF in horses without detectable cardiac pathology is recommended as there is a 
good prognosis (Collatos, 1995; Deem and Fregin, 1982; Reef et al., 1988). In our patient 
data, only one horse had a left atrial diameter at the end of systole and a left internal diameter 
during diastole that were slightly out of the normal reference range described by Patteson et 
al. (1995). However, this was thought to be partially related to the size of the animal. 
Disturbances in electrolyte concentrations are supposed to be a contributing factor to the 
occurrence of AF (Reef and McGuirk, 2002). Electrolyte values were determined in each 
horse before the procedure and normalized if necessary, although the exact effect on the 
outcome was unknown. 
In human patients, electrical cardioversion is highly effective in converting AF to sinus 
rhythm. The associated risk for embolic complications makes echocardiographic monitoring 
and anti-coagulation treatment mandatory prior to the procedure (Capucci et al., 2000; Ricard 
et al., 2003). Pre-treatment with anti-arrhythmic drugs is recommended because cardioversion 
recurrence of AF is common from between <1 min up to 2 weeks (Chugh et al., 2004; 
Duytschaever et al., 2000, 2002; Gorenek et al., 2002; Joglar and Kowal, 2004; Lévy et al., 
1997; Ricard et al., 2003; Sarubbi et al., 1998; Timmermans et al., 1998; Van Noord et al., 
2002). In horses, transvenous electrical cardioversion has been applied to cardiovert AF 
(Deem and Fregin, 1982; Frye et al., 2002; McGurrin et al., 2003, 2005a, 2005b; van Loon, 
2001b, 2005) but as thromboembolic events have not been associated with AF in horses, anti-
coagulation therapy is not indicated. 
To the authors’ knowledge, IRAF has not yet been reported in horses. This might be 
explained by the fact that during conventional QS treatment, the therapeutic drug level at the 
time of conversion prevents AF from re-occurring immediately. During electrical 
cardioversion without anti-arrhythmic drugs, IRAF is more likely to occur because of the high 
vulnerability of the atria at the time of conversion (Duytschaever et al., 2000, 2002). Because 
horse 2 relapsed to AF within 6 min of conversion, it was decided to load all subsequent 
horses with AD in the 24 hours preceding the electrical cardioversion procedure to reduce the 
risk for IRAF. 
In human patients, AD has proved efficacious in preventing IRAF (Gorenek et al., 2006) and 
therapeutic AD plasma concentrations for cardioversion in humans range between 0.1 and 
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11.9 μg/mL (Latini et al., 1984). Some authors have reported that cardioversion occurs at an 
AD concentration between 0.6 and 3.0 μg/mL, with a mean±SD of 2.5±1.3 (Canada et al., 
1983; Vardas et al., 2000), although Rotmensch et al. (1984) describe a weak or even absence 
of any concentration-effect relationship. Our goal in administering AD to horses was not to 
convert AF to sinus rhythm, but to change the electrophysiological properties of the atria as 
AD prolongs AFCL quickly (1–2 hours) in horses with chronic AF (De Clercq et al., 2006, 
2007b). 
In contrast with a prolonged IV administration, the 24-hour loading with amiodarone did not 
result in side-effects (De Clercq et al., 2006, 2007b). The diarrhea occurring in horse 8 after 
cardioversion was not thought to be directly caused by AD because of the late occurrence and 
the positive fecal Salmonella culture. 
McGurrin et al. (2005b) have described a success rate of 98% for electrical cardioversion in 
horses, but equine cardioversion catheters are not yet commercially available. Human 
cardioversion catheters are only 120 cm long, which is usually insufficient to place the 
catheter tip into the equine LPA. Therefore, we developed custom made catheters with a 
length of 180 cm. Electrode placement into the LPA is recommended because, when 
combined with a right atrial electrode, the current between both electrodes will “cover” more 
atrial myocardium, so lowering the threshold for cardioversion (Alt et al., 1997a, 1997b; 
Saksena et al., 1995). 
LPA catheter placement was hampered by a rather poor visibility, due to the depth of the 
thorax and the small diameter of the catheter. In addition, after passing through the RA, RV 
and pulmonary artery, the catheter entered more easily the right branch of the PA instead of 
the left. Repeated insertion and withdrawal while twisting the catheter was necessary in order 
for it to enter the LPA. 
In most horses, the distal part of the catheter, located in the LPA, could not be distinguished 
on ultrasound, but the more proximal part in the main pulmonary artery was clearly directed 
towards the LPA (Figure 2). In some horses, visualization and positioning of the catheter in 
the LPA was hampered due to echogenic linear artifacts in the main and right pulmonary 
artery. Fluoroscopic guidance of catheter placement, as used in humans, is difficult in horses 
because of their size. Exact placement of the catheter could not be guided by radiography due 
to technical limitations. Blood pressure monitoring was not possible with our custom made 
catheter, which challenged catheter placement rather more than was described by McGurrin et 
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al. (2005b). A pacing catheter was placed in the right ventricle as back-up because 
transvenous electrical cardioversion can provoke temporary complete atrioventricular block 
(van Loon et al., 2005). Webbing during the induction of general anaesthesia did not seem to 
prevent displacement of the LPA catheter, as we found this occurred in three horses. 
Shocks were delivered synchronously with the R waves to avoid ventricular arrhythmias 
(McGurrin et al., 2003). Mean cardioversion energy to restore sinus rhythm was higher in this 
study compared to the results (295±62 J vs. 162±10 J) described by McGurrin et al. (2005b). 
This difference might be explained by a different electrode position in the LPA, the smaller 
diameter and therefore the smaller surface of the cardioversion electrode, or indeed by other 
individual factors. Nevertheless, despite these higher cardioversion thresholds and number of 
shocks delivered, cardiac troponin I concentrations remained within normal limits. 
In the present study, the use of custom made catheters allowed us to undertake successful 
transvenous electrical cardioversion in six horses. The small diameter and the lack of 
intracardiac pressure monitoring challenged correct catheter positioning. High energy levels 
and a large number of shocks were required to achieve cardioversion, but were not associated 
with an increase in cardiac troponin I concentrations. Further adaptations of the catheter 
design to increase the surface of the cardioversion electrode and to facilitate catheter visibility 
and positioning are necessary to increase the success rate.  
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This thesis studies the pathophysiology of short (7 days) and long-term (4 months) atrial 
fibrillation (AF) in horses. It also describes alternative treatment possibilities for chronic AF 
in horses.  
 
A. Pathophysiologic aspects of AF in horses 
Since it is difficult to obtain information about the pathophysiology of AF in horses suffering 
from naturally-occurring AF, an experimental model was used in this PhD thesis. To realize 
this experimental model, a pacemaker and a neurostimulator were implanted in normal 
healthy horses as described by van Loon (2002). Although the technique for pacemaker 
implantation was similar as described in ponies, some horses presented an important increase 
in threshold value especially during the AF study period. Presumably pacemaker electrodes 
were more likely to wobble in the large equine atrium, which may result in irritation at the 
anchored tip, followed by formation of fibrosis. Especially during induction of AF, rapid 
movement of the atrial myocardium contributed to the swinging effect on the electrode. 
However, no post mortem data are available to prove this hypothesis. Because of an important 
raise in threshold above maximal pacemaker output, one horse was excluded from the AF 
study and the pacemakers were removed. 
Similar to ponies, dogs and goats, a rapid atrial electrical and contractile remodeling was 
observed in both study protocols of our horses (Morillo et al, 1995; van Loon et al., 2001; 
2002; Wijffels et al., 1995). After restoration of sinus rhythm reverse remodeling occurred 
within 2 days and 2 months for the 7-day and the 4-month AF protocol, respectively.  
An increase in AF vulnerability has been observed in ponies, goats and dogs (Morillo et al, 
1995; van Loon et al., 2001; 2002; Wijffels et al., 1995). However, long-term burst-pacing 
protocols resulted in short-term AF periods in dogs and ponies but in long-term AF periods in 
goats (Allessie et al., 2002; Morillo et al., 1995, van Loon et al., 2001; 2002). In our study, 
each horse developed self-sustaining persistent AF during the chronic protocol and even 2 of 
the 6 horses during the short-term AF protocol. Many factors play a role in the induction and 
maintenance of AF but the theory of Moe (1962) might at least in part explain why smaller 
animals with the presence of a small atrial area have less tendency to fibrillate than larger 
animals with a much larger atrial surface area. This investigator described that the presence of 
AF depends on the critical numbers of re-entry circuits that an atrium can contain. Allessie 
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and coworkers (1985) described that the critical numbers of wavelets for perpetuation of AF 
were between 3 and 6. However, not only atrial size but also the size of a re-entry circuit is 
important in the induction and perpetuation of AF. This size is determined by the wavelength 
(WL) of the re-entrant circuit and is defined by the atrial effective refractory period (AERP) 
and the conduction velocity (CV) (WL = AERP • CV). Due to technical limitations in horses, 
no information is available about CV. Subsequently, the appearance of a “relatively” large 
atrium and/or a decrease of the wavelength, i.e. a short AERP or a decrease in CV, are factors 
that contribute to the induction and persistence of AF. All the different parameters need to be 
interpreted as one entity to understand the pathophysiology of AF.  
Human researchers have suggested that electrical remodeling was an important factor of 
increase in AF vulnerability that sometimes may lead to persistent AF (Wijffels et al., 1995). 
However, since shortening of the AERP and a new steady state level appear very rapidly, 
other factors must be involved to explain the decreased efficacy of cardioversion and the 
reoccurrence of AF after conversion in patients with chronic AF. Besides electrical 
remodeling, important contractile remodeling occurs during AF, which could also influence 
AF susceptibility during AF. During AF an overload of intracellular calcium occurs which 
results in a downregulation of the L-type calcium channels which finally leads to a decrease in 
sarcolemnal calcium influx (Allessie et al., 2002; Courtemanche et al., 1998). The contractile 
dysfunction may lead to atrial paralysis and an increase in the atrial compliance. 
Subsequently, this may induce atrial dilatation with an increase of AF duration (Schotten and 
Allessie, 2001). A slight increase in atrial diameter was observed in our long-term AF study in 
horses.  
Only during the first days of AF a slightly increased heart rate was observed which might 
explain that atria have less time to fill and therefore contain less volume of blood. In human 
patients and dogs, AF is characterized by an increased ventricular rate (Hnatkova et al., 1998; 
King et al., 2002; Miller et al., 1999; Silbauer and Sulke, 2007). However, most likely, only a 
slight increase in heart rate was observed during the first 7 days of AF because horses have a 
high vagal tone. From 7 days onwards a normal heart frequency was observed in the horses. 
The latter observation might be explained by a decrease in atrial fibrillation cycle length 
(AFCL). As in human medicine, a long AFCL represents more atrial flutter and coincides 
with a higher ventricular rate than in atrial fibrillation because of less concealed conduction at 
the level of the atrioventricular node (Zipes, 1992). The influence of the parasympathicus in 
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horses with AF will play a role in a less elevated ventricular response. Therefore, in contrast 
to human patients, rate control is not necessary in horses suffering from AF (Herzog et al., 
2005; King et al., 2002). 
During the last years, besides the wavelet theory described by Moe (1962), new information 
about triggering factors has become available. Indeed, in human medicine, the presence of 
rotors and spiral waves has been described. A rotor is a stable rotating reaction around a pivot 
point which gives rise to spiraling wave fronts. Under adequate circumstances, these rotors 
may give intermittent or permanent high frequency activation which conducts to the other 
atrium and therefore induces and maintains atrial fibrillation. The presence of one or more 
rotors has been described in both atria but most dominant rotors are localized at or near the 
pulmonary veins and the posterior left atrial wall (Jalife, 2003). Currently, no information is 
available about these findings in horses. 
 
B. Treatment of AF in horses 
In many horses treatment of AF is recommended because horses suffer, in general, from lone 
AF. After conversion to sinus rhythm they usually return to their previous level of 
performance (Reef et al., 1988). Until now, quinidine sulphate (QS), a class I anti-arrhythmic 
drug, has been the drug of choice for pharmacological treatment of AF in horses. It has an 
efficacy of 85% in horses with AF duration < 2 months and without the presence of detectable 
cardiac disease. However, in up to 76% of treated horses this drug is associated with serious 
cardiac and non-cardiac side effects including urticaria, nasal edema, colic, diarrhea, laminitis, 
polymorphic ventricular tachycardia, anaphylactic shock, syncope or sudden death (Reef et 
al., 1988; 1995). Recently, QS has become more difficult to obtain in some countries 
(McGurrin et al., 2003). Therefore, we decided to explore alternative treatment options of AF 
in horses (section 2 and 3). We chose to study horses with chronic AF because drugs which 
might be useful in horses with acute AF are not necessarily effective in cases with chronic 
AF.  
Flecainide, a class I anti-arrhythmic drug, has been shown to be efficacious in horses with 
acute experimentally-induced AF but not in horses with chronic AF because of the appearance 
of potentially dangerous ventricular dysrhythmias (Ohmura et al., 2000; van Loon et al., 
2004). During the research work for this thesis, we have observed the dangerous adverse 
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effects of intravenous flecainide in an acute experimentally induced AF. In one specific horse 
we observed the appearance of very wide QRS complexes ending in a fatal ventricular 
fibrillation and asystole. In human medicine, administration of flecainide has been described 
as being safe in patients who have no structural cardiopathy, and is frequently used in the 
prevention of atrial fibrillation. However, in a patient with a history of infarction and 
conduction disorders, its proarrhythmia may be lethal (The Cardiac Arrhythmia Suppression 
Trial Investigators, 1989). Flecainide-induced torsades des pointes may appear if combined 
with the use of other anti-arrhythmic drugs and/or the presence of electrolyte disorders 
(Nogales et al., 2007; Ohki et al., 2001; Thevenin et al., 2003). No electrolyte disturbances 
were present and macroscopic and microscopic examination could not reveal any underlying 
myocardial disease in our horse.  
In human medicine, propafenone is used for treatment of supraventricular and ventricular 
arrhythmias and several studies describe that this drug is more or as efficient as QS and other 
class I or class III anti-arrhythmic drugs for prevention and suppression of arrhythmias (Dinh 
et al., 1985; Faucher et al., 1986; Klempt et al., 1982; Odeh et al., 2000; Waleffe et al., 1981). 
In addition, the use of intravenous propafenone has already been described for treatment of 
ventricular arrhythmias in horses (Reef, 1999). Therefore, we have investigated the treatment 
possibility of propafenone in chronic naturally-occurring or experimentally-induced AF in 
horses.  
Although the therapeutic propafenone plasma concentration is very variable and ranges from 
20-200 ng/mL in humans and 64-1044 ng/mL in dogs, in all treated horses the human 
reference ranges could be achieved and a prolongation in AFCL could be measured (Bifi et 
al., 1999; Chan et al., 1989; Connolly et al., 1983; Karagueurzian et al., 1982; Steurer et al., 
1991). However, restoration of sinus rhythm was not observed in the treated horses. Side 
effects as described in human medicine due to acute or chronic doses of propafenone 
including cardiac, hepatic, cholestatic, dermatologic or nerve disorders, were not observed in 
our study (Cocozzella et al., 2003; Gandolfi et al., 2001; Huang et al., 2005; Odeh et al., 2000; 
Spingler et al., 1992; Wiesfeld et al., 2006). During administration of propafenone infusion, 
horses had an increased reaction to auditory and visual stimuli.  
Because of the very low success rate of flecainide and propafenone, both class I anti-
arrhythmic drugs, we chose to change the direction of our research into the use of a class III 
anti-arrhythmic drug. Amiodarone (AD) is a class III anti-arrhythmic drug and is described as 
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being efficacious and safe for treatment of atrial fibrillation, atrial flutter and ventricular 
fibrillation in human patients (Anderson et al., 1995; Kerin et al., 1996; Kodama et al., 1997; 
Podrid, 1995; Singh, 1995). This drug inhibits outward potassium currents resulting in 
prolongation of the repolarization time which may lead to AF termination. The dose used in a 
first treatment protocol was extrapolated from reported human doses to the weight of a horse 
(Kerin et al., 1996; Kochiadakis et al., 1999a, 1999b; Vardas et al., 2000). In human patients, 
the therapeutic AD plasma concentration is very variable and ranges between 0.1-11.9 µg/mL 
but a reference value of 2-2.5 µg/mL has been suggested as being safe (Boppana et al., 1983; 
Haffajee et al., 1983; Latini et al., 1984; Mostow et al., 1982). With this treatment protocol a 
prolongation in AFCL was observed leading to termination of AF in 4 of the 6 horses. 
Adverse effects such as thyroid, pulmonary, gastrointestinal, ocular, epididymal and 
dermatological disturbances that occur in human patients were not encountered in the treated 
horses. Only nervous disorders due to slowing down of the sensory and motor nerve 
conduction velocity have been observed in some of the horses using the described treatment 
protocol (Besser et al., 1994; Gill et al., 1992). A variability in blood-nerve barrier efficacy 
between individuals has been suggested in man and might also be an explanation why this 
problem has been seen only in some of the treated horses (Santoro et al., 1992). In addition, a 
slight increase in total bilirubin was present in some horses but normalization occurred after 
termination of AD treatment. In humans and dogs, a few cases of hepatic disorders after acute 
IV and after chronic AD treatment have been described (Agozzino et al., 2002; Bravo et al., 
2005; Calvert et al., 2000; Fransi and Briedis, 2002; Gilbert et al., 2000; Kraus et al., 2005; 
Oyama and Prosek, 2006). A major advantage compared to QS and flecainide was that none 
of the horses showed any cardiac adverse effects. 
This information suggested that AD could be used as an alternative treatment option for 
naturally-occurring AF in horses. Since the encouraging results and in order to increase 
success rate we investigated the pharmacokinetics and the bioavailability of intravenously and 
orally administered AD in horses.  
As described in human studies (Chow, 1996), no changes in respiratory rate, P-R interval, 
QRS duration or Q-T interval and no arrhythmias were observed in the studied group of 
horses. These findings were in contrast to the prolonged QT-interval observed after a single 
dose of AD in ponies (Trachsel et al., 2004). In discrepancy to the findings in dogs but in 
accordance with the results in humans and ponies, a moderate increase in heart rate after a 
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single IV AD bolus was observed in horses (Connolly et al., 1984; Trachsel et al., 2004; 
Wellens et al., 1984). This increase in heart rate might be related to the occurrence of 
hypotension after IV administration most likely due to the solvent as suggested I human data 
(Gill et al., 1992; Vardas et al., 2000; Wellens et al., 1984). As described for dogs and 
humans, the pharmacokinetics of IV AD fitted best with a multi-compartmental model (Plomp 
et al., 1984; Saavedra et al., 1999). Values of mean volume of distribution (31.1 L/kg) and 
elimination half-life (51.1 hours) of AD were in accordance with those described for humans 
(Latini et al., 1983, 1984; Plomp et al., 1984; Riva et al., 1982). Trachsel et al. (2004) reported 
a much longer elimination half-life (16.3 days) in ponies but the difference is probably related 
to the fact that they used a mathematical based pharmacokinetic model.  
As observed in humans, dogs and rats, oral AD administration poorly fitted the 
compartmental model. The bioavailability in horses was less than 50% (19.4% ) comparable 
to that reported in dogs and rats, whereas in human patients, values range from 22-86% 
(Andreasen et al., 1981; Broekhuyzen et al., 1969; Canada et al., 1983; Haffajee et al., 1983; 
Holt et al., 1983; Plomp et al., 1984; Riva et al., 1982). These findings suggest that large 
amounts of oral drugs would be necessary to obtain therapeutic plasma concentrations in 
horses. This low bioavailability might explain why one horse treated for AF with oral AD for 
a period of 30 days could not be converted to sinus rhythm (Guglielmini et al., 2003).  
In contrast to the findings of Trachsel and coworkers (2004), no renal excretion of the drug 
appeared in the horses. Again, this difference might be explained because Trachsel et al. 
(2004) used a physiologically based pharmacokinetic model to estimate pharmacokinetic 
parameters and to predict elimination of AD in urine.   
Based upon the pharmacokinetic findings, an adapted intravenous AD protocol was calculated 
to achieve the advised therapeutic levels of 2 to 2.5 µg/ml (Boppana et al., 1983; Haffajee et 
al., 1983; Mostow et al., 1982). Although target AD levels were achieved by slightly 
increasing the AD dose, some horses exceeded this therapeutic AD plasma concentration. 
With this protocol no cardiac side effects or nerve disturbances were observed but diarrhea 
occurred in three of the six horses in which sinus rhythm could not be restored. The 
appearance of malabsorption syndrome with severe diarrhea has been described in dogs after 
chronic oral administration of sublethal doses of AD due to partial villous atrophy and the 
accumulation of macrophages with dislypidic inclusions (Vic et al., 1985). A similar 
mechanism might have been responsible for the diarrhea in our horses, although they were 
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only treated for a short period of time with much smaller doses. However, no postmortem data 
are available to prove this theory.  
Prediction of AD plasma concentration and its impact on successful treatment remains very 
difficult because of its multicompartmental pharmacokinetics especially in long-term infusion 
protocols. It was concluded that AD could be used as an alternative treatment but that adverse 
effects were likely, particularly with prolonged infusion time (>36 hours). 
Because of the moderate success rate of the previously studied pharmacological treatments 
and the known efficacy of internal electrical cardioversion of AF in human patients, the 
applicability of the latter technique in horses was studied. Because adapted cardioversion 
catheters for horses are not commercially available, we examined the use of a custom made 
cardioversion catheter for internal cardioversion in horses. However, we encountered the 
complication of immediate recurrence of AF (IRAF) in one horse. In human medicine, IRAF 
after successful electrical cardioversion is common and pre-treatment with anti-arrhythmic 
drugs is frequently used for prevention of AF re-initiation within <1 min to 2 weeks (Chugh et 
al., 2004; Duytschaever et al., 2000, 2002; Gorenek et al., 2002; ; Joglar and Kowal, 
2004Lévy et al, 1997; Ricard et al., 2003; Sarubbi et al., 1998; Timmermans et al., 1998; Van 
Noord et al., 2002). Administration of AD has proven to be successful in preventing IRAF in 
human patients (Gorenek et al., 2006). As our previous studies indicated that short-term (< 36 
hours) AD infusion was not associated with cardiac or non-cardiac side effects all subsequent 
horses were loaded with a 24-hour AD infusion. The pharmacokinetic-based AD dose was 
chosen to achieve higher plasma concentrations at the moment of electrical cardioversion. The 
goal of the AD administration in these horses was thus not to convert AF to sinus rhythm, but 
to change electrophysiological properties of the atria for preventing IRAF. IRAF has not yet 
been described in horses which might be explained by the fact that during conventional QS 
treatment, the therapeutic plasma concentration at the time of conversion and the gradual 
decrease afterwards protect the atria from IRAF. Until now, in the horses, pre-loaded with an 
AD infusion, we have not encountered the problem of IRAF anymore. 
 
In conclusion, this thesis provides background information about the pathophysiology of 
recent-onset (paroxysmal) and chronic AF. In addition, it gives information about alternative 
treatment possibilities for chronic AF in horses. The currently used intravenous propafenone 
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treatment achieved therapeutic propafenone plasma concentrations without severe cardiac or 
non-cardiac side effects but sinus rhythm could not be restored in horses with chronic 
naturally-occurring or experimentally-induced AF. The use of IV flecainide in horses with 
chronic AF as well as in recent-onset AF is strongly discouraged because of its pro-
arrhythmic effects. 
Intravenous AD can be used as an alternative treatment option with moderate success rate but 
non-cardiac side-effects such as hind limb weakness and diarrhea might be expected. 
Internal electrical cardioversion is possible with custom made electrical cardioversion 
catheters with a good success rate and might be advised especially when conventional drugs 
fails. A combined use of anti-arrhythmic drugs and electrical cardioversion might be 
recommended to prevent the occurrence of IRAF.  
This work gives important new information about the pathophysiology and treatment 
possibilities of AF in horses.  
 
Future prospects 
From human patients and from experimental work in dogs and goats, it is known that, besides 
electrical and contractile remodeling, also structural remodeling plays a major role in the 
pathophysiology of AF. It has been described that during atrial fibrillation adaptive reversible 
responses occur at the ionic level within 30 minutes or at the cellular level within one week 
(Ausma et al., 2001; Goette et al., 1996). However, if AF exists for a longer period of time (> 
5 weeks) structural changes might occur such as a change in the distribution of the protein 
connexin 40, myolysis characterized by disruption of the sarcoplasmatic reticulum and 
accumulation of glycogen (Ausma et al., 1997; Van der Velden et al., 1998). Some studies 
also showed alterations in gap-junctions, which influences conduction velocity (Ausma et al., 
1997; Elvan et al., 1997; Van der velden et al., 1998), or evidence of apoptosis and fibrosis 
(Li et al., 1999). No information is currently available about whether or not structural changes 
also play a role in horses. Compared to human patients, horses generally present AF for a 
much longer time (several months versus a few days or weeks) and as such, structural changes 
might become even more important. On the other hand atrial structural lesions (e.g. fibrosis) 
might also be a predisposing cause of AF in horses and might influence response to treatment 
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and risk for AF recurrence after conversion. As these structural lesions are unlikely to be 
detected by cardiac ultrasound these horses would erroneously be classified as ‘lone’ 
fibrillators. 
Although the exact mechanism of AF is still not fully understood, the left atrium and 
pulmonary veins are known to be an important ‘source’ for AF in human patients. Especially 
sleeves of myocardium extending into the pulmonary veins are thought to be important 
triggers for AF. The importance of these structures in the initiation or maintenance of AF in 
horses is currently unknown. Comparison of post mortem examination of normal horses and 
horses with chronic AF should be able to clarify whether structural lesions are involved in 
horses with AF and whether pulmonary sleeves of atrial myocardium are also found in horses.  
Concerning the treatment of AF, transvenous electrical cardioversion of AF is becoming 
increasingly important as it shows to be well tolerated and has a good efficacy. Further studies 
are still necessary to reveal the optimal electrode position within the heart and to explore the 
advantages of concurrent anti-arrhythmic drug treatment to improve success rate, decrease 
cardioversion threshold and to minimize early recurrence of AF after successful 
cardioversion. 
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SUMMARY 
 
 
Atrial fibrillation (AF) is the most common, clinically important cardiac arrhythmia in horses. 
Nevertheless, information regarding the pathophysiology of this complex arrhythmia remains 
limited. In human medicine, dogs, goats and ponies, electrical changes during AF have been 
investigated. However, limited information about electrical changes during short-term AF in 
horses is available. These data might give new information about the pathophysiology of 
paroxysmal AF in horses.  
The standard drug, quinidine sulphate, used in horses for treatment of AF, becomes more and 
more difficult to obtain in some countries. Despite a variety of treatment options in human 
medicine, information regarding alternative pharmacological or non-pharmacological 
treatment protocols in horses is scarce.  
 
In this thesis a general introduction discusses in a first section the pathophysiology of AF and 
in a second part the underlying mechanisms of the different classes of anti-arrhythmic drugs 
that could potentially be used to treat AF. 
The research of the thesis consists of three major sections. The first section (Chapters 1-2) 
describes the electrophysiological, contractile and dimensional changes associated with short-
term and long-term AF in horses. In the second section (Chapters 3-6) new pharmacological 
approaches for the treatment of AF in horses are being explored. The third section (Chapter 
7) describes the results of a new non-pharmacological treatment of AF in horses. 
 
In the first chapter, 6 horses were instrumented with a pulse generator and a pacemaker. The 
pulse generator was connected with an atrial lead and the pacemaker with an atrial and 
ventricular lead. With the pulse generator it was possible to induce and maintain AF with 
burst stimulations for a short period (7 days). With the pacemaker, electrophysiological 
measurements including atrial and ventricular effective refractory period, could be measured 
before, during and after this short-term AF period. At the same time, echocardiographic 
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measurements including atrial diameters and contractility were assessed. In 2 horses, AF 
became persistent necessitating pharmacological cardioversion. 
In all horses, atrial electrical and contractile remodeling was observed very quickly (24 hours) 
during maintained AF. But after restoration of sinus rhythm, values returned quickly (48 
hours) to baseline. No obvious changes could be observed at the level of the ventricle and 
atrial diameters and surface areas. 
Clinical relevance: 
These findings support the concept that early conversion of AF is preferable and that an early 
return to training is possible after treatment of a short AF episode. 
 
In the second chapter, in a similar setup, AF was maintained in 4 healthy horses and 
electrophysiological and echocardiographic measurements were followed.  
In all horses, atrial electrical and contractile remodeling was observed very quickly (24 hours) 
during maintained AF, however after restoration to sinus rhythm, values returned more slowly 
back to baseline (2 months). No obvious changes could be observed at the level of the 
ventricle. 
Clinical relevance: 
These findings suggest that after 4 months of AF, it takes 2 months for the atrium to regain 
normal size and function. 
  
In Chapter 3, the applicability of propafenone (Rhythmonorm®), a class I anti-arrhythmic 
drug, was investigated for its use in horses with chronic AF. Two horses with naturally-
occurring AF and 4 horses with experimentally induced AF received a treatment protocol as 
suggested in human medicine. Horses received 2 mg/kg of propafenone IV over 15 minutes. If 
AF persisted 20 minutes after this bolus, a continuous infusion of 7 µg/kg/min of propafenone 
was given for another 85 minutes. Infusion was discontinued when conversion was achieved 
or when any side effects were observed. 
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The current protocol did not result in cardiac or non cardiac side effects. An increase of atrial 
fibrillation cycle length was observed but conversion to sinus rhythm did not occur.  
Clinical relevance: 
Propafenone, given at this dose, is not likely to convert chronic AF in horses. 
  
The fourth chapter describes the applicability and adverse effects of intravenous amiodarone 
(AD) (Cordarone®), a class III anti-arrhythmic drug, in horses with chronic AF. Six horses 
received a treatment protocol as suggested in human medicine adapted to the weight of a 
horse. Horses received 5 mg/kg/h AD IV during 1 hour followed by 0.83 mg/kg/h IV for 23 
hours and then 1.9 mg/kg/h IV for the following 30 hours. Infusion was discontinued when 
conversion was achieved or when any side effects were observed. Four out of 6 horses could 
successfully be converted to sinus rhythm but one of these horses showed symptoms of hind 
limb weakness and weight shifting. The two other horses that did not convert to sinus rhythm 
showed similar side effects. However, side effects disappeared completely in all the horses 
within 6 hours after termination of the AD infusion. 
Clinical relevance: 
Because of the acceptable success rate and non-cardiac side effects, a pharmacological study 
was warranted to evaluate the pharmacokinetics and bioavailability of AD in normal healthy 
horses.  
 
In Chapter 5 the clinical effects and pharmacokinetics of AD after single doses of AD were 
studied in a cross – over study. Six healthy adult horses received a single dose of 5 mg/kg of 
AD intravenously or orally. No adverse clinical signs were observed. This study revealed 
values of elimination half-lives (median: 51.1 hours for AD and 75.3 hours for 
desethylamiodarone [DAD]), clearance (0.35 (L/h)/kg), apparent volume of distribution (31.1 
L/kg) and peak plasma concentrations of DAD (0.08 µg/mL after 2.7 hours) after the 
intravenous bolus. After the oral bolus, bioavailability (6.0- 33.7%), peak plasma for AD 
concentration (0.14 µg/ml attained after 7 hours) and for DAD concentration (0.03 µg/mL 
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attained after 8 hours) and elimination half-lives (median: 24.1 hours for AD and 58.6 hours 
for DAD) could be determined.  
Clinical relevance: 
The results of this study provide useful information for calculating an adapted AD treatment 
protocol for horses to achieve therapeutically plasma concentrations as described in human 
medicine. 
 
In Chapter 6 the adapted treatment protocol of intravenous AD (Cordarone ®) was used in 6 
horses with chronic AF. In the first phase of the protocol, horses received a loading dose of 
6.52 mg/kg/h of AD IV during 1 hour followed by 1.1 mg/kg/h IV for 47 hours. In the second 
phase of the protocol, horses received a second loading dose of 3.74 mg/kg/h of AD IV during 
1 hour followed by 1.31 mg/kg/h for 47 hours. Infusion was discontinued if conversion to 
sinus rhythm was achieved or if side effects were observed. Three of the six horses could be 
cardioverted successfully without side effects. In 3 horses adverse effects of diarrhoea 
occurred and no cardioversion occurred in these patients.  
Clinical relevance: 
With this protocol the expected concentrations of AD and DAD amiodarone were achieved 
but the success rate was less than with the first described protocol. Adverse effects did only 
appear in the horses that received an AD treatment for more than 36 hours. These findings 
confirm the complexity of the AD molecule. 
 
Indeed, as in human medicine, good results are obtained with electrical conversion. However, 
because cardioversion catheters to perform transvenous electrical cardioversion in horses were 
not available yet, a custom made catheter was constructed. 
In Chapter 7, the transvenous electrical cardioversion technique with custom made catheters 
is described. Eight horses with chronic AF were used. As in the initial stage of this study, one 
horse showed multiple atrial premature complexes immediately after successful electrical 
cardioversion resulting in rapid recurrence of AF, it was decided to treat all subsequent horses 
with AD prior to the cardioversion procedure.  
Summary 
 
219 
Six out of the 8 horses could successfully be converted to sinus rhythm, without obvious side-
effects.  
Clinical relevance: 
Transvenous electrical cardioversion with custom made cardioversion electrodes can be 
considered as a treatment option for atrial fibrillation, especially when conventional drugs fail. 
Pre-treatment with an anti-arrhythmic drug might help to reduce the risk of immediate 
recurrence of AF. 
 
General conclusion: 
In conclusion, horses suffering from short-term AF show rapid electrical and contractile 
remodeling and reverse remodeling after successful cardioversion suggesting that only a short 
rest period after successful cardioversion before returning to training is necessary. Horses 
suffering from long-term AF show rapid electrical and contractile remodeling, a slower 
increase in atrial dimensions and a slow reverse remodeling after successful cardioversion 
suggesting that a longer rest period after successful cardioversion is advisable before returning 
to training. 
Propafenone, at a dose of 2 mg/kg over 15 minutes followed by a continuous infusion of 7 
µg/kg/min during 85 minutes, is not efficient in horses with chronic AF. Intravenous AD has a 
moderate success rate and cumulative dosing (> 36 hours) may lead to adverse drug effects. 
Transvenous electrical cardioversion is a potential alternative to pharmacological treatment. 
The combination of electrical cardioversion with anti-arrhythmic drugs might lower the 
incident of immediate recurrence of AF.  
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SAMENVATTING 
 
Atrium fibrillatie (AF) of voorkamerfibrillatie is de klinisch meest belangrijke ritmestoornis 
bij paarden. Ook in de humane geneeskunde wordt deze aritmie erg belangrijk geacht en 
intens bestudeerd. Niettegenstaande de talrijke onderzoeken is er eigenlijk nog maar weinig 
informatie beschikbaar over de pathofysiologie van AF bij het paard. Er zijn studies over 
pathofysiologie van AF bij de mens, de hond, de geit en de pony maar tot op heden is er niets 
gekend over het verloop van acute en chronische AF bij paarden. Informatie hierover bij 
paarden zou daarom nuttig zijn voor de kennis van de pathofysiologie van deze aritmie bij 
deze diersoort. 
Tot op heden is quinidine sulfaat (QS) het meest gebruikte en beschreven anti-aritmicum voor 
de behandeling van AF bij paarden. Maar, wegens de toename van andere en/of betere anti-
aritmica voor de behandeling van AF bij de mens wordt QS in sommige landen moeilijk 
verkrijgbaar. Er is zeer veel informatie beschikbaar over deze alternatieve producten voor 
behandeling van AF bij de mens maar over de toepassing ervan bij paarden is weinig gekend. 
 
In het eerste deel van de algemene introductie worden de theorieën betreffende de 
pathofysiologie van AF beschreven zoals bekend uit de humane geneeskunde. In het tweede 
deel worden de werkingsmechanismen van de verschillende klassen van anti-aritmica en de 
behandelingsmogelijkheden voor AF bij de mens en het paard beschreven. 
 
In het onderzoeksgedeelte van dit doctoraat vindt men drie secties. In de eerste sectie 
(Hoofdstukken 1-2) beschrijven we de elektrofysiologische, contractiele en dimensionale 
veranderingen die optreden tijdens acute en chronische AF bij paarden. In de tweede sectie 
(Hoofdstukken 3-6) geven we een beschrijving van nieuwe farmacologische 
behandelingsmethodes voor paarden met chronische AF. De derde sectie (Hoofdstuk 7) 
beschrijft de resultaten van het gebruik van elektrische cardioversie voor het behandelen van 
AF bij het paard.  
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In het eerste onderzoek werden 6 paarden voorzien van een pacemaker en een 
neurostimulator. De neurostimulator werd verbonden met een elektrische draad (lead) in de 
voorkamer. De pacemaker werd verbonden met één lead in de voorkamer en één lead in de 
kamer. Met de neurostimulator was het mogelijk om via snelle lokale elektrische ontladingen 
AF te induceren en te onderhouden gedurende een relatief korte periode van 7 dagen. De 
pacemaker gaf ons de mogelijkheid om elektrofysiologische metingen (genoemd atriale en 
ventriculaire effectieve refractaire periodes) te verrichten t.h.v. de voorkamer en de kamer en 
dit voor en tijdens de AF-periode, en na herstel van het normale sinus ritme. Op dezelfde 
tijdstippen werden echocardiografische metingen (voorkamer dimensies en contractiliteit) 
uitgevoerd.  
Bij twee paarden echter, leidde dit korte AF-protocol tot persisterende AF waardoor het 
noodzakelijk was om een farmacologische behandeling in te stellen om het normale sinus 
ritme te kunnen herstellen. 
In al de paarden zagen we een zeer snelle elektrische en contractiele verandering (24 uur) 
optreden tijdens de AF-periode. Na het herstel van sinus ritme zagen we dat de elektrische en 
contractiele veranderingen snel reversiebel waren (48 uur). Er werden geen significante 
veranderingen opgemerkt t.h.v. de kamer en de voorkamer dimensies. 
Klinisch belang: 
Uit dit onderzoek kunnen we besluiten dat het aangewezen is om snel een behandeling in te 
stellen na het optreden van AF bij paarden wegens de snelle elektrische en contractiele 
veranderingen die ontstaan na AF initiatie. Daarnaast blijkt dat na een geslaagde cardioversie 
van een kort durende AF periode er slechts een korte rustperiode nodig is voor volledig 
herstel. 
 
In het tweede onderzoek werden er 4 paarden, geinstrumenteerd met dezelfde techniek als bij 
het acute protocol (hoofdstuk 1) gebruikt. Bij deze paarden werd er met de neurostimulator 
een langdurige AF periode (4 maanden) geïnduceerd en onderhouden. Wegens de 
aanwezigheid van de pacemaker kon men elektrofysiologische veranderingen voor en tijdens 
de AF-periode, en na herstel van het sinus ritme gaan opvolgen. Op dezelfde tijdstippen 
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werden er ook echografische veranderingen (voorkamer dimensies en contractiliteit) 
opgevolgd.  
Bij alle paarden traden er snel elektrische en contractiele veranderingen (24 uur) op, er werd 
ook een tragere toename van de voorkamer dimensies gemeten. Na herstel van sinus ritme 
duurde het echter 2 maanden alvorens de elektrische, contractiele en dimensionale 
veranderingen terug genormaliseerd waren. Er werden geen significante veranderingen gezien 
t.h.v. de kamer. 
Klinisch belang: 
Uit dit onderzoek kan men besluiten dat het aangewezen is om een rust periode van een 2-tal 
maanden in acht te nemen na een succesvolle behandeling van chronische AF (4 maand) om 
volledige normalisatie en remodellering te bekomen. 
 
In hoofdstuk 3, onderzochten we het gebruik van propafenone (Rhythmonorm®), een klasse I 
anti-aritmicum, voor de behandeling van chronische AF. Twee paarden met natuurlijke, 
chronische AF en vier paarden met chronisch geïnduceerde AF werden behandeld met een 
propafenone protocol zoals gebruikt bij de mens. Alle paarden kregen 2 mg/kg propafenone 
IV over 15 minuten. Indien 20 minuten na deze bolus AF nog aanwezig was, kregen de 
paarden een onderhoudsdosis van 7 µg/kg/min propafenone IV gedurende 85 minuten. Het 
infuus werd onderbroken indien er neveneffecten werden opgemerkt of wanneer conversie tot 
sinus ritme optrad. 
Met dit protocol zagen we geen cardiale of andere ernstige neveneffecten, maar, ondanks een 
significante verlenging van de atriale fibrillatie cycluslengte, trad geen cardioversie op. 
Klinisch belang: 
Uit dit onderzoek kunnen we besluiten dat het huidige gebruikte intraveneuze propafenone 
protocol niet efficiënt lijkt voor de behandeling van paarden met chronische AF. 
 
In het vierde hoofdstuk beschrijven we het gebruik van amiodarone (AD) (Cordarone®), een 
klasse III anti-aritmica, bij paarden met chronische AF. Zes paarden werden behandeld met 
een AD protocol zoals voorgesteld bij de mens. De paarden kregen een ladingsbolus van 5 
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mg/kg/h AD IV gedurende 1 uur gevolgd door een eerste onderhoudsdosis van 0.83 mg/kg/h 
IV gedurende 23 uur. Vervolgens werd een hogere onderhoudsdosis toegediend van 1.9 
mg/kg/h AD IV gedurende de volgende 30 uur. De behandeling werd stopgezet indien er 
neveneffecten optraden of indien er herstel van het normale sinus ritme optrad.  
Bij vier van de zes paarden trad er herstel van normaal sinus ritme op maar bij één van deze 
paarden merkten we een parese van de achterhand op. Bij de twee andere paarden kon herstel 
van sinus ritme niet bekomen worden en trad hetzelfde neveneffect op. Na het stopzetten van 
de intraveneuze behandeling verdwenen deze neveneffecten binnen de 6 uur. 
Klinisch belang: 
Uit dit onderzoek konden we besluiten dat AD eventueel kon gebruikt worden als een 
alternatieve behandelingsmethode maar dat het aangeraden was om onderzoek te verrichten 
naar een aangepast behandelingsprotocol aan de hand van de farmacokinetische gegevens van 
AD bij gezonde paarden. 
 
In Hoofdstuk 5 onderzochten we via een cross-over studie het klinische effect en de 
farmacokinetiek van AD na een eenmalige toediening bij gezonde paarden. Zes paarden 
kregen een éénmalige orale of een intraveneuze bolus van AD. Bij geen van de paarden 
werden er neveneffecten opgemerkt. De eliminatie halfwaarde tijd (mediaan: 51.1 uur voor 
AD en 75.3 uur voor desethylamiodoarone, een actief afbraakproduct van AD), klaring (0.35 
L/kg·h), volume distributie (31.1 L/kg) en piek plasma concentratie van desethylamiodarone 
(0.08 µg/ml na 2.7 uur) na een eenmalige intraveneuze toediening werden hieruit bekomen. 
Van de orale bolus bekwam men de biologische beschikbaarheid (6.0-33.7%), een piek 
plasma concentratie van AD (0.03 µg/ml na 8 uur) en een eliminatie halfwaarde tijd (mediaan: 
24.1 uur voor AD en 58.6 uur voor desethylamiodarone). 
Klinisch belang: 
De resultaten van deze farmacokinetsiche studie gaven ons de mogelijkheid om een aangepast 
behandelingsprotocol voor AD te berekenen voor het paard. Dit nieuwe protocol werd 
uitgerekend om plasma concentraties te kunnen bereiken die van therapeutische waarde zijn in 
de humane geneeskunde. 
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In Hoofdstuk 6 pasten we het berekend AD protocol toe bij 6 paarden met chronische AF. 
Tijdens een eerste fase kregen de paarden een ladingsbolus van 6.52 mg/kg/h IV gedurende 1 
uur gevolgd door een onderhoudsdosis van 1.1 mg/kg/h IV gedurende 47 uur. In een tweede 
fase werd er een tweede ladingsbolus van 3.74 mg/kg/h AD IV gedurende 1 uur gegeven 
gevolgd door een onderhoudsdosis van 1.31 mg/kg/h gedurende 47 uur. Het infuus werd 
onderbroken indien er neveneffecten optraden of normaal sinus ritme bekomen werd. In drie 
van de zes paarden was het mogelijk om normaal sinus ritme te herstellen maar in de andere 
drie paarden was dit niet mogelijk en trad er tijdelijk diarree op. 
Klinisch belang: 
Met dit aangepaste protocol was het mogelijk om de vooropgestelde plasma concentraties te 
bekomen. Het slaagpercentage was echter lager dan in het eerst gebruikte humane protocol. 
De neveneffecten traden enkel op indien langer dan 36 uur AD infuus gegeven werd. 
 
In de humane geneeskunde wordt er meer en meer gebruik gemaakt van transveneuze 
elektrische cardioversie als behandelingsmethode voor AF. De cardioversie katheters die 
hiervoor gebruikt worden bij de mens kunnen echter niet gebruikt worden bij het paard.  
 
In Hoofdstuk 7 beschrijven we de techniek en de mogelijkheid van gebruik van aangepaste 
cardioversie katheters voor de transveneuze elektrische cardioversie van AF bij het paard. 
Aangezien 1 paard, vlak na succesvolle cardioversie meerdere atriale premature complexen 
vertoonde die leidden tot onmiddellijk recidief van AF, werden alle erop volgende paarden 
vóór de eigenlijke elektrische cardioversie gedurende 24 uur behandeld met amiodarone. 
Met deze techniek werd bij zes van de acht paarden normaal sinus ritme hersteld zonder 
belangrijke neveneffecten. 
Klinisch belang: 
Transveneuze elektrische cardioversie met aangepaste cardioversie katheters is een goed 
alternatief voor de behandeling van voorkamer fibrillatie bij het paard. Een voorafgaande 
farmacologische behandeling lijkt aangewezen om het risico van onmiddellijk AF recidief te 
minimaliseren. 
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Algemeen besluit: 
Paarden die behandeld worden na een kortdurende AF-periode vertonen snel elektrische en 
contractiele veranderingen. Herstel van deze veranderingen na succesvolle behandeling is 
snel. Dit impliceert dat paarden best zo snel mogelijk behandeld worden na het optreden van 
AF en dat na conversie van een kortdurende AF-periode er slechts een korte herstel periode 
noodzakelijk is. 
Paarden met chronische AF vertonen snel elektrische en contractiele voorkamer 
veranderingen en een tragere toename van de voorkamer dimensies. Na herstel van sinus 
ritme na een langdurige AF-periode wordt er aangeraden om een relatief lange herstel periode 
in acht te nemen zodat alle voorkamer parameters terug kunnen normaliseren.  
Propafenone aan een dosis van 2 mg/kg gedurende 15 minuten gevolgd door een 
onderhoudsdosis van 7 µg/kg/min gedurende 85 minuten, lijkt niet efficiënt voor het 
behandelen van paarden met chronische AF.  
De behandeling van paarden met intraveneuze AD heeft een matig slaagpercentage en een 
aanhoudende toediening (> 36 uur) kan leiden tot neveneffecten. 
Men kan opteren voor interne elektrische conversie als alternatieve behandelingsmethode 
voor paarden met AF. Daarbij wordt er aangeraden om een farmacologische voorbehandeling 
te geven om het risico op direct herval van AF te verminderen. 
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DANKWOORD 
Ik herinner me het nog goed, een maand voor ik afstudeerde kwam Hendrik Nollens me plots 
zeggen dat ik eens bij “de assistenten” van “den dienst inwendige” moest langs gaan. Hij wou 
me niets meer zeggen en natuurlijk dacht ik al, wat heb ik verkeerd gedaan? Met wat 
onzekerheid vertoefde ik me toen maar bij Heidi Nollet. Ze stelde me direct gerust. Blijkbaar 
hadden alle toenmalige jonge assistenten erover gepraat om me te vragen of ik een jaartje wou 
blijven als vrije assistent op “den dienst inwendige”. Thuis gaven ze me de vrije keuze en 
zoals jullie nu kunnen lezen heb ik de beslissing genomen om te blijven. Het jaartje vrije 
assistent ontpopte zich redelijk snel tot “echte” assistent. Ondertussen ben ik negen jaar 
blijven plakken. Naast de talrijke kliniek ervaringen die ik opgedaan heb heeft dit ook 
uiteindelijk geleid tot dit doctoraatswerk.  
Natuurlijk wil ik als eerste Prof. Dr. Gunther van Loon, die al besmet werd via Prof. E. 
Muylle van het ‘I-love-cardiology’ virus, bedanken omdat hij ook mij geïnoculeerd heeft met 
deze toch heel speciale aandoening. Hij heeft me steeds gesteund, geïnformeerd en heel goed 
begeleid door deze periode. Uren hebben we gepraat, gediscussieerd en heel veel kritische 
opmerkingen over het onderzoek en de artikelen besproken. Ik hoop dat er nog vele jaren 
samenwerking zullen mogen komen om dit toch zo interessant onderwerp verder uit te 
pluizen, in de kliniek bij te springen en eventuele nog andere opdrachten te vervullen, en, 
indien de toekomst het niet toelaat dan wil ik je toch bedanken voor de voorbije jaren. 
Vervolgens wil ik Prof. Dr. Piet Deprez bedanken omdat hij ondanks zijn heel drukke agenda 
toch de tijd neemt om alle artikelen zorgvuldig te lezen, te bekritiseren en helpt aan te passen 
zodat het eindresultaat er nu toch gekomen is.  
Prof. Dr. Rene Tavernier is de volgende persoon die ik terecht wil bedanken voor het ter 
beschikking stellen van al het materiaal (programmers, pacemakers, leads, schroefjes, 
plugjes,….), zijn onuitputtelijke kennis en voor de vele uren dat we samen al knielend zaten 
voor al de toch zo “brave” proef-paardjes. Ik hoop na de afloop van dit doctoraat je toch nog 
af en toe eens te horen. Je bent een mens met het hart op de juiste plaats. 
Daarnaast wil ik ook de andere leden van de dienst cardiologie bedanken voor hun praktische 
hulp (Vida, Rudy (helpen bij implantaties), Thea (samen hebben we uren Holters zitten 
aflezen van de kliniek patiënten), Karlien (overbrengen van boodschappen),….). 
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Voor het farmacologische deel van dit werk wil ik Prof. Dr. Siska Croubels, Dr. Kris Baert, 
Prof. Dr. Patrick De Backer en An Maes bedanken. Voornamelijk Kris heb ik regelmatig 
lastig gevallen met mijn talrijke farmacologische vragen. En Siska wil ik extra bedanken dat 
ze wou zetelen in mijn begeleidings- en examencommissie maar ook omdat ik de lessen van 
de farmacologie mocht volgen. An Maes bedank ik voor de talrijke amiodarone en 
desethylamiodarone analysen. 
Speciale dank aan alle leden van het begeleidingscommissie Prof. Dr H. Amory die speciaal 
uit Luik komt om dit werk in goede banen te helpen leiden, merci pour votre collaboration, en 
Prof. Dr. S. Sys voor zijn interesse en opmerkingen bij het nalezen van dit werk. 
Alsvolgt wil ik de leescommissie (Prof. Dr. G. van Loon, Prof. Dr. H. Amory, Prof. Dr. S. Sys 
en Prof. Dr. I. Polis) bedanken voor het nogmaals herlezen en bekritiseren van het werk. Zoals 
jullie kunnen zien passeert zo’n doctoraatswerk heel wat handen voor ze als eindwerk aan het 
publiek vertoond wordt. 
Ook Prof. Dr. F. Gasthuys en Prof. Dr. I. Polis wil ik bedanken dat ze toestemden om te zetel 
in de examencommissie en ook om het werk zorgvuldig te lezen en te bekritiseren. 
Voor de statische verwerking van de informatie over remodeling en reverse remodeling van 
atrium fibrillatie bij paarden ben ik mijn dank verschuldigd aan Prof. Dr. L. Duchateau. 
Prof. Dr. R. Verbesselt van UZ Gasthuisberg van de K.U. Leuven dank ik voor de talrijke 
propafenone bepalingen. 
Het ontwerp van het kaft van dit doctoraatswerk is tot stand gekomen dankzij de 
medewerking van Dr. Sofie Muylle, bedankt voor je tekentalent. 
Ik wil heel graag Dr. Paul Audenaerde bedanken voor de praktische ervaring die hij me 
bijbracht in de diergeneeskundige (eerste rectale onderzoeken, maag-sondage, paarden 
castreren, voeten bekappen, verdoofde katten die aan het verdrinken zijn uit je vijver gaan 
halen, geweien van herten afzagen,…..en natuurlijk mag ik niet vergeten te vermelden hoe 
mooi je me toonde hoe je met een verdovingsgeweer geladen met immobilon in je eigen 
vinger moet schieten met alle gevolgen van dien,….gelukkig is alles goed afgelopen, het was 
voor beiden een leerrijke bedoening!). Gewoon in het kort gezegd het was een heel leuke 
periode. 
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Natuurlijk weet men al dat een doctoraat afleggen in een klinische vakgroep niet gemakkelijk 
is en dat dit onmogelijk zou zijn zonder de hulp van alle andere collega’s, internships en 
personeel. Daarvoor wil ik voornamelijk Laurence Lefère, Katleen Vanschandevijl, Heidi, 
Catherine, Sarah, Bart, Jessica, Stefanie, Isabelle, Katrien, Inge, Gerlinde, Stefanie en 
Benedict bedanken voor de morele- en werk steun. Ook Bea, Fernand, Christiane, Elvin, Hans 
en Sylvie bedank ik voor al het gesteriliseerde materiaal, het maken van speciale bestellingen, 
de talrijke bloedanalyses en praktische hulp. Apotheker E. Soenen wil ik bedanken 
voornamelijk voor zijn steeds snelle en speciale hospitaal bestellingen van amiodarone. Ik 
vergeet ook niet dat Tony, Jef, Jantje, Didier (laatste twee ondertussen al getransfereerd naar 
dienst Heelkunde), Carlos, Balder en Julien, Remy en Didier (laatste 2: hoefsmeden) hun 
steentje hebben bijgedragen aan de goede verzorging van al de proefpaardjes Armani, Azaro, 
Suzy, Kappa, Davidhoff en Gucci en de talrijke patiënten.  
Ook de vakgroep Heelkunde wil ik bedanken voor het bijstaan van de nodige anesthesie, het 
gebruik van chirurgisch materiaal en de leerrijke “talks”. Prof. Dr. F. Gasthuys, Stijn 
Schauvliege, Dr. L. Vlaminck, Prof. Dr. A. Martens, Dr. F. Pille, dierenartsen Stefaan 
Cockelaere en Jeroen Declercq, bedankt.  
Ik wil ook het Bijzonder Onderzoeksfonds van de Universiteit van Gent bedanken voor hun 
financiële bijdrage van dit werk. 
Ik ben me er echter van bewust dat ik nog talrijke mensen zal vergeten te vermelden zijn maar 
daarvoor wil ik me verontschuldigen. Bij het tot stand brengen van een doctoraat dragen er 
heel wat mensen hun steentje bij. 
 
Natuurlijk vergeet ik ook onze dichtste vrienden niet, waar we toch al heel wat leuke 
weekendjes en weekjes mee doorgebracht hebben. Marc, Mauricette, Pascale en Maurice 
bedankt voor de toffe sfeer en de steun in de moeilijkere tijden. 
 
Vooral mijn ouders en broer Patrick, zijn vrouw Annick en de kinderen, Tine, Evie en Michiel 
wil ik bedanken voor hun steun voor, tijdens en na mijn studies diergeneeskunde, zij zijn 
degenen die het dichtst bij me staan en die echt in me geloven. 
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Et en dernier, j’aimerai tout particulièrement remercier Eric, Thibaut et…. Eric, tu es la 
personne qui m’a soutenue à tout moment. Tu as toujours, dans les situations difficiles, voire 
orageuses, réussi à m’apaiser et à me réconforter en me disant « mais, ça va aller, ne 
t’inquiète pas, on trouvera bien une solution ». Et, tu as eu raison, finalement, tout s’est bien 
déroulé. Je voudrais également te remercier pour notre fils, Thibaut, qui ressemble si fort à 
toi, … un vrai garçon. Que notre vie puisse continuer pleine de bonheur….. 
 
 
